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1. Abstract 
Platelets are known to play a key role in acute coronary events, such as myocardial 
infarction, associated with advanced atherosclerosis, but a number of papers have 
recently been published suggesting that platelet adhesion may initiate atherosclerotic 
lesion formation. The proposed research aimed to investigate this by seeing whether 
platelet adhesion occurred, directly or via leukocytes, to the endothelium in diabetic 
conditions. Diabetic-like conditions were chosen because an accelerated rate of lesion 
formation occurs. This was achieved by incubating endothelial cells with high 
concentrations of glucose and various types of AGEs.  
 
Bovine serum albumin of different purity, a peptide of albumin, and haemoglobin were 
glycated with D-glucose. Samples were taken at 2 weeks intervals to allow for 
determining the extent of glycation and allowing for investigation into whether the 
extent of glycation affected platelet adhesion. It also made possible analysis of extent of 
glycation, to see whether these have a relation to endothelial dysfunction (including cell 
proliferation, cell adhesion molecule expression, and ROS and cytokine production). 
There are discrepancies in the finding of studies looking into the effect of AGEs on the 
endothelium and there are no reported studies looking at cytokine production. As such, 
it was hoped that this research would allow for a greater understanding of the processes 
involved and whether endothelial dysfunction could account for accelerated lesion 
formation associated with diabetes. 
 
As a whole, the research intended to explore the hypothesis that platelet adhesion to the 
endothelium is required for foam cell formation and their development into 
atherosclerotic lesions. It aimed to see whether hyperglycaemia and the presence of 
high levels of AGEs induces endothelial dysfunction and therefore increases monocyte 
adhesion by the presence of activated platelets. In doing so, a greater understanding of 
the processes involved in accelerated lesion formation would allow for targeted 
research to allow for treatments to reduce foam cell deposition. This could be the use of 
a cocktail of anti-platelet drugs or ones that reduce endothelial dysfunction. This would 
reduce the manifestation of cardiovascular disease and therefore improve diabetic 
patient life as well as reduce the cost of treatment for the NHS, and therefore for the tax 
payer.  
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2. Introduction 
Atherosclerosis is prevalent in the western world and accounts for high levels of both 
mortality and morbidity. Although a lot is known about the processes involved in this 
vascular disease, there are still aspects that are not clearly defined and areas where scientific 
opinions differ. 
 
 
2.1. Atherosclerosis 
Atherosclerosis is a form of macrovascular disease that is characterized by arterial fatty 
deposits that cause reduced elasticity of the blood vessel. The word was first coined by 
the German Pathologist, Felix Marchand, in 1904 from the Latin for gruel hardening, 
although Joseph Lobstein has previously used the term arteriosclerosis for describing the 
general loss of elasticity of blood vessels back in 1833 and Albrecht von Haller used the 
word atheroma in 1755 to describe the accumulation of cells in the blood vessel (Gotto, 
2005, Tedgui and Mallat, 2006). Atherosclerosis had, however, been described before 
this. For instance, Leonardo Da Vinci detailed the thickening of arteries with age in the 
1400s (Ose, 2008). Since the 1800s, there has been a wealth of research that has 
characterised the development and causes of this disease.  
 
In the 1890s, Karl von Rokitansky and Rudolf Virchow set out their opposing theories on 
atherosclerosis. Rokitansky believed that lesions developed from deposition of small 
blood clots within the intima. This led to infiltration of fibroblasts and deposition of 
lipids. Virchow, on the other hand, believed that lipid deposition, intimal injury and 
inflammation were key (Mayerl et al., 2006). Virchow‟s observations have been added to 
and form the basis of our understanding of this disease. 
 
Atherosclerosis is divided into a number of stages; these are determined by the stability of 
the plaque and by the state of the endothelium (see Table 1). The initial phase of 
atherosclerotic plaque formation, fatty deposits, occurs from early childhood (Jarvisalo et 
al., 2001, Napoli et al., 1997) which concurs with Da Vinci that atherosclerosis is part of 
the general aging process. These fatty deposits start as fatty streaks. Fatty streaks develop 
when monocytes engulf oxidised low-density lipids (ox-LDL) and migrate through the 
endothelium and into the intima of the blood vessel, becoming lipid-rich macrophages or 
foam cells. The macrophages are unable to process these lipids and therefore they are 
eventually dispersed resulting in the accumulation of more monocytes.  
 
Intermediate lesions occur from the accumulation of foam cells to form a layer on the 
artery wall. This results in proliferation and migration of smooth muscle cells. The lesion 
can eventually develop to form fibrous plaque that causes narrowing of the blood vessel 
and associated ischaemia. This is a complex lesion that consists of a cap and core. The 
cap is formed from muscle and endothelial cells and results in hardening of the vessel. 
The core is formed from foam cells, muscle cells, and general cellular debris – giving the 
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lesion gruel like appearance. These complex lesions are prone to become unstable and 
rupture, resulting in thrombus formation and the associated pathologies of stroke, 
gangrene, and myocardial infarcts (Ross, 1999a, Stary et al., 1995, Stary et al., 1994). 
 
 
 
Table 1: The Stages of Atherosclerosis (From the Findings of Stary et al. 1994 & 5)  
 
Type Description Details 
I Initial stage of atherosclerosis Lipid deposition in the intima 
Invisible to the naked eye 
Isolated FCs 
II Fatty streak (initial) Accumulation of FCs 
Visible as yellowy streaks / areas 
Stains red with Sudan (III/IV) dye 
SMCs contain lipid droplets 
T lymphocytes and mast cells present 
Increased number of macrophages 
Lipid visible in the extracellular space 
III Intermediate lesion Lipid pools 
Lipids present in extracellular space and SMCs 
Increased levels of cholesterol, fatty acids, 
sphingomyelin, lysolecitin, and triglycerides 
IV Atheroma (advanced) Lipid core 
Fibrous cap (macrophages, FCs, SMCs) 
Endothelium still intact 
No narrowing of the lumen 
Lipid accumulation in the extracellular space 
Increased lymphocytes and mast cells 
V Fibroatheroma (advanced) Narrowing of the lumen 
Fibrous connective tissue formation 
Lipid core calcification 
Vascularization 
Fissures possibly present – thrombus formation 
VI Complicated lesion (advanced) Significant narrowing of the lumen 
Disruption to the lesion surface 
Thrombotic deposits (haematoma / haemorrhage) 
 
(Key: FCs - foam cells; SMCs - smooth muscle cells) 
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Figure 1: Atherosclerosis 
 
 
 
At present, the processes involved in initiating atherosclerosis are not fully understood.  
In 1973, Ross and Glomerset suggested that lipid deposition occurred as a result of injury 
to endothelial cells, with endothelial denudation occurring prior to atheroma formation 
(Ross and Glomset, 1973). This was refined by Williams and Tabas (Williams and 
Tabas, 1998). They stated that there was no clinical evidence to suggest that endothelial 
denudation took place until latter stages of atherosclerosis. In vivo evidence suggested 
that an intact endothelium was necessary for the initial development of lesions. Their 
'response-to-retention' theory suggested that endothelial functional changes took place, 
but these were not sufficient for denudation. These functional changes were thought to be 
due to a number of possible factors including decreased production of the vasodilators 
nitric oxide (NO) and prostacyclin (PGI2), inactivation of NO and/or increased 
production of endothelium-derived contracting factors, cytokine production, cell 
adhesion molecule activation, and reactive oxygen species (ROS) formation. The results 
of these changes are that there is increased lipoprotein retention in endothelial cells 
leading to plaque formation.  
 
More recently, research has centred on the role of progenitor cells in atherogenesis (Daub 
et al., 2006, Daub et al., 2007, Xu et al., 2008). It has been postulated that because 
atherosclerosis increases with age it may result from the reduced capacity for, or 
dysfunction in, cell regeneration. Research has highlighted some evidence for linking 
endothelial cell repair mechanisms with lesion formation. Indeed, Xu and colleagues 
(2008) reported that endothelial apoptosis occurred in the lead up to lesion formation in a 
mouse model of atherosclerosis. They also showed CD31- positive cells a week after 
injury inducement by cuff placement, prior to visible lesions at 2 weeks, suggesting that 
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progenitor cells were involved.  It is clear, therefore that changes to the endothelium are 
involved in atherogenesis. 
 
 
2.2. Endothelium 
The endothelium acts as a semi-permeable barrier between the blood and the surrounding 
tissue. It is actively involved in regulating the vascular tone and hence the supply of 
blood and nutrients to the surrounding tissue. Under normal physiological conditions the 
endothelium maintains vasomotor control and an antithrombotic state.  
 
Blood vessels comprise a number of layers or tunicas: the adventitia, media, and intima, 
with the lumen making up the channel for blood transport. The adventitia is formed from 
dense connective tissue, which consists of elastin and collagen fibres. Nerves, small 
diameter vessels (vasa vasorum) and lymphatic vessels impregnate this layer. This forms 
the backbone of the blood vessels, allowing for rigidity, support, contraction, and for 
communication (Laflamme et al., 2006). The tunica media is formed from smooth 
muscle cells and elastin. These allow for maintenance of the vasomotor control and its 
thickness is dependent on the function of the vessel. For instance, muscular arteries have 
a thick media tunica to allow for diameter changes in response to the blood requirements 
of the target tissue (Avolio et al., 1998). The intima consists of a monolayer of 
endothelial cells, held extremely closely together with tight junctions, and another layer, 
called the basement layer, which is formed from elastin and collagen, as well as other 
cells, including fibroblasts, macrophages and smooth muscle cells (Millonig et al., 2001). 
The endothelium is primarily involved in maintaining a non-thrombotic surface and 
providing a semi-permeable barrier between the blood vessels and the blood. The 
endothelium therefore has a major role in blood vessel function.  
 
The endothelial cell monolayer is approximately 0.5 - 1.2 μm thick (Hoak et al., 1981) 
and is held together so tightly that under the microscope the cells look as if they overlap. 
The individual cells elongate in the direction of the blood flow and therefore provide a 
very large surface area to volume ratio. This allows for maximal diffusion of small 
macromolecules, leukocytes and fluid, which is essential for the health and wellbeing of 
the underlying cells. 
 
The endothelium is negatively charged, as are platelets (Sawyer and Srinivasan, 1972). 
Therefore repulsion of platelets is achieved in normal physiological conditions. This 
forms the basis of the vessel wall non-thrombogenic surface. The endothelium, however, 
also has the ability to prevent platelet adhesion and coagulation in other ways, such as 
the production of heparin-like molecules, ecto-ADPase, nitric oxide and prostacyclin 
(PGI2), and the binding and inactivation of circulating thrombin (Hoak et al., 1981, 
Sneddon and Vane, 1988, Venturini et al., 1989). 
 
Heparin-like molecules bind circulating antithrombin. Circulating thrombin is anchored 
to form thrombin-antithrombin complexes. The anchoring of thrombin results in this 
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compound not being available for fibrinogen cleavage. This process results in 
inactivation of a number of coagulation factors, including Xa and IXa, therefore the 
clotting cascade and clot formation is inhibited (Frebelius et al., 1996, Marcum and 
Rosenberg, 1984). 
 
The production of ecto-ADPase (CD39) by the endothelium has a major role in 
haemostasis. The conversion of ADP to AMP is catalysed by this enzyme. ADP is a 
platelet agonist and, as previously stated, is involved in platelet aggregation and 
thrombus formation (Gayle et al., 1998, Marcus et al., 1997). 
 
The production of vasodilators such as PGI2 and NO reduces platelet activation by 
increasing the concentrations of cAMP and cGMP and therefore the chances of 
circulating platelet interaction with the vessel wall.  These cyclic nucleotides activate 
protein kinases, cyclic GMP-dependent protein kinase G (PKG) and cyclic AMP-
dependent protein kinase A (PKA). PKG is known to inhibit platelet adhesion, partly via 
decreased production of type 3 phosphodiesterase (Wang et al., 1998) and it is also 
involved in inactivation of a number of pathways associated with platelet activation (den 
Dekker et al., 2002). 
 
It is clear that endothelial cells play a role in the maintenance of a 'normal' physiological 
state, but the endothelium can also be in a state of dysfunction. Cell permeability can be 
altered and the anti-thrombotic surface can become pro-adhesive to circulating platelets. 
Endothelial cells have the ability to synthesise and express the vasoconstrictor 
endothelin-1, a number of cell adhesion molecules, cytokines and chemokines that can be 
involved in platelet and leukocyte adhesion as well as an immune response, endothelial 
and smooth muscle cell chemotaxis and proliferation, and cell migration. 
 
 
2.3. Platelets 
Platelets are small (approximately 2 µm in diameter) anuclear blood cells. They are 
colourless, with a regular discoid shape and are present in the plasma of humans at a 
concentration of 150 – 400 x 109 per litre (Thaulow et al., 1991). Their disc shape and 
negatively-charged surface glycoproteins are important in minimising platelet-platelet 
interaction. The production of platelets occurs in megakaryocytes, which are rare cells 
mainly found in bone marrow. Fully differentiated megakaryocytes form numerous 
cellular protrusions, or pro-platelets, which hold the majority of the cytoplasm. Platelets 
are believed to be formed at the end of these pro-platelets by granule component transfer 
from the megakaryocytes, up the pro-platelets, into the platelets.  The platelets are then 
released into the blood stream, the mechanism has not been demonstrated but it is 
thought to be due to the action of proplatelet microtubules. 
 
Platelet production is normally in the region of 1 x 10
11
 per day, but synthesis can be 
increased to meet demand (Thaulow et al., 1991). The production of large numbers of 
platelets is required to maintain stasis due to the large turnover of platelets. The 
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approximate life-span of platelets is only 10 days and platelets are required in injury 
repair so, in these situations, there is an associated increase in platelet production. The 
spleen sequesters approximately one third of the circulating platelets and the liver 
removes the remaining non-functional platelets. Production and differentiation of 
megakaryocytes, and therefore production of platelets, is regulated by thrombopoietin, a 
glycoprotein produced by the liver, kidney, and bone marrow, although a number of 
cytokines (IL1, 6, and 11) are thought to play minor roles (Teramura et al., 1992, 
Wickenhauser et al., 1995).  
 
Platelets contain a range of specialised organelles (Figure 2). One of these, the 
canalicular system is made up of a series of channels that are connected to each other and 
to the surface (White and Clawson, 1980, George, 2000, Flaumenhaft et al., 2005). The 
platelet cytosol contains contractile proteins, actin and myosin, which allow for shape 
change upon activation (Zucker-Franklin and Grusky, 1972). There are also specialised 
storage vesicles, α-granules and dense granules. 
 
Upon stimulation by a number of compounds including ADP, adrenalin (epinephrine), 
collagen, and thrombin, contraction of cytoplasmic actin and myosin occurs. The 
platelets become irregular in shape, with pseudopodia protrusions. These allow for 
release of stored proteins (see Table 1 for an overview), via the canalicular system, from 
the α-granules (George, 2000, Zucker et al., 1979, Sweatt et al., 1985, Pengo et al., 1986, 
Lefebvre et al., 1993). 
 
The dense granules contain stores of adenine nucleotides (ADP and ATP), serotonin (the 
vasoconstrictor 5-hydroxytryptamine), and histamine. There is also evidence to suggest 
that the inner membranes contain adhesion proteins, including glycoprotein Ib (GPIb) 
and glycoprotein IIb / IIIa (GPIIb/IIIa). Adenine nucleotides and adrenalin are linked 
with platelet aggregation. ADP is principally involved in platelet activation and therefore 
aggregation, while adrenalin may potentiate other platelet agonists. Serotonin is known 
to be involved in vasoconstriction. Serotonin and ATP are also known to be 
inflammatory mediators and as such may well be involved in repair processes as well as 
vascular disease (for specific references see Table 2). 
 
Alpha granules contain a wide range of proteins, including adhesion proteins, such as 
GPIIb/IIIa, thrombospondin (TSP), and von Willebrand Factor (VWF); coagulation 
proteins such as factor V; plasma proteins such as albumin, fibrinogen, and 
immunoglobulin-G (IgG); growth factors such as platelet-derived growth factor (PDGF), 
vascular endothelial cell growth factor (VEGF) and transforming growth factor ß (TGF-
ß); and some protease inhibitors. Gawaz (Gawaz, 2004) suggests that neutrophil-
activating protein-2 (NAP-2) and plasminogen are found in α-granules, but more 
research is required to verify this. Some of these proteins, such as VWF, are synthesised 
by megakaryocytes prior to their fragmentation to form platelets. Others are acquired by 
platelets after they are formed, such as plasma fibrinogen, which is incorporated by 
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receptor-mediated endocytosis, and plasma proteins, which undergo fluid-phase 
pinocytosis (see Table 3 for specific references).  
 
Figure 2: A Platelet 
 
 
 
 
 
 
 
 
Both types of platelet granule contain calcium and magnesium, which associate with the 
coagulation factors in the coagulation cascade (Skaer et al., 1976). They also store 
proinflammatory cytokines and chemoattractants, the products of platelets themselves 
and internalized compounds (Ni et al., 2003, Boehlen and Clemetson, 2001). These 
mediators trigger platelet aggregation and can lead to coagulation and thrombosis. 
 
Coagulation and thrombosis is the response to injury (and the current understanding of 
the processes involved are reviewed in (Monroe and Hoffman, 2006)). Blood vessel 
injury results in platelet activation via specific cell surface receptors, G-protein-coupled 
receptors, and the associated shape change, as detailed previously (Schafer et al., 2004). 
This shape change results in cell adhesion molecule upregulation. The cell adhesion 
molecules, and associated calcium ions released from the storage granules, bind 
coagulation factors VII, IX, X, and prothrombin (II) (Hoffman et al., 1995). These 
coagulation factors are present in their inactive form (proenzymes) in the blood. 
Activation occurs either by cleavage of part of the proenzyme or by conformational 
change to reveal the active site.  
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Coagulation factor X is the key factor in bringing about coagulation. This factor is 
required for the conversion of prothrombin to thrombin. For activation of factor X both 
platelets and tissue factor-bearing cells are required. Factor VII is bound to the tissue 
factor-bearing cells and when it is activated it will also activate factor X and factor IX. 
Factor Xa then binds with Va, which results in the cleaving of thrombin from 
prothrombin (Hoffman et al., 1995). 
 
Activated factor VII from the tissue factor-bearing cells also interacts with platelet 
membranes. In so doing it can activate factor X. Platelets can also have factor Xa on their 
surface. Factor Xa leads to the conversion of prothrombin to thrombin (Esmon et al., 
1974). 
 
The production of thrombin requires calcium ions and phospholipids. Thrombin itself 
acts as an initiator for the production of more thrombin, albeit very slowly. This allows 
for control over thrombin formation. Cross linkage of the alpha chains of fibrin results in 
clot formation. This cross linkage is catalysed by coagulation factor XIIIa and calcium 
ions (Boyer et al., 1972). 
 
 
Table 2: Platelet Dense Granule Content  
 
Name Function Reference 
Serotonin (5-HT) Vasoconstrictor and 
inflammatory mediator 
(Carty et al., 1981, Smith, 
1996)  
Adenine 
nucleotides (ATP, 
ADP) 
Platelet activation and 
inflammatory mediator 
(Meyers et al., 1982, 
Mori et al., 1984) 
P-Selectin, GP Ib,  
GP IIb/IIIa 
CAMs (Youssefian et al., 1997) 
Granulophysin 
(CD63) 
 (Israels et al., 1992) 
Adrenalin & 
noradrenalin 
Platelet aggregation and 
vasomotor tone 
(Smith, 1996) 
Calcium, phosphate 
& magnesium ions 
 (Skaer et al., 1976, Skaer 
et al., 1974) 
 
(Key: 5-HT - 5-hydroxytryptamine; ATP - adenosine triphosphate; ADP - adenosine diphosphate; GP - 
glycoprotein; CAM - cell adhesion molecules) 
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Table 3: Platelet α-granule Proteins  
 
Name Function          References 
GP IIb/IIIa  CAM for firm attachment   (Cramer et al., 1990) 
TSP CAM for platelet-neutrophil 
and platelet-matrix interactions 
(Wencel-Drake et al., 1985) 
VWF CAM for platelet-collagen 
interaction 
(Wencel-Drake et al., 1985) 
Fibronectin, 
vitronectin, 
osteonectin, GP IV, 
GMP-33 
CAM (Berger et al., 1993, Wencel-Drake 
et al., 1985, Breton-Gorius et al., 
1992, Metzelaar et al., 1992)  
VWF:Ag II Proprotein of VWF (Scott and Montgomery, 1981) 
Fibrinogen Platelet adhesion via GPs and 
involvement in the clotting 
cascade  
(Wencel-Drake et al., 1985) 
Albumin Plasma protein (George and Saucerman, 1988) 
 Thromboglobulin, 
PDGF, VEGF and 
TGF-ß 
Cell proliferation and 
chemotaxis -  smooth muscle 
cells, macrophages / monocytes 
& fibroblasts 
(Assoian and Sporn, 1986, Salgado 
et al., 2001, Bowen-Pope et al., 
1984, Kaplan et al., 1979) 
IGF-1, ECGF, 
EGF, bFGF 
Mitogenic growth factors (Chan and Spencer, 1998, King and 
Buchwald, 1984)  
PBP, CTAP-III β-TG antigen molecules that 
are precursors for β-TG and 
PF-4 
(Castor et al., 1983, Varma et al., 
1982) 
ENA-78, IgA, IgG, 
IgM, PF-4, β-TG 
Immune response (George et al., 1985, George and 
Saucerman, 1988, McLaren and 
Pepper, 1982)  
PN-2 Inhibits protease and growth 
factor activity 
(Van Nostrand et al., 1991) 
PAI-1 Modulator of fibrinolytic 
activity 
(Booth et al., 1988) 
Platelet derived 
collagenase 
inhibitor 
Modulates collagenase activity (Cooper et al., 1985) 
Protein S Heparin cofactor - inactivate 
Factors Va and VIIa 
(Schwarz et al., 1985) 
α2-macroglobulin, 
α2-anti-plasmin, α2-
anti-plasmin 
Serine protease inhibitors (Gogstad et al., 1983, Nachman and 
Harpel, 1976) 
Multimerin Binds factors VIII and V (Hayward et al., 1998) 
C1 inhibitor, factor 
V, factor VIII, 
HMK, HRGP 
Coagulation (Chesney et al., 1981, Leung et al., 
1983, Schmaier et al., 1993, 
Schmaier et al., 1983) Yarerovi et 
al. 2003 
RANTES & MIP Cytokines (Klinger et al., 1995) 
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(Key for Table 3: CAM - cell adhesion molecule; GP glycoprotein; TSP - thrombospondin; VWF - von 
Willebrand factor; VWF:Ag II - von Willebrand antigen II; PDGF - Platelet-derived growth factor ; VEGF 
- vascular endothelial cell growth factor; TGF-ß - transforming growth factor ß; IGF-1 - insulin-like 
growth factor-1; ECGF - IGF-binding protein-3 endothelial cell growth factor; EGF -  epidermial growth 
factor; bFGF - basic fibroblast growth factor; PBP - Platelet basic protein; CTAP-III - connective tissue 
activating protein-III; ENA-78 - Epithelial neutrophil-activating protein- 78; PF-4 - platelet factor-4; β-TG 
- β -thromboglobulin; PN-2 -  Protease Nexin-2; PAI-1 - Plasminogen activator inhibitor-1; HMK High 
molecular weight kininogen; HRGP - Histadine-rich glycoprotein; RANTES - regulated upon activation, 
normal T cells expressed and secreted; MIP - macrophage inflammatory protein) 
 
 
 
It is generally accepted that platelets play a key role in acute coronary events such as 
myocardial infarction, but there is some evidence that they are involved in initiation 
plaque formation. It has been proposed that platelets accelerate lesion formation by 
increasing monocyte migration to the intima (Dole et al., 2005, Schulz et al., 2007, 
Massberg et al., 2002). This has been corroborated by animal studies where platelet 
adhesion is impaired (Methia et al., 2001). Also, platelets bind, take up and transport 
oxLDL, resulting in activation of the platelet. These lipid laden activated platelets are 
then phagocytosed by monocytes resulting in foam cell formation (De Meyer et al., 
2002). 
 
 
2.4. Accelerated Atherosclerosis 
It is widely accepted that atherosclerosis is an inflammatory state. There are many pro-
inflammatory and inflammatory molecules involved in the development and progression 
of lesions and there is a link between bacterial infection and the severity of 
atherosclerosis and chronic vascular disease (Epstein et al., 2000, Zhu et al., 2000). Also, 
many inflammatory diseases are associated with accelerated atherosclerosis including 
diabetes, systematic lupus erythematosus (SLE), rheumatoid arthritis (RA), osteoarthritis 
(OA), human immunodeficiency virus (HIV), chronic obstructive pulmonary disease 
(COPD), and vasculitis including Wegener‟s granulomatosis (de Leeuw et al., 2005, 
Roman et al., 2003, Hannawi et al., 2007, Tabib et al., 2000, Pope et al., 2004, Jarvisalo 
et al., 2001, Conaghan et al., 2005). There are, however, some inflammatory conditions 
that have not been documented as being linked with accelerated rates of lesion formation 
including pelvic inflammatory disease, coeliac disease, and asthma. This suggests that 
there may be other factors that account for or contribute to accelerated atherosclerosis.  
 
Accelerated atherosclerosis is associated with the above inflammatory disease but also 
with the following conditions also result in increased lesion formation: antiphospholid 
syndrome, radiation, smoking, obesity and dialysis (Friedlander and Freymiller, 2003, 
Hoving et al., 2008, Pawlak et al., 2004, Lakka et al., 2001, Bolinder et al., 1997). It may 
be that these cause some sort of inflammatory response. Smoking, for instance, has been 
reported to cause inflammation as well as oxidative stress (Agarwal, 2005). It is possible 
however, that because some inflammatory diseases are not associated with accelerated 
lesion formation and that there are other non-inflammatory conditions associated with 
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accelerated atherosclerosis that other factors are involved. One theory that could link all 
these risk factors is activated platelets.  
 
Activated platelets have been associated with RA (Endresen, 1989), diabetes (Tschoepe 
et al., 1991, Manduteanu et al., 1992, Shaw et al., 1967), COPD, SLE (Nagahama et al., 
2001), smoking (Nair et al., 2001), antiphospholipid syndrome (Emmi et al., 1997), HIV 
(Holme et al., 1998), radiation (Gresner et al., 2005), obesity (Corsonello et al., 2003), 
dialysis (Tschoepe et al., 1991), Wegener‟s granulomatosis (de Leeuw et al., 2005), and 
chronic kidney disease (Stasko et al., 2007). These studies used various markers of 
platelet activation including, soluble P-selectin (sP-selectin), PMPs, Annexin V, cell 
adhesion molecules and cytokines.  
 
A number of cell adhesion molecules have been reported to be up-regulated in diabetics 
including P-selectin and GPIIb/IIIa (Tschoepe et al., 1995, McDonagh et al., 2003). 
Increase in these adhesion molecules suggest that platelets become activated in diabetics. 
This is supported by reports of increased levels of  platelet thromboxane (Lagarde et al., 
1980).  Evidence for an increase in plasma levels of granule proteins are, however, not as 
clear cut. The levels of β-thromboglobulin, for instance, have been shown to be increased 
in diabetics but, an increase was also reported in some non-diabetics (Burrows et al., 
1978, Campbell et al., 1977). It is possible that an increase in β- thromboglobulin is 
associated with some predisposing conditions, such as obesity, and therefore many be 
present prior to diagnosis of diabetes. 
 
 
2.5. Diabetes 
Diabetes mellitus is a chronic metabolic disease that affects large numbers of people in 
the Western world and nearly every ethnic group. Evidence suggests that the disease has 
been around since ancient times, with symptoms detailed by the Egyptians and Romans 
(Patlak, 2002). In 2004 Wild and colleagues estimated that there were 171 million people 
over the age of 20 worldwide diagnosed as suffering from diabetes (Wild et al., 2004). 
This figure is unlikely to represent the total number of people with diabetes because this 
disease is inherently difficult to diagnose. Estimations, based on the current rate of 
increase, suggest that 344 million people globally will have diabetes by 2030 (Wild et 
al., 2004). As this figure is dependent on the prevalence of obesity remaining the same, it 
is probable that the actual number will be much higher due to the general increase in 
sedentary lifestyle and “fast food” culture. The already increased demands that diabetes 
has created on the NHS has been highlighted (Fitzsimons et al., 2002). These demands 
are on top of the increased expectations of patients for treatments that would previously 
only been available privately, and the increase in number of people prepared to seek 
compensation. Studies have suggested that diabetics cost the NHS more than twice as 
much as non-diabetics, with this cost increasing to 2 – 5 times as much when the cost of 
treating diabetic complications were included (Morsanutto et al., 2006). 
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Diabetes mellitus is a group of metabolic diseases that include type 1 diabetes mellitus 
and type 2 diabetes mellitus. They are both characterised by chronic hyperglycaemia 
(fasting glucose levels of greater than 7.0 mmol/L) resulting from reduced insulin 
secretion and/or sensitivity, but they differ in terms of clinical characteristics (such as 
age, weight and rate of onset), pathophysiology (for instance genetic factors), and 
epidemiology (WHO, 2006). 
 
Type 1 accounts for approximately 10 % of patients with diabetes. This disease is 
characterised by autoimmune destruction of pancreatic insulin secreting β-cells. It is 
unknown what causes leukocytes to attack the β-cells, although genetic influences have 
been suggested and there is some evidence to suggest that environmental factors may be 
involved (Group, 2007, Gusdon et al., 2006). This destruction of β-cells causes decreased 
insulin secretion, which results in the inability of glucose to cross cell membranes and 
therefore poor regulation of blood glucose levels.  
 
The pathogenesis of type 2 diabetes is also not fully understood at present, even though 
its high prevalence has led to a great deal of research in this area. It is thought that a 
number of factors play a role, such as dysregulated hepatic glucose production, impaired 
glucose tolerance, insulin resistance, and a slow decrease in pancreatic β-cell function 
(Basu et al., 2005, Festa et al., 2006). Many of these factors have been linked to obesity, 
a family history of Type 2 or gestational diabetes (which, although it is transient, it is 
similar to Type 2 except that the onset is linked to pregnancy), a sedentary lifestyle, and 
increasing longevity. In a small number of patients a genetic predisposition has been 
attributed, but poor lifestyle choices and other environmental factors are the primary 
factors in the development and progression of Type 2. 
 
People with diabetes are more likely to suffer from cardiovascular disease than non-
diabetics. It is the major cause of morbidity and mortality in patients with diabetes (Dale 
et al., 2007, Stamler et al., 1993, DCCT, 2005). A large proportion of premature deaths 
in diabetics are due to cardiovascular disease. There is a greater prevalence of 
cardiovascular disease in males than females. This gender gap, however, is reduced or 
eliminated when that female also has diabetes (Dale et al., 2007, Laing et al., 1999). 
Cardiovascular disease, therefore, is a serious complication of diabetes.  
    
Diabetic vascular disease can be both micro- and macrovascular. Microvascular disease 
is associated with retinopathy, neuropathy, and nephropathy. These are thought to result 
from metabolic injury to the endothelium resulting from hyperglycaemia, changes in 
vascular reactive vasodilation, advanced glycation endproduct (AGE) formation, and 
endothelial injury (UKPDS, 1998, Kawano et al., 1999, Negrean et al., 2007). 
Macrovascular complications, such as atherosclerosis, do not show this clear link with 
hyperglycaemia, and therefore the underlying mechanisms are still being debated. 
 
Diabetic accelerated atherosclerosis is thought to be due to hyperglycaemia because 
patients with poor glycaemic control are much more likely to suffer from cardiovascular 
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events associated with atherosclerosis (UKPDS, 1998). The processes involved in 
hyperglycaemia-induced atherosclerosis are not known. One theory suggests that AGEs 
alter endothelial cell function by causing upregulation and expression of cell adhesion 
molecules, pro-coagulatory and pro-inflammatory molecules, and transcription factors. 
This results in increased leukocyte and platelet adhesion to endothelium, and monocyte 
migration into the vessel wall. They are therefore likely to increase the formation of 
atheromas (Abordo et al., 1996, Kirstein et al., 1992, Schmidt et al., 1995).   
 
AGEs are a heterogeneous group of compounds formed by autoxidation of Amadori 
products; a process known as the Maillard reaction. Amadori product is 1-amino-1-
deoxyketose. This compound is produced when the carbonyl group of a reducing sugar 
attaches to the amino group of a protein. AGEs can also be formed from auto-oxidation 
of reducing sugars, by glycation intermediates, and by glycation of lipids. Once they 
have been formed, AGEs are almost completely irreversible. 
  
The effect of AGEs can be three fold. Firstly, intercellular AGEs formation results in 
highly reactive intermediates that can directly alter protein function in cells that do not 
need insulin for glucose transport (such as endothelial cells). Secondly, extracellular 
AGEs can change matrix and cell interactions causing differences in permeability and 
tissue rigidity. And thirdly, AGE-receptor interactions alter gene expression by NF-kB 
activation and by the production of ROS (Otero et al., 2001, Quehenberger et al., 2000, 
Schmidt et al., 1995).  
 
AGEs are known to bind to cell surface receptors, such as scavenger receptors and 
RAGE (receptor for AGE). Binding of AGEs to RAGE, expressed on endothelial cells, 
results in activation of these cells and therefore increases endothelial permeability. This 
increase in permeability is thought to be the result of NF-kB activation. The activation of 
this transcription factor results in increased gene expression of cytokines (such as IL6 
and TNF-alpha), growth factors, and cell adhesion molcules (such as VCAM-1) (Morigi 
et al., 1998, Valencia et al., 2004).  
 
AGEs also bind to monocytes, macrophages, and smooth muscle cells. This induces the 
production of inflammatory cytokines, such as interleukin-1 (IL-1), interleukin-8 (IL-8), 
and tumour necrosis factor alpha (TNFα) (Pertynska-Marczewska et al., 2004). These 
cytokines are known to increase monocyte adhesion to endothelial cells, stimulate the 
proliferation of macrophages and smooth muscle cells.  
 
Studies have been carried out to determine whether poor glycaemic control is the main 
cause of accelerated atherosclerosis (DCCT, 1993, Malmberg et al., 2005, Malmberg et 
al., 1999, UKPDS, 1998). Epidemiology studies indicate that there may be a correlation 
between glycaemic control and atherosclerosis. The Diabetes Mellitus Insulin Infusion in 
Acute Myocardial Infarction (DIGAMI) trial showed a decrease in mortality following 
aggressive treatment and control of hyperglycaemia but the DIGAMI 2 trial, which 
looked at different treatments, did not support the previous findings (although it did 
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indicate that glycaemic control was a marker of mortality following myocardial 
infarction) (Malmberg et al., 1999, Malmberg et al., 2005). Indeed, autopsy findings in 
people between the ages of 18 and 34 with poor glycaemic control indicated that they 
had an increased prevalence of more advanced plaques (Ledru et al., 2001). The 
DIGAMI, as well as the Diabetes Control and Complications (DCCT) Trial, indicated 
that there may be other factors, not just hyperglycaemia, involved in accelerated 
atherosclerosis (Malmberg et al., 1999, UKPDS, 1998). 
 
Although atherosclerosis is believed to be an inflammatory disease, at present what 
causes this inflammation, or indeed whether this response is a key factor in the 
progression of accelerated atherosclerosis in unclear. Animal studies have indicated that 
endothelial cell injury in conjunction with hyperglycaemia results in lesion formation 
(Nishida et al., 1997, Ribau et al., 1998). Cell injury will result in an immune response 
and therefore it is possible that platelet adhesion will occur via exposed upregulated cell 
adhesion molecules, either directly to these adhesion molecules or via adherent 
monocytes. 
 
Diabetic patients have impaired platelet function, as mentioned previously and therefore 
this may result in their adhesion to the endothelium. Diabetic platelets have also been 
shown to be glycated (Cohen et al., 1989). Glycation of platelet membrane proteins alters 
their function resulting in decreased fluidity (Watala et al., 1996). With both an increase 
in endothelial and platelet activation it is possible that these factors result in accelerated 
lesion formation in diabetics.   
 
 
2.6. Overview of the Research Proposal 
There is still no clear understanding of what initiates accelerated atherosclerosis in 
diabetics. Over the last 10 years, however, Gawaz and colleagues have published a 
number of papers suggesting that platelet adhesion may initiate lesion formation (Gawaz, 
2006, Gawaz, 2004, Gawaz et al., 1998, Gawaz et al., 1997, Lindemann et al., 2007a, 
Siegel-Axel et al., 2008). Their rationale has been that blocking platelet adhesion results 
in reduced lesion formation and that platelets, unlike leukocytes express adhesion 
molecules that allow them to phagocytose modified lipids.   
 
It is known that diabetes causes both endothelial and platelet dysfunction, so it is 
plausible that they could account for the accelerated rate seen in this disease.  The 
mechanisms that result in dysfunction are, however, not clearly determined and whether 
platelets are a requirement for lesion formation to occur, or just play a minor role, needs 
further investigation. Therefore, this research explores the hypothesis that the adhesion 
of activated platelets to the endothelium is required for atherosclerotic lesion formation; 
with specific reference to accelerated atherosclerosis seen in diabetics. 
 
In doing so, further understanding of the processes involved in diabetic associated 
accelerated atherogenesis. It is hoped that greater understanding of the processes 
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involved in accelerated lesion formation will allow for further targeted research to allow 
for treatments to reduce foam cell deposition. If platelets are found to be involved in the 
atherogenesis then further research could be done to investigate how they are involved, 
for instance, what kind of cell adhesion molecules are up-regulated, and drugs that 
specifically target this could be used in primary prevention as well as following acute 
manifestation of this condition, such as myocardial infarction. This would allow for 
extension in the length and quality of diabetic patient life, as well as significantly 
reducing the cost burden to the NHS of their treatment and care.  
 
To do this, the initial aim of this research was to investigate whether platelets adhered 
directly to the endothelium in the early stages of atherosclerosis in diabetic-like 
conditions. These conditions were to be induced by treating cells with a combination of 
high concentrations of glucose and AGEs. Further investigations were to explore reports 
that platelet adhesion, in the form of platelet-leukocyte complexes, increase lesion 
formation and, if this is the case, whether this could partly be the cause of accelerated 
lesion formation seen in diabetics. In addition to the platelet studies, research into the 
role of endothelial dysfunction was carried out to investigate whether the conditions 
experienced in diabetics could exacerbate platelet adhesion via cell adhesion molecule, 
cytokine / chemokine expression, advanced glycated end-products and reactive oxygen 
production. To determine these, a combination of literature review, cell culture, and 
studies with isolated tissue were done. By doing this, it was proposed to determine 
whether endothelial dysfunction was induced by diabetic condition, whether this could 
allow for platelet adhesion, and whether this was the cause of accelerated atherosclerosis 
in diabetics.  
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3. Platelets Adhere to the Endothelium in Atherogenesis 
3.1. Introduction 
To determine whether adhesion of activated platelets to the endothelium is required 
for foam cell formation, it is first necessary to determine whether platelets can adhere 
to the endothelium in conditions that are known to result in lesion formation. If 
platelets do not adhere to the endothelium, either directly or indirectly, it is likely that, 
at best, they would only have a limited role in lesion formation.  
 
Although Rotikansky suggested that blood component (platelet) deposition on the 
vessel wall caused lesion formation, until relatively recently it was thought that the 
endothelium was an inanimate monolayer that only provided a smooth surface that 
would deter thrombosis (Becker and Murphy, 1969, Jones, 1887, O'Nejll J, 1947, 
Samuels and Webster, 1952, Warren, 1963). It was believed that platelets adhered to 
the sub-endothelium only. Drs Sawyer and Srinivasan (1972) suggested that the 
endothelium acted as an anti-platelet „policeman‟ by maintaining a negative 
electrochemical surface that repelled platelets. The underlying layers, however, were 
known to be positively charged and therefore would attract platelets. Endothelial 
denudation results in exposure of collagen and von Willebrand Factor (VWF), both of 
which were known to allow platelet adhesion. 
 
However, as early as the 1960s there was some evidence to suggest that platelets 
might also adhere to the endothelium. Poole and colleagues (1963) found, by chance, 
adherent platelets in rabbits with very early thrombosis. Their studies of the small 
vessel in a rabbit ear chamber using electron microscopy indicated that platelets 
adhered to endothelial cells of damaged vessels. They reported that the platelets 
initially retained their discoid shape but following aggregation they became elongated 
and lost their granular appearance, suggesting activation and granule release. 
Leukocytes then adhered to the thrombus. 
 
For thrombus formation to occur it would suggest that either the platelets were 
activated, the endothelium was activated / damaged, or that both were activated.  
Indeed, there was evidence to suggest any one of these possibilities could have 
resulted in platelet adhesion. Thrombin activated platelets have been reported to 
adhere to a monolayer of unactivated, undamaged, human endothelial cells 
(Czervionke et al. 1978). Cr-labelled platelets were found to adhere to cultured human 
umbilical cells (HUVECs) in the presence of thrombin. Adhesion increased with 
concentration but was significantly more when the endothelial cells were treated with 
aspirin. Treatment with relatively high concentrations of aspirin was likely to result in 
endothelial apoptosis but may also cause cell adhesion molecule up-regulation (Chen 
et al., 2007a, Yoshida et al., 1993). Endothelial activation, as a result of a reduction in 
PGI2, following incubation with aspirin, is likely to account for this increase in 
platelet adhesion. 
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Non-activated platelets have also been reported to adhere to injured endothelium in 
male albino rats, cultured bovine cells, and pig specimens (Cotran and Majno, 1964, 
Booyse et al., 1975, Booyse et al., 1977). Booyse and colleagues suggested that 
activation of the endothelium by adrenalin, serotonin, sodium chloride, trypsin, heat 
treatment, and scraping all resulted in platelet adhesion (Booyse et al., 1975). This 
adhesion was reduced by treatment with platelet inhibitors (prostaglandin (PGE1) and 
low concentrations of aspirin). 
 
It wasn‟t until the 1980s, however, that platelet-endothelial interactions were thought 
to have a significant physiological role. This was mainly because there had not been 
any reports of platelet-endothelial interaction resulting in platelet activation and 
release of granule content. Granule release had only been reported as a result of 
platelet interactions with collagen or VWF present in the sub-endothelium (Mustard et 
al. 1977). Without release of granule components it was believed that platelet 
adhesion could have no significant role in dysfunctional states, including 
atherosclerosis. 
 
Since then, it has become well established that platelets adhere to the sub-
endothelium, the extracellular matrix, and to the endothelium, as seen in Table 4. 
Research has continued to investigate the finer points of platelet interaction with the 
vasculature, especially in association with disease states. From this research it was 
found that atherosclerotic lesion formation normally develops in areas where the 
endothelium is intact (Katsuda et al., 1992). 
 
In autopsy studies of 15-35 year old humans, the majority of fixed vessel segments 
that contained either foam cells or fatty streaks had a thin layer of endothelial cells 
(Katsuda et al., 1992). This was determined by light microscope analysis. 
Immunocytochemistry studies, using ulex lectin and anti-von Willebrand factor 
antibodies confirmed that the endothelium was intact in all but a few cases.  
 
Considerable research has, therefore, been carried out to investigate what types of 
adhesion molecules, platelets and endothelial cells express to allow them to interact. 
There are a number of cell adhesion molecules, that are either constitutively expressed 
or can be expressed upon activation, in both platelets and endothelial cells. Platelets 
and endothelial cells are known to express different types of adhesion molecules, 
including selectins, integrins, and members of the immunoglobulin family (see Table 
5 and 6 for details).  
 
Both endothelial cells and platelets also express a number of associated adhesion 
ligands that are known to be involved in cell-to-cell interactions. Most notable are a 
number of glycoproteins, such as fibrinogen, fibronectin, and VWF. These ligands are 
expressed and adhere to cell adhesion molecules. Like the cell adhesion molecules 
discussed previously, their expression can be increased upon activation.  
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From this research, it is clear to see that there are a number of adhesion molecules and 
ligands that play a significant role in platelet adhesion. These include P-selectin, 
VWF, VCAM-1, and GPIIb/IIIa. (The theoretical interactions are shown in Figure 3.) 
These were therefore highlighted as key to evaluating interaction in diabetic 
conditions to investigate whether platelet-endothelial interactions were required for 
lesion formation. 
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Table 4: Overview of Research Reporting Platelet-Endothelial Interactions  
 
Cell 
line/Animal 
Technique Details Reference 
HUVECs & 
EAhy 926 
Light microscope 
& flow cytometry  
ADP activated platelets adhere to 
ECs 
Author‟s own 
observations 
BAECs Plate reader under 
flow conditions 
CRP-treated platelets adhered to 
ECs 
(Yaron G et al., 2006) 
HUVECs & 
SMCs 
In situ fluorescent 
microscopy 
Activated platelets adhered to 
ECs under flow conditions. 
Increased binding upon activation 
of both ECs & platelets 
(Tull et al., 2006) 
HUVECs SEM Platelet adhesion was dependent 
on glycocalyx levels 
(Chen et al., 2007b) 
ApoE 
-/-
 mouse Video fluorescent 
microscopy 
Platelet adhesion to the intact 
endothelium 
(Massberg et al., 2002) 
HUVECs Fluorescent plate 
reader 
Platelets adhered to VEGF 
activated ECs 
(Verheul et al., 2000) 
HUVECs Flow cytometry Platelets adhered to thrombin 
activated ECs 
(Bombeli et al., 1998) 
ECV-304 Flow cytometry Activated platelets adhered to 
ECs. Increased adhesion when the 
ECs were also activated 
(Gawaz et al., 1997) 
VECs Radiolabelled 
platelets & SEM  
Diabetic platelets adhered to ECs (Manduteanu et al., 1992) 
NZW Radioactive 
platelets & 
scintillation 
counter 
Platelet adhesion to the 
endothelium and to the 
subendothelium 
(Tloti et al., 1991) 
Rabbit 
thoracic aorta 
Weight gain of 
the tissue 
Platelet adhesion  (Korbut et al., 1990) 
Wistar rats 
and guinea 
pigs 
SEM of tissue Platelet adhesion (Maes et al., 1985) 
BEACs SEM & TEM 
with thrombin 
activated platelets 
Platelet adhesion (Trusal et al., 1984) 
Pig artery Microscope 
studies 
Platelet adhesion was inhibited by 
aspirin or dipyridamole treatment 
(Booyse et al., 1977, 
Silver et al., 1984) 
HUVECs Radioactive 
platelets 
Thrombin activated platelets 
adhered to ECs 
(Czervionke et al., 1978) 
BAECs Radioactive 
platelets 
Platelet adhesion to ECs (Booyse et al., 1975) 
HAECs Microscope 
studies 
Platelets & ECs form intercellular 
attachments 
(Rafelson et al., 1973) 
Rabbit artery Microscope 
studies 
Platelet adhesion (Poole et al., 1963) 
Rat artery Microscope 
studies 
Platelet adhesion to gaps ECs  (Cotran and Majno, 
1964) 
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(Key for Table 4: HUVECs - human umbilical vein endothelial cells; ADP - adenosine diphosphate; 
BAECs - bovine aorta endothelial cells; CRP - C-reactive protein; SMCs - smooth muscle cells; ECs - 
endothelial cells; SEM - scanning electron microscope; ApoE 
-/-
 - apolipoprotein E deficient; VEGF - 
vascular endothelial growth factor; VECs - vascular endothelial cells; BAECs - bovine aortic 
endothelial cells; TEM - transmission electron microscopy; ECV-304 - Japanese spontaneously 
transformed cell line derived from HUVECs; NZW - New Zealand white mice; HAECs - human aortic 
artery cells) 
 
(Key for Table 5: VWF - Von Willebrand factor; PSGL -  P-selectin glycoprotein ligand; GP - 
glycoprotein; Fb - fibrinogen; Fn - fibronectin; Vn - vitronectin; TSP - thrombospondin; ADAM - a 
disintegrin and metalloproteinase; ICAM - intercellular adhesion molecule; LFA - lymphocyte 
function-associated antigen; PECAM - platelet-endothelial cell adhesion molecule; JAM - junctional 
adhesion molecule; VLA - very-late antigen) 
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Table 5: Expression of Cell Adhesion Molecules in Platelets  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Name Expression Receptor for Reference 
P-selectin 
(CD62P) 
On activation  PSGL-1, CD24 (Moore et al., 1995, Stenberg et 
al., 1985) 
PSGL-1 
(CD162) 
Constitutively; 
increased upon 
activation 
P-selectin (Moore et al., 1995, Hsu-Lin et 
al., 1984, Frenette et al., 2000) 
GP IIb/IIIa 
(CD41/61, 
αIIbβ3) 
Constitutively; 
increased upon 
activation 
Fb, Fn, VWF, Vn, 
TSP, ADAM15 
(Bombeli et al., 1998, Langer et 
al., 2005, Nachman and Leung, 
1982)  
VLA-4 
(CD49d/29, 
α4β1) 
On activation VCAM-1, 
collagen, laminin 
& Fn 
(Takada et al., 1987, Elices et 
al., 1990)  
ICAM-2 
(CD102) 
Constitutively LFA-1 (αLβ2), 
Mac-1 (αMβ2) 
(Diacovo et al., 1996) 
PECAM-1 
(CD31) 
Constitutively PECAM-1 &  
αvβ3  
(Albelda et al., 1991, Dhanjal et 
al., 2007)  
JAM-A (F11R) Constitutively JAM-A  (Langer et al., 2005)  
JAM-C Constitutively JAM-B, JAM-C,  
Mac-1 (αMβ2) & 
αVβ2 
 (Santoso et al., 2002) 
GPIb (CD42a/b) Constitutively Thrombin, VWF, 
P-selectin, Mac-1, 
GPIb & TSP 
(Nachman et al., 1979, 
Clemetson, 1983, Jurk et al., 
2003, Romo et al., 1999, 
Takamatsu et al., 1986, Wang et 
al., 2005)  
GP VI Constitutively, 
increased upon 
activation 
Collagen  (Clemetson et al., 1982) 
GPIV (CD36) On activation Collagen & TSP (Asch et al., 1987, Tandon et al., 
1989)  
GPV (CD42d)  VWF, thrombin (Calverley et al., 1995, Dong et 
al., 1997)  
αvβ3 (CD51/61) On activation Osteopontin, Fb, 
Fn, Vn, TSP, 
VWF, LI & 
PECAM-1 
(Bennett et al., 1997, Columbo 
and Bochner, 2001, Gawaz, 
2004)  
GPIa/IIa (α2β1, 
CD49b/29, 
VLA-2) 
Constitutively Collagen and 
laminin 
 (Elices and Hemler, 1989, 
Saelman et al., 1994)  
VLA-5 
(CD49e/29, 
α5β1) 
Constitutively CD40 ligand, Fb, 
Fn, & LI 
(Hemler et al., 1988, 
Podolnikova et al., 2003, 
Ruppert et al., 1995)  
VLA-6 (CD49f, 
α6β4) 
 Laminin (Hemler et al., 1988, 
Sonnenberg et al., 1988)  
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Table 6: Expression of Cell Adhesion Molecules on Endothelial Cells  
 
Name Expression Receptor for Reference 
P-Selectin 
(CD62P) 
On activation PSGL-1, CD24 (Chen et al., 2007b, Johnston et 
al., 1989) 
E-Selectin 
(CD62E) 
On activation 
 
PSGL-1, ESL-
1, L-Selectin 
(Wild et al., 2001, Bevilacqua et 
al., 1987) 
PSGL-1 (CD162) Constitutively; 
increased on 
activation 
P-Selectin (Chen et al., 2007b, da Costa 
Martins et al., 2007) 
GPIa/IIa 
(CD49b/29, α2β1, 
VLA-2) 
Constitutively Collagen (Zutter and Santoro, 1990) 
VLA-4 
(CD49d/29, α4β1) 
On activation VCAM-1, Fn (Elices et al., 1990, Garmy-Susini 
et al., 2005) 
αvβ5 (CD51) On activation Collagen, Fn (Pedchenko et al., 2004, Walton 
et al., 2000) 
ICAM-1 (CD54) Constitutively  Fn, LFA-1, 
Mac-1, αXβ2 
(Bombeli et al., 1998, Abbassi et 
al., 1993, Steinhoff et al., 1993, 
D'Souza et al., 1996, Dustin and 
Springer, 1988)  
ICAM-2 (CD102) Constitutively Fb, LFA-1, 
Mac-1 
(de Fougerolles et al., 1991) 
VCAM-1 
(CD106) 
Constitutively VLA-4, α4β7, 
αDβ3 
(Van der Vieren et al., 1999, 
Dobrina et al., 1991, Newham et 
al., 1997) 
PECAM-1 
(CD31) 
Constitutively PECAM-1, 
αvβ3 
(Albelda et al., 1990, Sun et al., 
1996, Piali et al., 1995) 
JAM-A Constitutively JAM-A, LFA-1 (Aurrand-Lions et al., 2001, 
Ozaki et al., 1999)  
JAM-B Constitutively JAM-B, JAM-
C, VLA-4 
(Arrate et al., 2001, Aurrand-
Lions et al., 2001, Cunningham 
et al., 2000, Cunningham et al., 
2002, Ludwig et al., 2005) 
LOX-1 On activation Include 
modified 
lipoproteins & 
activated 
platelets 
(Moriwaki et al., 1998) 
GPIb (CD42) On activation VWF, Mac-1, 
TSP, thrombin, 
GPIb, P-
Selectin 
(Bombeli et al., 1998, Clemetson, 
1983, Jurk et al., 2003, 
Takamatsu et al., 1986, Wang et 
al., 2005, Romo et al., 1999, 
Jones et al., 1981)  
αVβ3 (CD36) On activation Osteopontin, 
Fn, Fb, Vn, 
TSP, VWF, 
PECAM-1 
(Tandon et al., 1989, Asch et al., 
1987) 
GPIV (CD36) On activation Collagen, TSP (Asch et al., 1987, Tandon et al., 
1989) 
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Table 6 Continued: Expression of Cell Adhesion Molecules on Endothelial Cells  
 
Name Expression Receptor for Reference 
VLA-6 
(CD49f/29, α6β1) 
Constitutively Laminin (Leu et al., 2002) 
α6β4 (CD49f/104) Constitutively Laminin (Sepp et al., 1995, Sonnenberg et al., 
1988) 
VLA-5 
(CD49e/29, α5β1) 
Constitutively; 
increased on 
activation 
Fb & fn (Suehiro et al., 1997, Collo and 
Pepper, 1999) 
CD147 On activation MMP-1 (Seulberger et al., 1992, Guo et al., 
2000) 
N-cadherin On activation N-cadherin (Salomon et al., 1992) 
VE-cadherin 
(CD144) 
Constitutively VE-cadherin (Lampugnani et al., 1995) 
MUC18 (CD146) On activation Not known (Bardin et al., 2001, Sers et al., 1994) 
Syndecan-1 
(CD138) 
On activation Laminin (Hoffman et al., 1998, Kainulainen et 
al., 1996)  
CD39 Constitutively CD39 (Kansas et al., 1991, Wang and 
Guidotti, 1998) 
PCLP-1 Constitutively L-selectin (Sassetti et al., 1998, Kershaw et al., 
1997) 
 
 
(Key for Table 6: PSGL-1 – P-Selectin glycoprotein ligand; ESL – E-Selectin ligand; VLA – Very late 
antigen; VCAM – vascular cell adhesion molecule; Fn – Fibronectin, ICAM – Intracellular adhesion 
molecule;  LFA - lymphocyte function-associated antigen; PECAM – Platelet-endothelial cell adhesion 
molecule, JAM – junction adhesion molecule; LOX - Lectin-like oxidized low-density lipoprotein 
receptor; Fb – Fibrinogen, TSP – Thrombospondin, VWF, Von Willibrand factor, MMP - matrix 
metalloproteinases; N-cadherin - neural cadherin; VE-cadherin - vascular endothelial cadherin; PCLP - 
podocalyxin-like protein) 
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Figure 3: Theoretical Representation of Interactions between Platelet and Endothelial Cells. 
 
 
 
 
 
 
 
 
 
 
                                       JAM-A                            αvβ3                         VLA-4                      PSGL-1 
                           JAM-B               ICAM-1     VLA-5                      Fibinogen      
                  JAM-C                              ICAM-2                   GPIIb/IIIa                 Fribronectin   
                  E-Selectin                         VCAM-1                   GPIb                        Vitronectin       
                  P-Selectin                         PECAM-1                  GPV          VWF 
                 
                                                        Platelet                                                       Endothelial cell 
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3.2. My Proposed Research 
There has been considerable research into platelet activation but this has failed to 
establish whether platelets are involved in the initial stages of atherosclerosis. In order 
to establish this, I proposed to investigate whether diabetic conditions resulted in 
platelet adhesion to cultured endothelial cells. Initially, studies were to involve 
mimicking diabetic conditions by treating cultured monolayers of commercial 
endothelial cells with either high concentrations of glucose or AGEs, or a 
combination of both. Adhesion was to be determined by fluorescently labelling the 
platelets and using a fluorescent microscope or a flow cytometer. Platelet adhesion 
would then be compared against control conditions to determine whether any increase 
in adhesion was statistically significant. By doing so, it was hoped that this would 
give an insight into whether platelet adhesion could be involved in accelerated lesion 
formation in diabetics. 
 
There has already been research published that has shown diabetes causes changes to 
platelets, including activation and increased adhesion to the endothelium 
(Manduteanu et al., 1992, Nievelstein et al., 1991, Wautier et al., 1981). Obviously, 
changes to platelets are only part of the possible effect of diabetes on interactions 
between platelets and the endothelium. There appears to be, however, no research into 
the effects of non-activated (or non-diabetic) platelet adhesion to diabetic 
endothelium. Therefore, this leaves a gap in knowledge that may hold the key into 
understanding the processes involved. 
 
High glucose and AGE concentrations were used for these studies because diabetes is 
associated with increased levels of blood glucose and glycation of proteins (both of 
which have been reported to increase leukocyte adhesion by increasing cell adhesion 
molecule expression (Morigi et al., 1998, Altannavch et al., 2004)). It is therefore 
possible that this would result in increased platelet adhesion, although there appears to 
be no published research investigating in vitro platelet-endothelial interactions under 
diabetic conditions. 
 
Research using AGEs, however, appear to give conflicting results (Otero et al., 2001, 
Morigi et al., 1998, Gilcrease and Hoover, 1991, Altannavch et al., 2004). Various 
studies have reported that AGEs increase leukocyte adhesion, Glicrease & Hoover, 
however, found that the apparent increase in monocyte adhesion seen in vitro was not 
directly related to the increase in AGE formation but as a result of increased NaCl 
concentrations. Another paper found no significant increase in monocyte adhesion 
under static conditions (Kim et al., 1994). Therefore, as part of this research I 
proposed to look at whether the type of protein used for glycation purposes affected 
platelet adhesion. Most AGE studies have restricted their research to using albumin 
(generally bovine serum albumin). As such, by comparing platelet adhesion following 
endothelial incubation with both albumin and haemoglobin I hope to get a greater 
understanding.  
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Further to these studies, I wanted to establish whether the length of time the protein 
was exposed to high concentrations of glucose, and therefore the extent of glycation, 
could also have an impact on platelet adhesion. To enable this, platelet adhesion 
studies were done with 2 – 12 weeks (in 2 week intervals) glycated proteins. 
 
 
3.2.1. Peptide Synthesis of Part of Albumin 
To complement this study, a sequence of albumin that did not contain the 
majority of known drug binding sites (between residues 124 and 585), was 
chosen for synthesis and then glycation (Fehske et al., 1981). It was hoped that by 
omitting the majority of known drug binding sites it would reduce the likelihood 
of unspecific binding. The sequence, however, contained amino acids that were 
known to be involved in the glycation process, such as arginine, histidine and 
lysine. It was also taken into consideration that lysine and glutamate catalyse the 
glycation of nearby lysines (Johansen et al., 2006, Coussons et al., 1997).  
 
Synthesis of the selected sequence was carried out using an N-α-Fmoc strategy, 
based on the Merrifield Technique (Merrifield, 1969). Rink amide resin was used 
to build a 12 amino acid sequence (His-Arg-Phe-Lys-Asp-Leu-Gly-Glu-Glu-Asn-
Phe-Lys). Following synthesis, the peptide was purified using High Performance 
Chromatography (HPLC) prior to glycation with D-glucose.  
 
 
3.2.2. Glycation 
The peptide, haemoglobin and bovine serum album were glycated with D-glucose 
using a slight adaption to the technique detailed by Morigi and colleagues (Morigi 
et al., 1998). Various purities of albumin were glycated. These included greater 
than 96%, 98% and 99%. The rate of glycation, for both the peptide and the 
proteins, were recorded, at 2 week intervals, using MALDI-TOF (Matrix assisted 
laser desorption ionization - time of flight) and fluorescent spectrophotometry. 
Finally, any unincorporated glucose was removed from the glycated peptide and 
proteins using dialysis before quantifying the concentration using a protein assay 
kit. 
 
 
3.2.3. Platelet Adhesion Assay – Flow Cytometry 
The various types of glycated proteins / peptide were added to the medium of the 
cultured endothelial cells, with or without glucose, to determine whether they 
resulted in an increase in platelet adhesion. Flow cytometry was chosen for 
detection of endothelial bound platelets because it allows for investigating the 
interaction of these cells without the possibility that the extracellular matrix or 
other components resulted in platelet interactions.  
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A method published by Bombeli and colleagues was chosen for these studies 
(Bombeli et al., 1998). They used flow cytometry to investigate the cell adhesion 
molecules involved in platelet-endothelial interactions and therefore the method 
was believed to be ideal for platelet adhesion studies.  Slight variations were 
made because it was found that their use of vigorous pipetting did not 
successfully detach endothelial cells from the culture flask. The use of a cell 
scraper created a lot of cellular debris and therefore trypsin detachment was 
preferred. (This was also the standard method recommended by the cell supplier.) 
The procedure also used 80% ethanol to fix the endothelial cells. This resulted in 
fragmentation. As such, various other methods were investigated, including 
concentrations of ethanol or methanol/acetone but it was found that a flow 
cytometry cell fix solution (saline solution containing 4% w/v paraformaldehyde) 
resulted in the minimum amount of fragmentation and cellular debris. 
 
To visualize platelet-endothelial conjugates, endothelial cells were stained using 
propidium iodide (PI), an intercalating agent that stains DNA. This resulted in the 
endothelial cells emitting in the 562-588 nm spectrum, and therefore they were 
detected by scatter from the FL2 filter. Platelets were stained with acetomethoxy 
calcein. Calcein is a fluorescent dye, emitting at 515nm, which binds to 
intracellular calcium in such a way that there is no transfer between cells. Light 
scatter from the FL1 filter allowed for platelet detection and platelet-endothelial 
complexes were both FL1 and FL2 positive. 
 
There are a number of ways to investigate cell-cell adhesion, including flow 
cytometry, immunocytochemistry, and microscope studies. Flow cytometry was 
used to reduce the potential experimental variables associated with using 
monolayers. It is known that in vitro studies using endothelial monolayers can 
give misleading results. Chen and colleagues found that the amount of platelet 
adhesion to human umbilical endothelial cells (HUVECs) cultured on hydrogel 
scaffolds was dependent on the type of gel that was used and this was related to 
the amount of glycocalyx produced by the cells (Chen et al., 2007b). Glycocalyx 
covers the luminal surface of endothelial cells and is known to have a role in their 
alignment under shear stress (Yao et al., 2007).  
 
Cell preparation, therefore, can have a large impact on platelet adhesion. Indeed, 
it has also been shown to affect interaction with the endothelial extracellular 
matrix (Aznar-Salatti et al., 1991). This suggests that investigations into platelet 
interactions can give misleading results. It was noted, for instance, that 13-
hydroxy octadecadienoic acid (13-HODE) concentration and distribution pattern 
vary based on how the cells were prepared. 13-HODE is a lipoxygenase pathway 
intermediate that is known to be an inhibitor of platelet-platelet interaction 
(Coene et al., 1986).  It has been reported that this compound inhibited platelet 
adhesion to both the endothelial monolayer and to the extracellular matrix. There 
33 
 
was a greater inhibitory effect on the endothelium than on the extracellular matrix 
(Tloti et al., 1991).  
 
To minimize variation in cell preparation on platelet-endothelial interactions, 
HUVECs and all cell media were to be purchased from a reputable supplier 
(Cambrex). The cells were to be stored and cultured as per the supplier‟s 
instructions and all experiments were to be performed using cells between 
passages 4-6. Negative controls consisted of endothelial cells cultured in normal 
conditions, with 100 µg/ml of non-glycated protein or unactivated platelets, while 
adenosine diphosphate (ADP) activated platelets were used as a positive control. 
These were used to compare the affect of incubation of the endothelial cells with 
high glucose (11mM and 22 mM) and/or AGEs (100 µg/mL) for 24 and 48 hours 
on platelet adhesion. These times were chosen so that comparison could be made 
with other published results to determine whether the type of protein could 
account for discrepancies. All experiments were carried out in triplicate (with 3 
samples for each control and treatment) and the whole experiment was repeated 3 
times to check for reproducibility and allow for statistical analysis. 
 
 
3.2.4. Platelet Adhesion Assay – Immunocytochemistry 
Obviously, although flow cytometry allows for investigation into platelet and 
endothelial interactions and rules out the involvement of the extracellular matrix, 
there are a number of limitations to this technique. This includes the fact that 
endothelial cells are not normally found in isolation. They are present as a 
monolayer and are elongated rather than spherical. This may result in endothelial 
cell adhesion molecules, such as junction adhesion molecules (JAM), being 
available when they would otherwise not be. For analysis, the endothelial cells 
also need to be removed from the culture flask. This requires either cell scraping 
of enzyme treatment. This leads to cell disruption and an increase in potential for 
cellular debris. 
 
Immunocytochemistry was used to complement the flow cytometry results, to 
give an insight into the role of the endothelial monolayer, as opposed to 
endothelial cells in suspension. Both fluorescent and confocal microscope 
analysis were run in parallel. Endothelial cell culture was performed in 6-well 
plates containing sterile coverslips. (In situ coverslips were used, as opposed to 
growing the cells to confluence and then transferring them to coverslips, to 
reduce the amount of disturbance required for the experiments. Once the cells 
were between 75 and 85 % confluent (depending on whether they were being 
incubated for 24 or 48 hours) any treatments were initiated (as mentioned above). 
Cell fixing procedures were investigated to minimize cell disturbance, including 
various concentrations of methanol, methanol/acetone, acetone, 
paraformaldehyde and ethanol. From some initial investigations, many of these 
fixation methods appeared to result in protein denaturing and endothelial cell 
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detachment. The best results were obtained using 70% ethanol and 4% 
paraformaldehyde fixation. I proposed to label VCAM-1 using an anti-VCAM-1 
antibody and then a Texas red conjugated secondary antibody. The endothelial 
nucleus was to be stained using 4',6-diamidino-2-phenylindole (DAPI) and 
platelets labelled with FITC-CD42b antibodies. A mounting medium would also 
be used to prevent loss of fluorescence and bleaching of fluorescein 
isothiocyanate (FITC). 
 
 
3.2.5. Dynamic Flow 
Neither of the above procedures ruled out the effect of sub-endothelial 
interactions that are likely to take place in vivo, the effect of dynamic flow within 
the vessel or indeed, the fixation and staining methods needed for these studies. It 
was therefore proposed to run time-lapse studies using a flow chamber, both with 
endothelial monolayers and with vascular biopsy specimens from diabetic 
patients. 
 
The use of diabetic tissues would obviously have some disadvantages in that the 
tissue would have been taken from diseased vessels. The process of removing the 
disease tissue would however include a margin of non-diseased tissue (to make 
sure that all the diseased area was removed). This non-diseased tissue would have 
been subjected to diabetic conditions and therefore would give a good indication 
of whether platelet adhesion was increased. Obviously, the biopsy procedure may 
well have caused some stress to the sample but, it would still provide a 
comparison for cell culture studies. 
 
The tissue would be placed or the cells would be cultured on a coverslip prior to 
placing into a parallel-plate flow chamber with perfusion system, as described by 
Lawrence and colleagues (Lawrence et al., 1987). Platelet-rich-plasma, from a 
reservoir at 37ºC, would then be circulated, by a peristaltic pump, at 
physiologically normal (0.9 dyne/cm
2
) and high shear rates (1.5 & 3 dyne/cm
2
) to 
investigate the effect of dynamic flow conditions on platelet adhesion to the 
endothelium. Platelet adhesion would be investigated under normal conditions, 
with ADP activated platelets for the controls and then with high glucose and or 
AGE incubated endothelial cells. Images were to be obtained by using a video 
recorder connected to a light microscope. 
 
 
3.2.6. Research To Date 
3.2.6.1. Platelet Adhesion to the Endothelium 
Various investigations have looked into the adhesion molecules involved in 
platelet-endothelial interactions. Bombeli and colleagues used monoclonal 
antibodies and flow cytometry to determine that platelets adhered to 
endothelial cells (Bombeli et al., 1998). They found that platelets adhered to 
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apoptotic HUVECs, partly via β1 integrins (α2β1 (GPIa/IIa), α5β1 (VLA-5), 
α6β1 (VLA-6)) and by GPIIb/IIIa. Blocking of all three platelet β1 integrins 
only resulted in a 20 % reduction in platelet adhesion, while blocking 
GPIIb/IIIa reduced adhesion by approximately 50 %. Platelet adhesion was 
also found to be significantly reduced by blocking endothelial ICAM-1, αvβ3, 
GPIb. Blocking of endothelial E-Selectin and VCAM-1, platelet GPIb and 
GPIV, and both endothelial and platelet PECAM-1 and P-Selectin showed no 
significant decrease in adhesion. 
 
This research highlighted that results differ based on what monoclonal 
antibody is used. There were a number of different antibodies used for a 
specific cell adhesion molecule. The majority selected for this investigation 
did not vary significantly but there were large differences for anti- αvβ3.  This 
is probably because one was blocking and the other non-blocking. The 
blocking antibodies used also only inhibited specific types of binding. For 
instance, ICAM-1 monoclonal antibody P6.5 blocks the β2 integrin-binding 
site while 2D5 blocks the fibrinogen-binding site. 
 
Others have also suggested that GPIIb/IIIa was responsible for firm, but not 
for transient adhesion (Massberg et al., 2002, Gawaz et al., 1997, Verheul et 
al., 2000). They also reported that platelets deficient in GPIIb/IIIa did not 
firmly adhere to activated endothelial cells.  However, blocking αvβ3 or GPIbα 
resulted in reduced platelet adhesion, suggesting that platelet adhesion via 
GPIIb/IIIa was either GPIb or αvβ3 -dependent. 
 
Further studies have confirmed that GPIb is involved in platelet adhesion to 
activated endothelium using HUVECs or mice (Andre et al., 2000, Etingin et 
al., 1993). Blocking VWF, a ligand for GPIb, was reported to reduce platelet 
adhesion to virally infected cells by 90 %. Another investigation using 
HUVECs found that blocking GPIb had no effect on platelet adhesion 
(Verheul et al., 2000). These discrepancies may result from culture 
differences. Most of these studies are in vitro and have centred on the use of 
cultured cells. The use of cells grown as monolayers has its own drawbacks, 
including batch-to-batch variation, differences in cell adhesion molecule 
expression with increasing passage number, and due to origin; therefore the 
results may not reflect physiological situations. Also, by using blocking 
studies variability occurs from differences in the antibody binding affinity and 
cell adhesion molecule expression levels. By looking at knock-out models 
there is the potential to carry out in vivo experiments, which should give a 
more accurate representation of physiological conditions. 
 
Animal studies have been performed to look at platelet adhesion to the 
endothelium (Korbut et al., 1990, Pettersson and Bjork, 1992, Tloti et al., 
1991). Korbut and colleagues (Korbut et al., 1990) detailed a model for 
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investigating adhesion under flow conditions. Rabbit aortic segments were 
attached to apparatus that allowed for weight measurements to be taken to 
determine thrombus formation. During their investigation they observed that 
increased weight was associated with thrombus formation. Microscope 
analysis determined platelet adhesion to the intact endothelium.  
 
Radioactively-labelled platelets have also been used to analyse platelet 
adhesion in rabbits (Pettersson and Bjork, 1992). The rabbit vein was 
cannulated to allow for administration of the radioactively-labelled platelets 
into healthy rabbits.  They observed platelet adhesion to the vessel wall. 
(Deposition of platelets was greater at regions of vessel branching. This is 
where lesion formation is reported to be most likely to occur (Tanganelli et al., 
1993).) However, these findings were not confirmed at slaughter and therefore 
could have been the result of transient attachment or platelet aggregation. If 
transient attachment occurs, cross-talk (communication potentially involving 
activation or transfer of cytokines) between the platelets and endothelial cells 
is possible. Detection of this, either in vivo or in autopsy findings, would 
potentially be problematic because of the transient nature. 
 
Platelet adherence to sheep pulmonary artery endothelial cells has also been 
reported (Tloti et al., 1991). Platelet adherence increased approximately 
threefold then the platelets were activated by thrombin. Co-incubation of 
activated platelets and activated endothelial cells resulted in nearly a fivefold 
increase in platelet adhesion when compared to non-treated cells. This would 
indicate that platelet adhesion is significantly increased when both the 
endothelium and the platelets are activated. 
 
It has been reported that mice lacking endothelial P-selectin exhibited 
decreased platelet adhesion when compared to wild type mice (Frenette et al., 
1998, Frenette et al., 1995). When P-selectin deficient platelets were 
introduced adhesion still occurred, suggesting that endothelial, but not platelet, 
P-selectin is involved in platelet-endothelial interactions. These findings 
contradict other investigations (Andre et al., 2000, Bombeli et al., 1998, 
Verheul et al., 2000). This may be because the in vivo studies used intravital 
microscopy in the mouse tail vein and mesenteric venules, while the in vitro 
investigations used umbilical vein endothelial cells. It is also possible that the 
origin of the endothelium, including species and vessel type, could result in 
cell variance, which includes cell adhesion molecule expression (Kuzu et al., 
1993). Obviously, although in vivo animal experiments are more likely to 
mimic the conditions that are available naturally, in animals, the findings may 
not give an accurate picture of what happens in humans. It is possible that they 
may also be specific to those species only. Also, the methods used are often 
invasive and therefore many unknown variables could be introduced including 
activation of both endothelial cells and platelets. 
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It is clear to see that there are some discrepancies in the literature as to what 
adhesion molecules are involved. It does, however, indicate that platelets do 
indeed adhere to the endothelium. This interaction does not rely on one set of 
adhesion molecules. It is likely that many are involved, with potentially 
physiological conditions determining certain interactions. These studies, 
however, do not determine whether platelet adhesion is involved in the initial 
stages of atherosclerosis. Other research has been done that may give insight 
into whether platelet-endothelial interactions initiate lesion formation. These 
include studies on lesion formation, blocking of platelet adhesion, and whether 
platelet abnormalities reduce or stop atherogenesis. 
 
 
3.2.6.2. Platelet Adhesion in Atherogenesis 
Histological and immunocytochemical investigations have been carried out to 
investigate the stages of atherosclerotic lesion formation and provide 
classification (Gown et al., 1986, Katsuda et al., 1992, Stary et al., 1994, Stary, 
2000, Stary et al., 1995). During these studies platelet adhesion was not 
associated with the initial stages of atherosclerosis, only the later stages where 
the fibrous plaque becomes brittle and can fissure – exposing collagen and 
other thrombogenic components, and therefore allowing for platelet adhesion. 
 
The initial stages are usually associated with leukocyte and not platelet 
adhesion. Indeed, Walker and colleagues (Walker et al., 1986) studied 
leukocyte and platelet adhesion to rabbit endothelium. They reported 
leukocyte adhesion to the initial stages of atherosclerosis (type 1 and type 2 
lesions; see table 1 for details), but no platelet interactions. There was no 
mention of platelet adhesion. The fixation and preparations used for imaging 
the thoratic artery were unlikely to have resulted in detachment of adhered 
platelets but would certainly have removed transiently attached cells. It is 
therefore unlikely in these rabbits that firm adhesion platelets occurred in the 
initial stages of atherosclerosis. 
 
In humans, there is a distinctive lack of publications reporting platelet 
adhesion to the endothelium. There are, however, microscope investigations 
into lesion formation that show leukocyte adhesion (Emeson and Robertson, 
1988, Millonig et al., 2002, Stary, 1990, Stary and Malinow, 1982). An 
overview of these papers can be found in Table 7. Many of these studies have 
specifically looked for leukocyte adhesion. For instance, the Pathobiological 
Determinants of Atherosclerosis in Youth (PDAY) study used antibodies to 
investigate leukocyte interactions (Millonig et al., 2002). Sections of aortic 
tissue from people aged 17 to 34, who had no clinical signs of cardiovascular 
disease, were labelled with monoclonal antibodies for T-lymphocytes, 
interleukin-2 receptors, macrophages, dendritic cells, mast cells, natural killer 
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cells, major histocompatibility complex class II-expressing cells 
(macrophages, dendritic cells and B-cells), and B-cells. As such, any adherent 
platelets would not be detected.  
 
The lack of evidence for adherent platelets may well be telling in its own right 
however, it could be a result of the methodology. There is also, no mention of 
adherent platelets, unless in relation to advanced lesions. These investigations 
involve fixing, blocking, with their various washing stages, and 
immunocytochemistry imaging. These processes are likely to eliminate any 
transiently attached platelets, but may also result in detachment of those that 
are more firmly adhered. This is because the studies were centred on leukocyte 
adhesion and therefore platelet monoclonal antibodies were not used. Platelets 
would therefore not be picked up by fluorescent microscopy. 
 
Spurlock and Chandler (Spurlock and Chandler, 1987), however, reported 
adhesion of isolated platelets or micro-thrombi to arterial endothelium in a 
small percentage of people, aged 15-34, who died from sudden trauma. 
Analysis was carried out using a scanning electron microscope (SEM). The 
SEM allowed for rapid examination of large sections of intima. This 
observation does not directly suggest that platelet adhesion occurs prior to 
lesion formation, but it is known that lesions occur in childhood, so there may 
be a link. Indeed, platelet adhesion has been reported to occur prior to 
leukocyte adhesion and before lesion formation in mice (Massberg et al., 
2002). Platelet adhesion was observed ex vivo at sites where later lesions 
occurred. Increasing age corresponded with increased platelet adhesion in the 
atherosclerotic prone apolipoprotein E deficient (Apo E
-/-
), but not in the wild 
type mice. Blockade of GPIbα and GPIIb/IIIa resulted in reduced leukocyte 
accumulation in the intima and also decreased lesion formation.  This would 
suggest that platelets are required for leukocyte adhesion because GPIIb/IIIa is 
expressed constitutively by platelets and allows for leukocyte adhesion via 
Mac-1. Lack of Apo E results in increased fat deposition and therefore lesion 
formation, making these mice a very useful tool for studies into 
atherosclerosis, however, the results may not resemble human physiology. It is 
possible that the inability to catabolise lipoproteins causes specific 
endothelium injury resulting in platelet adhesion, which is not seen in 
endothelial dysfunction related to hyperglycaemia, for instance. 
 
Another report found that platelets tethered, rolled, and arrested on early 
lesions in this atherosclerosis mouse model (Huo et al., 2003). Adhesion was 
mainly for short periods of time. It was thought that this transient adhesion 
allowed for transfer of platelet mediators, such as regulated upon activation 
normal T-cell expressed and secreted (RANTES) and platelet factor 4 (PF-4). 
Platelet adhesion, however, was reported to be rarely in isolation. Platelets 
mainly adhered to monocytes, via platelet P-selectin, and promoted monocyte 
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adhesion to the endothelium. These findings partially concur with those of 
Massberg and colleagues (Massberg et al., 2002), but because this 
investigation focused on platelet and leukocyte adhesion prior to lesion 
formation it is not possible to determine whether platelet adhesion initiates 
lesion formation. There was also no definition for „early lesion‟. Mean lesion 
area coverage was determined at eighteen weeks on an atherogenic diet. 
However, it is clear that platelets are involved prior to advanced lesion 
formation in Apo E
-/-
 mice. 
 
Platelet adhesion prior to noticeable lesion formation was also found in rabbits 
(Theilmeier et al., 2002, De Meyer et al., 1999). It was found that platelet 
adhesion occurred after three months of the rabbits being fed on an 
atherogenic diet. Although the rabbits exhibited mild hypercholesterolaemia, 
no fatty streaks were present until twelve months of the diet. Platelet adhesion 
was seen at sites near segmented arteries, where lesions would be expected. 
Platelets were not found adhered to other areas of the arteries. The use of ex 
vivo and in vitro experiments determined that platelet adhesion was due to 
increased endothelial VWF (-GPIb) and platelet P-selectin.  This is partly 
supported by other studies that have reported that there was a significant 
increase in platelet adhesion at the carotid bifurcation compared to the 
proximal carotid artery in mice (Massberg et al., 2002).  
 
These reports suggest that platelet-endothelial interactions occur prior to lesion 
formation. Obviously, this cannot be stated as fact because, using these 
methods, it is not possible to see the time lapse of events. If it was, then 
evidence showing that following on from platelet adhesion monocytes 
interacted with the endothelium and differentiated into macrophages and then 
developed into foam cells and lesions would give greater clarity. To do this 
kind of research, however, would result in disturbance to the endothelium and 
therefore damage would occur. As such, this in its own right might result in 
platelet and monocyte interactions for wound healing and infection control. It 
would therefore be impossible to determine the sequence of events in 
accelerated atherosclerosis in diabetes. 
 
Although there is some evidence to suggest that platelets adhere to the 
endothelium prior to lesion formation this is more circumstantial rather than 
direct. Perhaps it is telling that there is very little evidence to suggest that 
platelets adhere to the endothelium in the initial stages of atherosclerosis or 
perhaps it is that the research to date has not been designed with this 
investigation in mind. By looking at published research into inhibition of 
platelet binding it may be possible to extrapolate further which of these is most 
likely to be correct. 
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Table 7: Evidence for Platelet Adhesion to Endothelial Cells in the Initial 
Stages of Atherosclerosis  
 
Animal Detail Reference 
Primates (human) No evidence for platelet adhesion 
seen 
 
Mural thrombi in children 
(Millonig et al., 2002, Emeson 
and Robertson, 1988, Stary, 
1990, Spurlock and Chandler, 
1987) 
Primates (non-
human) 
Platelet adhesion in the initial 
stages of atherosclerosis 
No evidence for platelet adhesion 
(Faggiotto et al., 1984a, 
Faggiotto and Ross, 1984b) 
(Stary and Malinow, 1982) 
Rabbits Adherent leukocytes for type 1 & 
type 2 lesion, but no adherent 
platelets 
Platelet adhesion to the 
endothelium in rabbit aorta 
Platelet adhesion prior to fatty 
streak formation 
(Walker et al., 1986)  
 
 
(De Meyer et al., 1999) 
 
(Theilmeier et al., 2002) 
In vitro (HUVECs on 
fibroblasts) 
Platelet adhesion was the same 
for diabetic platelets and controls 
(Nievelstein et al., 1991) 
In vitro (BVEC) Increased adhesion of diabetic 
platelets 
(Manduteanu et al., 1992) 
Mice  Platelet adhesion to the 
endothelium prior to leukocyte 
adhesion and lesion formation 
Platelets adhered to early lesions, 
but mainly in conjunction with 
monocytes. 
(Massberg et al., 2002) 
 
 
(Huo et al., 2003) 
 
(Key: HUVECs - human umbilical endothelial cells; BVEC - bovine vascular endothelial 
cells; ApoE
-/-
 - apolipoprotein E deficient) 
 
 
3.2.6.3. Inhibition of Platelet Binding 
If platelets are indeed involved in atherogenesis then blocking platelet 
adhesion should reduce lesion formation. Therefore, by looking at the presence 
of lesions, and their progression, it should be possible to determine whether 
anti-platelet drugs have an effect. There are a number of anti-platelet drugs 
that are available to treat patients with conditions such as cardiovascular 
disease. These include aspirin, cilostazol and clopidogrel. 
 
One such drug, aspirin, is used for the secondary treatment of cardiovascular 
disease. It reduces platelet adhesion by blocking the production of platelet 
thromboxane A2 and prostaglandin via inhibition of the cyclo-oxygenase 
pathway, and therefore inhibits platelet activation. It also inhibits prostacyclin 
synthesis by the endothelium therefore, it might increase thrombus formation. 
Animal investigations into the effect of aspirin on atherogenesis suggest that it 
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may or may not inhibit lesion formation, but it does reduce the severity of 
atherosclerosis (Guo et al., 2006, Pick et al., 1979). 
 
Monkeys and rabbits fed on a high cholesterol diet and treated with aspirin 
have been reported to have lesions that were less widespread, had fewer layers, 
reduced total area of coverage and that vessel narrowing was only seen in the 
control animals. There was, however, no significant reduction in lesion 
formation (Pick et al., 1979, Guo et al., 2006). This would suggest that aspirin 
reduced the severity of atherosclerosis. It is possible that this is due to the 
antioxidant effect of high dose aspirin. (Therapeutic doses of aspirin have been 
reported to reduce the effect of oxidative stress on brain and endothelial cells 
(Podhaisky et al., 1997, Bode-Boger et al., 2005, Guerrero et al., 2004).) By 
acting as an antioxidant aspirin could reduce the availability of ox-LDL and 
thereby reduce foam cell formation. Indeed, aspirin has been reported to 
decrease platelet expression of ox-LDL (Marwali et al., 2007). It has also been 
suggested that aspirin reduces the inflammatory effect of ox-LDL on the 
endothelium (Zhao et al., 2008). 
 
Other research has suggested that aspirin does reduce lesion formation as well 
as area of lesion coverage, in rabbits and humans (Cyrus et al., 2002, 
Kouraklis et al., 2004, Li et al., 2007, Mittal et al., 1990). Treatment of low-
density lipoprotein receptor deficient (LDLR
-/-
) mice with low doses of aspirin 
led to a decrease in mean size of the lesions and reduced presence of 
macrophages. There was, however, an increased level of collagen and smooth 
muscle cells – which could result in an increased stability in advanced lesions.  
 
This research suggests that although aspirin may not stop atherogenesis, it may 
reduce monocyte recruitment and therefore foam cell formation. This might be 
partly due to its antioxidant effects partly reducing endothelial dysfunction and 
therefore cell adhesion molecule upregulation rather than platelet adhesion. 
 
Although aspirin blocks the production of thromboxane it does not block 
intermediates in prostanoid production, F2-isoprostane and 
hydroxeicosatetraenoic acids (HETEs). S18886, a thromboxane receptor 
antagonist, however decreases synthesis of these. S18886 has been reported to 
reduce monocyte and macrophage recruitment to primary lesions and fatty 
streaks as well as to advanced lesions in rabbits fed on a high cholesterol diet 
(Worth et al., 2005).  
 
Treatment of Apo E-/- mice with S18886 decreased lesion size and reduced 
soluble levels of both ICAM-1 and thromboxane B2, while, celecoxib, another 
cyclo-oxygenase inhibitor, was found to nearly completely inhibit the 
formation of atherosclerotic lesions (Cayatte et al., 2000, Jacob et al., 2008, 
Zuccollo et al., 2005). There was a decrease in lesion area of 81 % associated 
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with administration of this compound. Administration of celecoxib following 
lesion formation had no effect on further development and advancement. 
 
Another drug, cilostazol, a cAMP phosphodiesterase inhibitor, reduced 
intimal-media thickness in Japanese patients with type 2 diabetes (Mitsuhashi 
et al., 2004). Intimal-media thickness is thought to be a marker of the early 
stages of atherosclerosis and therefore it is possible that, by inhibiting platelet 
aggregation and increasing vasodilation, cilostazol inhibits platelet adhesion.  
 
A pronounced reduction in lesion formation was also reported in rabbits that 
were administered with a cocktail of anti-platelet drugs, including the platelet 
ADP receptor inhibitors clopidogrel and ticlopidine as well as aspirin (Li et al., 
2007). Damage to the vasculature was induced at week one. The rabbits were 
then fed on an atherogenic diet before being slaughtered after seven weeks. At 
this point the reduced formation of lesions, compared to the controls, was most 
pronounced in the animals treated with clopidogrel, as opposed to those treated 
with ticlopidine or aspirin. This reduction was associated with decreased 
expression and serum levels of P-selectin, ICAM-1, VCAM-1 and MCP-1. 
 
Herbert and team (Herbert et al., 1993) also found that clopidogrel and 
ticlopidine reduced platelet adhesion to the subendothelium in vivo and in 
vitro, but that aspirin had no effect. These findings are supported by other 
investigations (Jawien et al., 2007, Evangelista et al., 2005). Treatment of Apo 
E and LDLR deficient mice with ticlopidine resulted in a reduction in lesion 
area and reduced adhesion of CD68
+
 macrophages and CD3
+
 T lymphocytes 
(Jawien et al., 2007). The lymphocytes present, instead of being widely 
dispersed within the lesion, were accumulated in the peripheral areas of the 
plaque. Clopidogrel reduced platelet-leukocyte adhesion, platelet P-selectin 
expression, and platelet-derived reactive oxygen species production in mice 
(Evangelista et al., 2005). Experiments carried out, both ex vivo in mouse 
models, and in vitro, using human platelets, produced the same results. Both 
clopidogrel and ticlopidine block one of the ADP (P2Y12) receptors and 
therefore reduce platelet aggregation by inhibiting activation of the cell 
adhesion molecule GPIIb/IIIa. There does not appear to be any investigations 
that investigate GPIIb/IIIa specific anti-platelet drugs (abciximab, eptifibatide, 
tirofiban). Findings from such studies could highlight whether platelet 
adhesion, via GPIIb/IIIa (ICAM-1 or αvβ3) is involved in lesion formation. 
 
Other anti-platelet drugs have also been investigated. Reduced lesion 
formation was found in animal models treated with drugs that inhibit platelet 
degranulation and thrombus formation sulfinpyrazone and dipyridamole 
(Dembinska-Kiec et al., 1979, Grodzinska and Dembinska-Kiec, 1980, 
Landymore et al., 1988, Mittal et al., 1990). Dogs fed on a high cholesterol 
diet and treated with dipyridamole also exhibited a significant reduction in 
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intimal thickness. Combined treatment with aspirin also reduced intimal 
thickness, but no more so than dipyridamole on its own. The combined 
treatment did, however, reduce platelet count and thromboxane B2 
concentrations. Another study, however, found increased lesion formation 
following treatment with dipyridamole in rabbits (Dembinska-Kiec et al., 
1979). The differences in results suggest that there are variations between 
animal models and therefore these findings be different again in humans. It 
would, however, be interesting to establish whether drugs that block platelet 
GPIIb/IIIa had a significant effect on lesion formation. These drugs would 
give a much clearer idea of whether platelets are involved. Therefore, by 
comparing these results with those from patients that lack specific platelet cell 
adhesion molecules or have abnormalities in platelet structure or function it 
may be possible to gain a better understanding. 
 
Many of the anti-platelet drugs show a reduction in lesion formation. They do 
not, however, stop lesion formation altogether, even when a cocktail of these 
pharmaceuticals are used. This may well be because they do not stop 
upregulation of all the cell adhesion molecules that are associated with 
platelet-endothelial interactions and therefore platelet adhesion still takes 
place. The reduction seen may well be a consequence of the drugs having anti-
inflammatory properties or unknown actions on the endothelium and 
leukocytes. It this is the case then, the reduction in lesion formation may not 
be the result of reducing platelet interactions. It is too early to tell whether new 
anti-platelet drugs, such as prasugrel and ticagrelor, which are likely to replace 
replace pre-existing treatments will result in a reduction in atherosclerosis. 
Therefore, this information currently available cannot, on its own, be used to 
determine whether my hypothesis is correct.  
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Table 8: Evidence for Reduced Lesion Formation as a Result of Anti-Platelet 
Therapies  
 
Treatment Detail Reference 
Aspirin Coronary atherosclerosis less widespread and 
lesions were less obstructive in monkeys 
Low dosage decreased lesions and 
macrophage presence 
Decreased layers of foam cells, lesion 
distribution, coverage, and formation  in 
rabbits & humans 
No effect on lesion formation 
(Pick et al., 1979, Li et 
al., 2007, Cyrus et al., 
2002, Kouraklis et al., 
2004, Guo et al., 2006, 
Mittal et al., 1990, Napoli 
et al., 2002, Paul et al., 
2000, Tous et al., 2004) 
(Schulz et al., 2008) 
Ticlopidine Decreased platelet adhesion to damaged 
vessels 
Decreased lesion area, CD68 and CD3 
adhesion 
(Herbert et al., 1993) 
(Jawien et al., 2007) 
Clopidogrel Decreased platelet adhesion and lesion 
formation  in rabbits 
Decreased platelet-leukocyte adhesion, P-
selectin, and platelet-dependent ROS 
production 
(Herbert et al., 1993) 
(Evangelista et al., 2005) 
 
Celecoxib Decreased lesion formation in Apo E
-/-
 mice (Jacob et al., 2008) 
Cilostazol Reduced IMT (Mitsuhashi et al., 2004) 
S18886 Smaller lesions, decreased soluble ICAM-1 
and TxB2 
Decreased monocyte recruitment to primary 
lesions and fatty streaks in rabbits 
(Cayatte et al., 2000) 
 
(Worth et al., 2005) 
Dipyridamole 
 
Decreased lesion and intimal thickness 
formation 
Increased lesion formation in rabbits and 
humans 
 
 
Combined treatment with aspirin decreased 
platelet count and TxB2 levels 
(Harker et al., 1976b) 
 
(Dembinska-Kiec et al., 
1979, Mittal et al., 1990) 
(Landymore et al., 1988) 
Sulfinpyrazone Decreased lesion formation (Grodzinska and 
Dembinska-Kiec, 1980, 
Mittal et al., 1990)  
prasugrel, 
ticagrelor, 
cangrelor and 
ProCorde 
GmbH 15 
(PR-15) 
 
No evidence found None 
 
(Key: ROS - reactive oxygen species; Apo E
-/-
 - apolipoprotein E deficient; IMT - intimal-
medial thickness; ICAM - intercellular adhesion molecule; TxB2 - thromboxane B2) 
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3.2.6.4. Platelet Abnormalities 
Another way of investigating the role of platelet adhesion in atherosclerosis is 
by looking at patients who have platelet defects that might result in 
abnormalities in platelet adhesion. There are a number of genetic and acquired 
conditions that affect platelets including genetic disorders that are associated 
with specific cell adhesion molecules or receptors, and acquired disorders 
associated with drugs. A literature review of these platelet abnormalities and 
the association with atherosclerosis was carried out.  
 
Von Willebrand disease is a heterogeneic disorder that has a large number of 
variations, all of which are associated by genetic inheritance of changes in 
structure, function, or concentration of the cell adhesion molecule von 
Willebrand factor. This disease has been divided into three types (with 
associated variants). Type 1 is associated with decreased levels of VWF. This 
is the mildest and most common form of this disease. Type 2 is divided into 
groups dependent on which defects are present. It incorporates changes in 
multimer lengths and affinities for GPIb and factor VIII resulting in increased 
platelet adhesion. Type 3, on the other hand, is associated with almost 
complete deficiency of VWF. 
 
Atherosclerosis has, however, been found in patients with von Willebrand 
disease (Silwer et al., 1966, Sramek et al., 2004). In type 3, the most severe 
form, atherosclerosis was found, even though the patients were almost 
completely deficient in VWF (Sramek et al., 2004). Intimal thickness in type 
2B patients was reported to be the same as in atherosclerotic matched controls 
(Bilora et al., 2007). Lesions were, however, not reported. As type 2B is 
associated with increased affinity of VWF for GPIb/V/IX I would have 
expected that there would be an increase in atherosclerosis. Both studies only 
included information from a relatively small cohort, less than 50 VWD 
patients, but it would appear that the lack of VWF-GPIb adhesion does not 
deter lesion formation and an increase does not show accelerated lesion 
formation. 
 
Further investigations have been done using animal models of von Willebrand 
disease, most notably in pigs (Fuster et al., 1982, Fuster et al., 1978, Griggs et 
al., 1981, Methia et al., 2001). Fuster and colleagues have been working with 
von Willebrand pigs for a number of years (Badimon et al., 1985, Badimon et 
al., 1989bb, Fuster et al., 1978, Bowie and Fuster, 1980, Badimon et al., 
1989aa, Fuster et al., 1985, Fuster et al., 1977, Fuster and Bowie, 1978, Fuster 
et al., 1982). They initially detailed research that indicated that pigs were less 
inclined to develop atherosclerosis than controls in 1977. Since that point they 
have carried out a number of trials that have investigated the role of their diet 
in atherogenesis, the composition of fatty deposits and platelet adhesion.  
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Their investigations into spontaneous lesion formation found that seven of the 
eleven control pigs developed atherosclerotic lesion by the time of their 
slaughter. Five of these exhibited a maximum lesion diameter of greater than 
2mm. In type 3 von Willebrand disease animals, three out of eleven had 
lesions, only one had a lesion with a diameter of greater than 2mm. It was 
reported, however, that there were flat fatty lesion in seven of the eleven of 
these pigs, but none in the controls. These flat lesions are not found in humans 
therefore this could suggest that the process of lesion formation or initiation is 
different in von Willebrand disease pigs. In high-fat, high cholesterol 
experiments, however, these flat fatty lesions were also seen in four of the 
controls. All of these animals had raised fatty and fibrous plaques. In contrast 
only three of the seven von Willebrand diseased pigs presented raised fatty 
plaque, with one of these also having raised fibrous plaque. All but one also 
exhibited flat fatty lesion. This would suggest that inhibition of VWF-
dependent platelet adhesion does not stop foam cell formation but that it may 
slow the progression into raised lesions, and therefore more advanced 
atherosclerosis. 
 
A later investigation found that the mean lesion coverage was less in type 3 
von Willebrand disease pigs than the controls (Fuster et al., 1982). In controls 
28% of the vasculature exhibited lesions. In von Willebrand disease pigs there 
was a significant reduction to only seven percent coverage. Both groups were 
fed the same non-fatty diet for 4 years. Potential genetic involvements were 
investigated by carrying out transplantations of aortic segments. Normal 
segments were transposed. The resulting atherosclerosis amounted to 20% 
coverage. Transplantation of a normal segment into a von Willebrand disease 
pig, on the other hand, resulted in only 4% coverage – a notable decrease. This 
would suggest that there are no differences in vessel genetics that allow for 
reduced lesion formation. 
 
Investigations were also carried out to look at heterozygous and homozygous 
von Willebrand disease pigs (Griggs et al., 1981, Badimon et al., 1985). 
Griggs and colleagues reported that there was no significant decrease in tissue 
lipid deposits (as determined by Sudan dye staining) for either of the disease 
types. The homozygous animals did, however, exhibit a significant decrease in 
fibrous plaque formation. This, on the whole supported the finding of Badimon 
et al., although they did report that the heterozygous VWD pigs had a similar 
percentage of raised fatty and fibrous plaque as control pigs. Both 
heterozygous and controls had a significantly higher percentage of lesion 
coverage than homozygous von Willebrand disease pigs.  
 
There have been criticisms of these investigations. One of these is that 
Apolipoprotein B100 polymorphisms can be found in swine. Changes to these 
genes have been linked with higher blood cholesterol (Griggs et al., 1981, 
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Nichols et al., 1992). Feeding these animals on a high-fat, high-cholesterol diet 
would increase foam cell formation and therefore make the investigations 
using the hypercholesterolaemia diet unreliable. The reports, however, looking 
at spontaneous lesion formation do not fall into this category. 
 
Mice have also been used as a model of type 3 von Willebrand disease (Methia 
et al., 2001). VWF
-/-
 and low-density lipoprotein receptor LDLR
-/- 
mice were 
crossed to produce a mouse model that was susceptible to atherosclerosis. 
After 8 weeks of an atherogenic diet, the mice were found to have 40% less 
mean plaque area. This decrease in lesion formation was still apparent at 22 
weeks, but had normalized by 37 weeks, at the point in which fibrous lesions 
occur in the control animals. Therefore, it can be proposed that VWF is 
required for lesion initiation but is not involved in progression to fibrous 
plaque formation. This is supported by the observation that macrophage 
infiltration was lower in LDLR and VWF deficient mice than in the control 
animals. It is possible that this is a result of reduced P-selectin associated with 
this mouse model (Denis et al., 2001). The extent of reduction, nevertherless, 
does not appear to correlate with the reduction in P-selectin alone. 
 
Glanzmann thrombasthenia is associated with genetic defects in platelet 
GPIIb/IIIa and αvβ3 receptors. A number of mutations have already been 
determined that result in changes to transportation of the GPIIb/IIIa complex 
to the surface, surface expression, ligand binding, and increased sensitivity to 
calcium. In one study, seven Iraqi-Jewish patients with Glanzmann 
thrombasthenia who were 46 years of age or over underwent screening for 
atherosclerosis. Six of these seven patients had signs of the early stages of 
atherosclerosis. This was determined by the presence of plaque and 
intermedial thickness. A pathologist would normally expect to find more 
advanced stages of atherosclerosis in patients of this age. Five of these patients 
had no GPIIb/IIIa or αvβ3 adhesion molecules (Shpilberg et al., 2002). It is 
therefore possible that reduced lesion formation was a direct result of a 
reduction in the amount of platelet GPIIb/IIIa and αvβ3 associated binding to 
the endothelium. 
 
Abnormalities in other platelet cell adhesion molecules have also been 
investigated, including β3 and α2 integrins. Weng and colleagues also looked at 
the role of β3 integrins in lesion formation (Weng et al., 2003). They 
developed β3, apolipoprotein E (β3
-/-
apo E
-/-), and β3, low-density lipoprotein 
receptor (β3
-/-
LDLR
-/-
) deficient mice. Both mouse models were fed on an 
atherogenic diet, with those mice without β3 receptors having greater lesion 
development than their litter mates. While there was no significant changes 
were seen in lesion formation in α2
-/-
Apo E
-/-
 when compared with wild type 
and α2
+/+
Apo E
-/-
 mice. Macrophage infiltration also remained the same 
(Grenache et al., 2003).  
48 
 
  
Fibrinogen deficiency has also been reported to lead to substantial decreases in 
lesion formation in apolipoprotein(a) (Apo(a)) active and fibrinogen deficient 
mice (Apo(a)Fib
-/-
) (Lou et al., 1998). This mouse model allows for in vivo 
investigations into the contribution of Apo(a) and fibrinogen in lesion 
formation. A large increase was indicated both by fatty deposit staining and by 
measurement of the total lesion area. Another study has, however, reported 
that the lack of fibrinogen increased the formation of lesions (Iwaki et al., 
2006). The investigation used low density lipoprotein (LDLR) / apolipoprotein 
B-edisome complex (APOBEC1) / fibrinogen deficient mice, to look at the 
effect of fibrinogen on cholesterol driven lesion formation. The rate of 
formation was not increased, just the surface area and size of the plaque, 
suggesting that atherogenesis is initiated faster than in the controls. 
 
Atherosclerosis has been reported in a number of conditions associated with 
platelet abnormalities. These abnormalities relate to a specific function of 
platelets and therefore do not completely rule out platelet adhesion to the 
endothelium in these patients. Indeed, you would expect some platelet 
interactions, and therefore a significantly reduction in atherogensis if platelet 
adhesion was involved. The published information does, on the whole, suggest 
that lesion formation is reduced in a number of these conditions. It is difficult, 
however, to determine the severity of the abnormalities, in relation to platelet 
adhesion. The evidence to date, as a whole, leaves a lot of unanswered 
questions. It would suggest that platelets may have a role in initiating lesion 
formation but that it is possible that they are not an absolute requirement for 
atherogenesis. It is not clear, however, whether platelet adhesion occurs prior 
to lesion formation under diabetic conditions. I believe that it is clear to see 
that further investigation is required to establish whether this is the case. 
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Table 9: Details of Platelet Pathologies and Evidence for Decreased Lesion 
Formation  
 
Abnormality CAM Detail Reference 
VWD in 
humans 
VWF Atherosclerosis found in all 
patients with VWD. The 
incidence of atherosclerosis is 
the same as controls 
 
(Silwer et al., 1966, 
Sramek et al., 2004, 
Bilora et al., 2007) 
VWD pigs VWF (& 
VIII) 
Decreased lesion formation 
 
 
VWF was not involved in 
lesion formation in pig aortas 
Heterozygous VWD pigs did 
not have reduced lesions 
(Fuster et al., 1978, 
Fuster et al., 1982)  
(Griggs et al., 1981) 
(Badimon et al., 1985) 
VWD mice VWF Reduced lesion formation. 
Decreased monocyte 
infiltration 
(Methia et al., 2001) 
VWD or 
deficiency in 
VIII or IX 
VWF, 
factor IX 
No effect on lesion formation 
or coagulation (haemophilia, 
moderate & severe 
haemophilia, mild 
haemophilia & VWD, mild 
VWD) 
(Sramek et al., 2001) 
Glanzmann 
Thrombasthenia 
GPIIb, 
GPIIIa & 
αvβ3 
Atherosclerosis was present (Shpilberg et al., 2002) 
β3 deficiencies GPIIb/IIIa 
& αvβ3 
Increased lesion formation (Weng et al., 2003) 
Bernard-Soulier GPIb Patient had atherosclerosis – 
could not find any other 
instances of lesions in GPIb 
deficiencies 
(Humphries et al., 1992) 
α2 deficiencies GPIIb/IIa No significant difference (Grenache et al., 2003) 
Abnormal 
fibrinogen 
Fibrinogen Decreased lesion formation 
seen in Apo (a)/Fib
-/-
 mice 
Increased lesion formation in 
mice 
(Lou et al., 1998) 
(Iwaki et al., 2006) 
 
(Key: CAM – cell adhesion molecule; VWD - von Willebrand disease; T3 - type 3; Apo 
(a)/Fib
-/-
 - apopolipoprotein A/fibrinogen deficient) 
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3.3. What can be concluded? 
Although it was initially thought that the endothelium was passive, with platelet 
adhesion only resulting from endothelial denudation, it is now clear that this is not the 
case. Platelet adhesion to the vessel walls has been established as involving 
interactions with the sub-endothelium, the extracellular matrix and with the 
endothelium. Adhesion is known to occur when either, or both, platelets or the 
endothelial cells are activated, as a result of upregulation of cell adhesion molecules. 
 
There has been a lot of research into platelet and endothelial cell adhesion molecules, 
as well as their associated ligands, over the last couple of decades. There is also a 
large amount of literature covering cell adhesion molecule and receptor interactions. 
These have suggested that adhesion molecule interactions differ based on whether 
platelets and / or endothelial cells are activated. There are also some discrepancies, 
which are probably a result of different methodologies being used, (including cell 
preparation or culture), as well as what cells or animal models used. It is still clear, 
however, that endothelial αvβ3, GPIb, and platelet GPIIb/IIIa are key receptors, with 
fibrinogen, and VWF acting as important ligands.  
 
Platelet rolling has been associated with GPIb, PSGL-1, and P-selectin. Firm 
adhesion, on the other hand, has been reported to require GPIIb/IIIa, ICAM-1, and 
αvβ3. It is thought that platelet adhesion is initiated by tethering and rolling, followed 
by firm adhesion. Whether this research mimics physiological interactions in humans 
is unclear. Indeed, it is unlikely that any one specific receptor-counter-receptor 
interaction holds the key, rather the contribution of many. Therefore, for platelet 
adhesion to be involved in the initiation of atherosclerosis, an array of platelet and 
endothelial cell adhesion molecules may be involved. As such, I proposed to stay 
away from looking at specific cell adhesion molecules for my studies into platelet 
adhesion in the initial stages of atherosclerosis. 
 
A number of papers have looked at the development of lesions. The majority of these 
have not reported platelet adhesion. The lack of information may suggest that they 
have no role. It could, however, just be the result of studies concentrating on 
leukocyte, particularly monocyte, interactions because they are a pre-requisite for 
lesion formation. Otherwise, a lot of research has concentrated on lesion development 
without any reference to how they develop. Therefore, a lot of studies will not have 
looked for the presence of platelets.  
 
There are, however, a few reports of platelets adhering to the endothelium prior to 
lesion formation in animal studies and also at sights known to be key areas for lesion 
development in humans. Obviously, these may well be a result of the procedures used 
to collate this information. If, however, platelets were indeed involved it would be a 
fair assumption to make that blocking platelet adhesion or abnormalities that result in 
decreased activation or adhesion would reduce lesion formation.  
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The evidence in the literature is not very expansive. From what information there is, it 
is possible to conclude that there may well be a reduction in lesion formation but that 
either lesion formation still occurs. The studies looking at patients who regularly take 
anti-platelet drugs are likely to have developed lesions, based on the likelihood that 
they were placed on these drugs to treat cardiovascular disease or other conditions 
associated with atherosclerosis. Investigations into patients with platelet 
abnormalities, on the other hand, may well not have complete inhibition of platelet 
activation and / or adhesion. From this, I believe that it is clear to see that there is a 
lack of information already available that can determine whether platelet adhesion is 
an absolute requirement for lesion formation in diabetic conditions.  
 
My proposed research aimed to bridge this gap.  The aim was to compare, under 
similar laboratory conditions, various methods of investigating platelet adhesion to 
the endothelium. As such, it was hoped that a clearer understanding, of whether 
platelets adhere to the endothelium in diabetic conditions, could be achieved.  
 
The research was to centre on cultured endothelial cells (HUVECs), although it was 
hoped to acquire diabetic tissue for comparison. Platelet adhesion was to be 
determined by first incubating the cells with high glucose and / or various AGEs and 
then using flow cytometry or immunocytochemistry to visualise any platelet-
endothelial interactions. 
 
Dynamic flow studies were to be carried out to complement these studies. It was 
hoped that by using this technique it would allow for investigation into whether the 
processes involved for staining and fixing had any effect as well as to determine what 
difference flow conditions had on platelet interactions.  
 
I would have liked to be able to carry out an investigation into platelet adhesion in 
patients who suffered premature death. (One similar to that detailed by Katsuda and 
colleagues but with collection and imaging that would allow for any platelet adhesion 
to be determined (Katsuda et al., 1992).) This would have allowed me to see whether 
platelet adhesion was seen prior to and during lesion formation. The university 
facilities meant that this was not possible but, I believe that this type of research 
would be required to give a more accurate view. 
 
To expand on this research, I also proposed to look at platelet-leukocyte interactions 
with the endothelium. It is clear that leukocytes, in particular monocytes, are required 
for foam cell formation, and therefore lesion development. Platelets have cell 
adhesion molecules for leukocyte so it is likely that they interact. It may well be that 
platelets adhesion to leukocytes is an initiating factor for the creation of foam cells. 
Therefore, adhesion studies, using platelets and leukocytes were proposed. 
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4. Platelet-Leukocyte Complexes Increase Lesion Formation in the 
Initial Stages of Atherosclerosis 
4.1.  Introduction 
Platelet adhesion to the endothelium cannot alone account for atherosclerosis. For 
lesions to develop, foam cell formation is required. Therefore, monocyte adhesion and 
transmigration into the subendothelium is required. Leukocytes have cell adhesion 
molecules for both platelets and endothelial cells. (From the previous chapter and 
from Table 10, it was clear to see that both platelets and endothelial cells express cell 
adhesion molecules that act as receptors for leukocytes; for instance Mac-1 and LFA-
1.) It is possible that leukocyte interaction with platelets accelerates lesion formation 
by amplifying transmigration and differentiation into macrophages.  Indeed, evidence 
that platelet-leukocyte interactions may hold the key has already been mentioned in 
the previous chapter. It was reported that platelets rarely adhered in isolation and that 
platelets adhered to monocytes. These monocytes were reported to interact with the 
endothelium (Huo et al., 2003). I therefore hypothesize that platelet leukocyte 
complexes increase monocyte transmigration, above that normally expected, and as 
such contribute to accelerated atherosclerosis in diabetics. As such, I proposed to 
investigate whether platelet adhesion to leukocytes increases their adhesion to the 
endothelium under diabetic conditions. 
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Table 10: Leukocyte Cell Adhesion Molecules  
 
Name Receptor for Leukocyte Reference 
LFA-1 ICAM-1 
ICAM-2 
ICAM-3 
JAM-A 
Lymphocytes, monocytes, 
macrophages, and 
granulocytes 
(Bell et al., 1998, Casasnovas 
et al., 1999, Jun et al., 2001, 
Ostermann et al., 2002)  
Mac-1 Fibrinogen 
GPIIb/IIIa 
GPIbα 
JAM-C 
ICAM-1 
ic3b 
Factor X 
NIF 
HMW kininogen 
Neutrophils, monocytes, 
eosinophils, baophil and 
NK cells 
(Beller et al., 1982, Chavakis 
et al., 2003, Santoso et al., 
2002, Wang et al., 2005, 
Altieri and Edgington, 1988, 
Kawabata et al., 2002, 
Diamond et al., 1990, Rieu et 
al., 1994, Wright et al., 1988)   
P150.95 JAM-C 
Heparin 
ic3b 
Fibrinogen 
Denatured proteins 
High levels on monocytes 
and macrophages but also 
found on other leukocytes 
(Loike et al., 1991, Santoso et 
al., 2002, Vorup-Jensen et al., 
2007, Micklem and Sim, 1985, 
Davis, 1992) 
VLA-4 VCAM-1 
E-selectin, 
Fibronectin 
Thrombospondin 
Lymphocytes (Elices et al., 1990) 
  
Shimizu et al. 1991 
Wayner et al. 1989 
Yabkowitz et al. 1993  
VLA-5 Thrombospondin Lymphocytes and 
monocytes 
Yabkowitz et al. 1993  
L-selectin 
(CD62L) 
Sialyl Lewis(x) 
PSGL-1 
Carbohydrate 
ligands 
P- & E-selectin 
Leukocytes (da Costa Martins et al., 2004, 
Finger et al., 1996, Foxall et 
al., 1992, Walcheck et al., 
1996)  
PECAM-1 αVβ3 Leukocytes (Ashman and Aylett, 1991) 
PSGL-1 P-selectin 
E-selectin 
Neutrophils, monocytes, 
most T lymphocytes and 
some B lymphocytes 
(Zou et al., 2005, Moore et al., 
1995) 
JAM-A ? Leukocytes (Williams et al., 1999) 
JAM-C JAM-A Leukocytes (Liang et al., 2002) 
 
(Key: LFA-1 - lymphocyte function-associated antigen, αLβ2 or the CD11a/CD18 complex; ICAM - 
intracellular adhesion molecule; Mac-1, αMβ2 or the CD11b/CD18 complex; JAM - junctional adhesion 
molecule; iC3b - inactivated complement compound 3b; NIF - hookworm neutrophil inhibitory factor; 
p150.95, αXβ2 or the CD11c/CD18 complex; VLA - very-late antigen; VLA-4, αIVβ1 or the 
CD49d/CD29 complex; VCAM - vascular cell adhesion molecule; VLA-5, αVβ1 or the CD49e/CD29 
complex; PSGL - P-selectin glycoprotein; PECAM - platelet endothelial cell adhesion molecule) 
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4.2.  My Proposed Research 
To determine whether platelet-leukocyte interactions with the endothelium were 
required for lesions to develop in diabetic conditions I proposed to expand on 
adhesion studies. As in Chapter 3, cultured endothelial cells were to be incubated with 
high concentrations of glucose and / or AGEs prior to exposure to a suspension of 
platelets and leukocytes. Platelet-leukocyte interactions with the endothelium were 
then to be investigated by flow cytometry and immunocytochemistry, using the 
techniques already optimized for platelet adhesion studies. Dynamic flow studies 
would also allow for real time interactions as well as to determine whether platelets 
increased leukocyte adhesion. 
 
 
4.2.1. Flow Cytometry 
Flow cytometry detection of platelet and leukocyte interactions with cultured 
endothelial cells was to be achieved by using the method detailed in Chapter 3, 
with the inclusion of leukocytes. To achieve this, erythrocytes were to be lysed 
from whole blood samples. Platelets (both ADP-activated and non-activated) and 
endothelial cells were then to be stained, as previously described, with calcein-
AM or propidium iodide. Leukocytes would then be labelled with a tandem 
conjugated anti CD45 antibody (Peridinin chlorphyll protein conjugated with the 
Cy5.5 dye [PerCP-Cy] allowing for reduced compensation, less leaching, and less 
background for monocytes/macrophages than when using PerCP or PE-Cy.). This 
would allow for the detection of FL-1 scatter to represent platelets, FL-2 filter 
scatter for endothelial cells, and FL-4 filter scatter for leukocytes. As such, this 
would allow for determining whether endothelial incubation with high glucose 
and/or AGEs increased leukocyte-endothelial, platelet-endothelial, or platelet-
leukocyte interaction with the endothelial cells in comparison with the controls.  
 
Both diabetic and non-diabetic blood were to be used for these adhesion studies. 
This was so that it could be ascertained whether changes to platelets associated 
with long-term diabetes (such as hyperglycaemia and AGEs) could affect 
leukocyte adhesion. These changes were not expected to be seen from 30 minute 
incubation in conditions of high glucose and AGEs and therefore needed 
exploring further. 
 
 
4.2.2. Immunoctochemistry 
To compare the flow studies with adhesion to a monolayer, 
immunocytochemistry was planned.  The protocol determined for platelet 
adhesion studies was to be expanded to allow for detection of adhered leukocytes. 
The platelet and leukocyte were to be collected as for the flow cytometry studies 
and then administered to wells containing near confluent cultured endothelial 
cells on coverslips. (Again both diabetic and non-diabetic platelets were to be 
administered.) Following fixing, platelets would be labelled with FITC-CD42b 
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and leukocytes with Texas red-CD45. The endothelial cell nuclei would be 
stained with DAPI and a mounting medium applied. This would allow for 
visualization of whether platelets and leukocytes adhered to the monolayers under 
diabetic conditions. 
 
 
4.2.3. Dynamic Flow 
Adhesion was also to be investigated in real-time. With the use of a flow 
chamber, video analysis would allow for determination of whether blood flow 
affected interactions with the monolayer or tissue sample. Again, by adapting the 
procedure, detailed in Chapter 3, to pass both platelets and leukocytes across the 
endothelium, at various flow rates, it would be possible to see whether diabetic 
conditions resulted in increased leukocyte adhesion as a result of platelet 
interaction. A comparison could be made between leukocyte adhesion with or 
without the presence of platelets by lysing the red blood cells and counting the 
leukocytes present at various time intervals. Quantifying the amount present is 
much easier with this method that using flow cytometry and 
immunocytochemistry. These rely on quantifying by intensity of the 
fluorescence. With the flow cytometer, it was possible to gate a specific 
population and find out how long it takes to reach a certain cell count. This, 
however, is not that accurate because the population may contain cellular debris 
as well as some cells from other populations. 
 
 
4.3.  Research so Far 
There has been some research published that has investigated the role of platelets in 
leukocyte adhesion to the endothelium. This research is briefly reviewed here and 
includes cell culture as well as animal studies to investigate leukocytes, platelets and 
endothelial complexes. Studies have also looked into cell adhesion molecules 
involved in these interactions. 
 
The combined interaction of platelets, leukocytes and the endothelium has been 
reported by several research groups (Hirafuji and Shinoda, 1991, Huo et al., 2003, 
Ishikawa et al., 2007, Ishikawa et al., 2004, Ludwig et al., 2004, Massberg et al., 
2003, Mine et al., 2001). In a mouse model of atherosclerosis, it was found that 
platelet adhesion to the endothelium occurred via monocytes (Huo et al., 2003). In 
this study, the carotid bifurcation and external branch were exposed prior to perfusion 
of calcein labelled platelets and injecting rhodamine 6G to label leukocytes. 
Leukocyte-platelet interactions with the vessel wall were observed by intravital 
microscopy. Indeed, platelets rarely interacted with the endothelium individually.  
When isolated monocytes were administered, there was an increase in their arrest in 
the presence of activated platelets. This is also supported by other studies where the 
presence of platelet-mononuclear leukocyte conjugates has been reported to increase 
platelet recruitment and increased leukocyte arrest on the endothelium in the presence 
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of activated platelets (Massberg et al., 2003, Mine et al., 2001, da Costa Martins et al., 
2004, Hirafuji and Shinoda, 1991, Huo et al., 2003, Ishikawa et al., 2004).  
 
This does not necessarily intimate that platelet-leukocyte-endothelium (PLECs) or 
leukocyte-platelet-endothelial complexes (LPECs) occur, but that there is some sort of 
interaction, or cross talk, between them in some way that result in increased monocyte 
adhesion to the endothelium. There is, however, evidence to support the theory of 
PLECs and LPECs (Schulz et al., 2007, Ishikawa et al., 2007, Ishikawa et al., 2004, 
Diacovo et al., 1996, Bernardo et al., 2005).  
 
PLECs were clearly shown by intravital fluorescence microscopy (Ishikawa et al., 
2007, Ishikawa et al., 2004). Following bilateral common carotid artery occlusion in 
mice, a few LPECs were found but PLECs were much more numerous. There does 
not, however, appear to be evidence from other sources to support these findings. 
 
Leukocytes have been reported to adhere to endothelial-bound platelets by a number 
of different research groups (Bernardo et al., 2005, Diacovo et al., 1996, Schulz et al., 
2007). Schulz and colleagues investigated interactions in mice as well as with cultured 
cells (Schulz et al., 2007). Similar experimental conditions were used as those of 
Ishikawa et al. (Ishikawa et al., 2004, Ishikawa et al., 2007). However, different types 
of mice were used and different techniques were chosen for labelling leukocytes. This 
study concentrated on monocyte specific adhesion and therefore it is possible that 
monocytes adhere to the endothelium via platelets while other types of leukocytes 
interact directly. 
 
Cell culture studies have also shown that LPECs occur (Schulz et al., 2007). Flow 
cytometry was used to show adhesion to IFN-γ (interferon gamma) and TNF-α 
tumour necrosis factor alpha) activated endothelial cells (Schulz et al., 2007). This 
was supported by dynamic flow studies using thrombin activated platelets and non-
activated neutrophils, as well as histamine stimulated endothelial cells and leukocytes 
(Diacovo et al., 1996). All these in vitro studies used HUVECs 
 
Interestingly, Schulz and colleagues (Schulz et al., 2007) stated that leukocyte 
adhesion to HUVECs was observed mainly at sites of platelet adhesion and inhibition, 
using platelet blocking antibodies or the absence of platelets, significantly reduced 
leukocyte adhesion under arterial flow conditions (1000/s). With venous flow 
conditions (100/s), however, leukocyte adhesion was not dependent on platelet 
adhesion.  
 
A number of adhesion molecules have been reported to be involved in PLEC or LPEC 
interactions, including the selectins, PSGL-1, ICAM-1, Mac-1, LFA-1, VLA-4, and 
VWF (da Costa Martins et al., 2007, da Costa Martins et al., 2004, Alvarez et al., 
2004, Barry et al., 1998, Bernardo et al., 2005, Diacovo et al., 1996, Kirton and Nash, 
2000, Schulz et al., 2007).  
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Leukocytes have also been observed adhered to HUVEC bound platelets under high 
shear flow conditions (Bernardo et al., 2005, Diacovo et al., 1996). Diacovo and team 
found that neutrophil adhesion was Mac-1 dependent and that ICAM-2 and LFA-1 
were not involved. Adhesion was reported to decrease with increasing flow rates 
(from 0.75 to 35 dyn/cm
2
). On the other hand, Bernardo and colleagues looked at 
higher shear rates (20 and 40 dyn/cm
2
). Under these conditions, leukocytes interacted 
and rolled on platelets adhered to mouse mesenteric venule endothelium-bound ultra 
large von Willebrand factor (ULVWF) via P-Selectin. 
 
P-selectin has been extensively reported to be involved in platelet-leukocyte 
interactions (da Costa Martins et al., 2007, Alvarez et al., 2004, Diacovo et al., 1996, 
Kirton and Nash, 2000, Schulz et al., 2007, da Costa Martins et al., 2004). Other cell 
adhesion molecules have, however, limited published information to determine their 
involvement.  
 
Cell culture studies have shown that monocyte adhesion to HUVECs could be 
inhibited via platelet P-Selectin and PSGL-1 (da Costa Martins et al., 2007, da Costa 
Martins et al., 2004, Schulz et al., 2007). A reduction in adherence was also found by 
blocking E-Selectin, L-Selectin and Mac-1, but not LFA-1 or ICAM-2 (da Costa 
Martins et al., 2007, da Costa Martins et al., 2004, Diacovo et al., 1996). In human 
microvascular endothelial cells, however, it has been reported that blocking Mac-1 
and LFA-1 reduces neutrophil interactions with endothelium-bound platelets (Kirton 
and Nash, 2000). 
 
One other study, interestingly, highlighted the variation in cell adhesion molecule 
contribution associated with vessel type (Alvarez et al., 2004). They found that mice 
infused with anti-P-selectin and anti-E-selectin antibodies exhibited a decrease, to 
basal level, in platelet-leukocyte adhesion in arterioles, suggesting the role of the 
endothelium in platelet interactions with leukocytes. There was no effect reported in 
venules. 
 
This poses the question as to whether the type of interaction seen is dependent on the 
cells used and the experimental design. For instance, the type of cells used, whether 
the investigations are in vivo or in vitro, the antibodies used, and the detection 
methods. However, my hypotheses were not dependent on determining this, instead 
whether platelet adhesion could allow for increased leukocyte adhesion. 
 
Other research has investigated whether platelet depletion or thrombocytopenia 
affects leukocyte adhesion (Nishijima et al., 2004, Merhi et al., 1997, Kovacs and 
Caen, 1979). Anesthetised pigs and rats given an anti-platelet serum showed a 
reduction in leukocyte adhesion. Other studies, however, suggest that 
thrombocytopenia resulted in increased leukocyte adhesion (Kovacs and Caen, 1979). 
The experimental design, however, was quite different. Firstly one used pigs and the 
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other rats for the research. They used different sedation and anesthetic drugs. One 
looked at radio labelled neutrophils while the other just counted granulocyte adhesion 
using a microscope and they used different time frames for anti-platelet serum 
administration prior to analysis.  This makes comparison very difficult and does not 
really help to determine whether the discrepancies are a result of the animal model 
used or the experimental procedure. They also do not determine whether monocyte 
adhesion is increased, which is of most interest for my research.  
 
There also does not appear to be any studies that have concentrated on investigating 
increased leukocyte adhesion to the endothelial as a result of platelet adhesion under 
diabetic conditions. My research would therefore allow for determination as to 
whether increased platelet-leukocyte interactions with the endothelium occur 
following endothelial exposure to diabetic conditions – high glucose and / or AGEs. If 
the research points to this then it is likely that platelets have a key role in the initiation 
of accelerated atherosclerosis. It may also highlight whether physical interaction is 
required between platelets and leukocytes or whether there is some sort of cross talk 
that leads to increased leukocyte interaction. This will be ascertained by seeing 
whether the presence of platelets and leukocytes increase leukocyte adhesion 
compared with leukocytes on their own. 
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Table 11: Overview of Research Indicating Platelet-Leukocyte-Endothelial 
interactions  
 
Adhesion Molecule Detail Reference 
General Platelet adhesion to ECs when 
PMN are present 
Activated platelets caused 
leukocyte adhesion to ECs 
Platelet-leukocyte interactions 
increased leukocyte rolling on the 
endothelium in mice 
Platelets interacted with leukocytes 
that were arrested on the 
endothelium.  
 
Platelet-leukocytes rolled on 
endothelium in vivo 
(Hirafuji and Shinoda, 
1991) 
(Ishikawa et al., 2004)  
(Huo et al., 2003) 
 
 (Massberg et al., 2003, 
Mine et al., 2001, 
Ludwig et al., 2004)  
(Ishikawa et al., 2007) 
P-selectin Platelets adhered to ECs and 
initiate the expression of platelet P-
selectin. This results in adhesion of 
leukocytes 
(Schulz et al., 2007) 
L-selectin PMCs adhered to the endothelium. 
This is reduced by mAb anti-L-
selectin 
(da Costa Martins et al., 
2004) 
P-selectin, PSGL-1, β1, β2 Monocytes in PMCs have greater 
affinity for the endothelium 
(da Costa Martins et al., 
2007) 
P-selectin, β2, α4, ICAM-
1, E-selectin 
P-selectin & β2 are involved in 
arterioles, ICAM-2, β2 & α4 are 
involved in veins, none are 
involved in venules 
(Alvarez et al., 2004) 
P-selectin & Mac-1 P-selectin-Mac-1 interaction for 
platelet-leukocyte adhesion when 
the platelets were attached to the 
endothelium 
(Diacovo et al., 1996) 
P-selectin, Mac-1, LFA-1 Blocking P-selectin stopped 
leukocyte adhesion to bound 
platelets. Initial interaction was 
mainly by Mac-1. LFA-1 involved. 
(Kirton and Nash, 2000) 
P-selectin & VWF Leukocytes adhered to bound 
platelets (ULVWF strings) under 
shear stress 
(Bernardo et al., 2005) 
 
(Key: ECs - endothelial cells; PMN - Polymorphonuclear; ICAM - intercellular adhesion molecule; 
LFA - lymphocyte function associated antigen; PMCs - platelet-monocyte complexes; PSGL - P-
selectin glycoprotein ligand; VWF - von Willebrand factor; UL-VWF - ultra large von Willebrand 
factor) 
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4.4. What can be concluded? 
Leukocytes, specifically monocytes, are recruited in the initial stages of 
atherosclerosis. Indeed, lipid phagocytosis by macrophages is a prerequisite for lesion 
formation. Leukocyte adhesion has been shown to occur when platelets are adhered to 
the endothelium and therefore it is possible that platelets may have a role to play in 
leukocyte recruitment. Platelet interaction with leukocytes under diabetic-like 
conditions was explored to ascertain whether they accounted for accelerated 
atherosclerosis in these circumstances.  
 
My studies aimed to investigate whether platelet adhesion increased leukocyte 
adhesion to the endothelium under diabetic-like conditions. I also hoped to determine 
whether this was via platelet-leukocyte-endothelial, leukocyte-platelet-endothelial, 
some sort of cross talk between platelets and leukocytes, or a mixture of all of these. 
If increased leukocyte adhesion was observed it is likely that platelets are involved in 
lesion formation.  
 
Published work, to date, highlights that the role of platelets in leukocyte adhesion in 
diabetic-like conditions has not been explored. It does, however, show that activated 
platelets, or platelets under high shear flow conditions, increase leukocyte affinity for 
the endothelium. Both platelet-leukocyte-endothelial and leukocyte-platelet-
endothelial interactions have been reported. The precise nature of these interactions 
has not been resolved conclusively; however, blocking studies suggested that ICAM-
1, E-Selctin, P-Selectin, PSGL-1, VWF, VLA-4, LFA-1, and Mac-1 may be involved. 
 
From this research I hypothesized that diabetic-like conditions would lead to 
increased leukocyte adhesion in the presence of platelets. Whether this was as a result 
of direct interaction or as a result of cross-talk was to be determined and also, whether 
platelet activation under high shear rate conditions was required. To continue on from 
this research, I also proposed to determine what effect diabetic-like conditions would 
have on endothelial activation or dysfunction that would allow for increased lesion 
formation. This would allow a clearer understanding of what processes are involved 
in accelerated lesion formation associated with diabetics. 
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5. Diabetes Causes Accelerated Atherosclerosis by Increasing 
Endothelial Dysfunction 
5.1.  Introduction 
Diabetes results in increased lesion formation. As such, this disease must increase 
leukocyte adhesion to the endothelium. It is believed that this is the result of 
endothelial dysfunction. There is no specific definition for the term endothelial 
dysfunction, but it is generally considered to be any changes that result in a pro-
inflammatory, pro-adhesive, pro-thrombotic condition that is often associated with 
altered protein expression following stimulation with cytokines (and this is the basis 
for the definition used here) (Zimmerman et al. 1999). It is therefore a term used to 
encompass a number of disturbances in the normal function of the endothelium, 
including changes in vasomotor responses, permeability, proliferation, and cell 
adhesion molecule expression. There are a number of pathologies linked to 
endothelial dysfunction; these include hyperglycaemia, insulin resistance, advanced 
glycation end-product (AGE) formation, and oxidative stress (overviewed in Tables 
12-14). Any one or a combination of conditions may be present at a specific point in 
time.  
 
There are many reviews that discuss, in detail, endothelial dysfunction and its various 
causes (Caballero, 2003, Cai and Harrison, 2000, De Vriese et al., 2000, Esper et al., 
2006). Research investigating the effects of hyperglycaemia and AGEs, due to 
diabetes, on various markers of endothelial dysfunction is concentrated on here, due 
to the link between diabetes and accelerated atherosclerosis. 
 
Diabetes, both type 1 (T1DM) and type 2 (T2DM), is considered to be one of the 
main causes of endothelial dysfunction and reactive oxygen species (ROS) formation. 
It has been suggested that endothelial dysfunction in T2DM is likely to be caused by 
poor blood glucose control and increases in glucose metabolism via the polyol 
pathway. In T1DM endothelial dysfunction has also been linked with oxidative stress 
but what causes this is unknown. The exact cause of endothelial dysfunction in 
diabetes is still, however, in question. 
 
In T2DM, exposure to higher than normal levels of blood glucose, over a prolonged 
time period, results in a condition known as glucose toxicity. Glucose toxicity is 
known to cause severe deterioration in the function and number of pancreatic β-cells 
(Robertson et al., 1992). It is therefore likely that high concentration of glucose will 
have an adverse effect on other tissues, including the endothelium.  
 
Research suggests that hyperglycaemia does indeed affect the endothelium. High 
levels of glucose cause changes in vasomotor control, increased production of the 
reactive oxygen species, formation of glycation end products (AGEs), production of 
metalloproteinases (MMPs), and potentially irreversible increased endothelial 
permeability as well as monocyte adhesion (De Vriese et al., 2000, Donnini et al., 
2003, Graier et al., 1999, Heitzer et al., 2001, Uemura et al., 2001).  
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Hyperglycaemia also results in an increase in glucose metabolism via the polyol 
pathway. (Under normal physiological conditions, glucose metabolism occurs, almost 
exclusively, via glycolysis.) This increase in flux results in a reduction in (Na
+
 / 
K
+
)ATPase activity due to activation of the PKC pathway and an increase in the 
NADH:NAD ratio (Brownlee, 2001). As such, it also increases production of oxygen-
derived free radicals. Free radical production in diabetics is therefore higher. It has, 
however, not only been reported to be caused by an increased flux in the polyol 
pathway, but also due to increased glycation, decreased NO availability (due to 
increased peroxynitrile formation), and decreased eNOS activity (uncoupled eNOS 
has been found in diabetic patients, which is thought to be due to decreased 
availability of NO) (Jay et al., 2006). 
 
Enhanced levels of circulating free radicals in diabetics have been linked with cellular 
damage. This is exacerbated by a decrease in the production and effect of antioxidants 
(Jay et al., 2006). The result is oxidative stress. Evidence suggests that oxidative 
stress is linked to the occurrence of complications associated with diabetes, including 
microvascular disease, cardiac complications and atherosclerosis (Jay et al., 2006, 
Heitzer et al., 2001, Aydin et al., 2001, Delbosc et al., 2005). Oxidative stress is 
known to result in endothelial dysfunction and therefore will result in an array of 
changes to the endothelium, including making it pro-adhesive. (Markers for oxidative 
stress and endothelial dysfunction in diabetics can be seen in Figure 13.) It is possible 
that it would result in platelet adhesion as well as increased monocyte interactions. To 
investigate whether this is likely, under diabetic conditions in vitro, various 
experiments were planned. These included looking at whether incubation of 
endothelial cells with high concentrations of glucose and / or AGEs resulted in 
changes to the viability of the monolayer, increased expression of cell adhesion 
molecules, pro-inflammatory and adhesive cytokines, as well as various reactive 
oxygen species. I hypothesized that a combination of these diabetic conditions would 
results in changes to all these markers of endothelial dysfunction and therefore it was 
likely that increased monocyte (and possibly platelet) adhesion was a direct result.  
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Table 12: Endothelial Dysfunction  
 
Physiological Pathological 
Impaired NO function Decreased vasodilation and increased 
platelet adhesion 
Impaired prostacyclin production Decreased vasodilation and increased 
platelet adhesion 
Increased endothelin-1 Increased vasoconstriction 
Increased plasma PAI-1 Inhibits fibrinolysis 
Decreased tPA activity Decreased fibrinolysis 
Increased VWF Increased platelet adhesion 
Increased levels of IL-6 Inflammatory response 
Increased levels of pro-inflammatory 
chemokines 
Inflammatory response 
Increased expression of CAMs (ICAM-1, 
VCAM-1, E-selectin, PECAM-1, P-selectin 
Increased binding of leukocytes and 
platelets. 
Activation of inflammatory response 
Increased levels of hs-CRP Inflammatory response 
Increased cell permeability  
Increased LDL oxidation  
Increased VSMC proliferation and migration Lesion development 
Increased leukocyte adhesion Initiation of plaque formation 
 
(Key: NO - nitric oxide; PAI - plasminogen activator inhibitor type-1; tPA - tissue plasminogen 
activator; VWF - von Willebrand Factor; IL - interleukin; CAMs - cell adhesion molecules; ICAM - 
intercellular adhesion molecule; VCAM - vascular cell adhesion molecule; PECAM - platelet-
endothelial cell adhesion molecule; CRP - C-reactive protein; LDL - low density lipoprotein; VSMCs - 
vascular smooth muscle cells) 
 
 
Table 13: Overview of the Causes of Endothelial Dysfunction  
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Hyperglycaemia 
 
+/- +/- + + + + +  + + + 
Insulin resistance 
 
+ + +/-    +  +  + 
Glycation 
 
+ + + + + +   +  + 
Oxidative Stress 
 
+ + + + +  + + + + + 
 
(Key: ROS - reactive oxygen species; AGEs - advanced glycated end-products; CAM - cell adhesion 
molecule; MMP – metalloproteinase; + = for, - = against, +/- = both evidence for and against) 
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Table 14: Markers of Endothelial Dysfunction in Diabetes mellitus  
 
T1DM T2DM 
Plasma VWF (except in early, uncomplicated, 
regulated diabetes) 
Plasma VWF 
VCAM-1 up-regulation Thrombomodulin expression 
Endothelin-1 expression tPA expression 
PAI-1 expression PAI-1 expression 
Collagen type IV fragments Collagen type IV 
Microalbuminuria Microalbuminuria 
Impaired NO-mediated vasodilation (except in 
early, uncomplicated, regulated diabetes) 
 
 
(Key: type 1 diabetes mellitus (T1DM); type 2 diabetes mellitus (T2DM); von Willebrand factor 
(VWF); vascular cell adhesion molecule (VCAM); tissue plasminogen activator (tPA); plasminogen 
activator inhibitor (PAI)) 
 
 
 
5.2.  My Proposed Research 
To test this hypothesis, a number of studies were planned. These included looking at 
the effect of high concentration of glucose and AGEs on the endothelium by 
investigating their effect on endothelial cell viability, cell adhesion molecule up-
regulation, reactive oxygen species generation, and cytokine production. The findings 
from these would give an indication to whether these diabetic-like conditions directly 
result in abnormal endothelial function that could indicate endothelial dysfunction. 
They may also allow for further understanding into whether these conditions could 
account for the accelerated formation of lesion associated with diabetes. 
 
 
5.2.1. Cell Proliferation 
Cell proliferation and apoptosis are both indicators of endothelial dysfunction. 
They have also been reported to be increased as a result of hyperglycaemia 
(Curcio and Ceriello, 1992, Cagliero et al., 1995, Esposito et al., 2001). This 
research, however, does not look at the indirect effects of increased glucose 
concentrations, such as higher levels of AGEs. Therefore, I planned to investigate 
whether AGEs, individually or in conjunction with high concentrations of 
glucose, resulted in changes to cell proliferation rates.  
 
Cell proliferation is a measure of the number of cell dividing within a sample. As 
such, it is closely linked indicators of the viability of the endothelium. To 
measure changes to endothelial cell proliferation I used a commercial cell 
proliferation assay as well as growth curves. For the proliferation assay a 
suspension of 20,000 endothelial cells were added to each well of a 96-well plate. 
The cells were then incubation overnight to allow for adhesion prior to 
treatments. Treatments consisted of a range of glucose concentrations (11, 22, 
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33mM), various purities and concentrations of glycated albumin, glycated 
haemoglobin, and a mixture of the glycated proteins with concentrations of 
glucose. Controls included 5.5mM glucose and non-glycated protein. To check 
for consistency and reproducibility, four wells were tested under each condition 
in three separate experiments. 
 
The cells were then incubated for 24, 48, or 72 hours before using a commercial 
cell proliferation solution and a fluorescent plate reader (at 492nm) to determine 
viability. ANOVA and the Tukey test were used for determining statistical 
significance between the control and treatments. 
 
To complement the cell proliferation studies, growth curves were to be obtained 
for each treatment. The growth curves were to be done by plating 24-well plates 
with a suspension of 10,000 cells. Each day, for 5 days or until confluent, four 
random areas would be counted using an inverted microscope and photographic 
images taken. The cell counts would then be plotted onto a graph to give a growth 
curve. The growth curve could then be used to compare the treatments with those 
of the controls to determine whether they resulted in growth inhibition, 
acceleration, or had no effect at all. 
 
 
5.2.2. Cell Adhesion Molecule Expression 
Endothelial dysfunction is associated with activation of the endothelium. 
Activation causes changes in the expression of cell adhesion molecules and 
therefore likely to result in cell adhesion.  (There are a number of cell adhesion 
molecules that have been reported to have increased expression associated with 
endothelial dysfunction. An overview of these can be found in Table 15.) To 
investigate whether the consequence of diabetic-like conditions is endothelial 
activation, research was proposed to look at up-regulation of cell adhesion 
molecules associated with both platelet and leukocyte adhesion. The cell adhesion 
molecules proposed for investigation were αvβ3 (firm platelet adhesion), P-
selectin (transient platelet interactions), E-selectin (leukocyte adhesion) and VWF 
(an intermediate associated with lots of cell adhesion molecules for both platelets 
and leukocytes). All these cell adhesion molecules are expressed on endothelial 
activation and therefore quantitative analysis was required to determine whether 
these conditions resulted in activation. 
 
It was decided to look for both protein and gene expression for these cell 
adhesion molecules. This would provide both a check on the results obtained 
from one of the procedures but also allow for determining whether activation was 
transient or sustained. 
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Table 15: Cell Adhesion Molecules Involved in Endothelial Dysfunction  
 
CAM Detail Reference 
VCAM-1 High glucose increased expression of 
VCAM-1. This was inhibited by blocking 
PKCβ 
Kouroedov et al. 2004 
VCAM-1 & 
ICAM-1 
Incubation of HAECs with glucose 
increased the expression of VCAM-1 but 
no effect on ICAM-1 expression 
Incubation of HUVECs with glucose 
increased the expression of VCAM-1 and 
ICAM-1 
Piga et al. 2007 
 
 
Tsuneki et al. 2007 
VCAM-1,  E-
selectin, & 
ICAM-1 
High concentrations of glucose up-
regulated the expression of these CAMs on 
HUVECs (tissue sample) 
Altannavch et al. 2004 
E-selectin & 
ICAM-1 
Incubation of HSVECs with glucose 
increased the expression of these  
Haubner et al. 2007 
P-selectin & 
ICAM-1 
HUVECs expressed P-selectin & ICAM-1 
upon incubation with glucose 
Puente Navazo et al. 
2001 
ICAM-1 & 
PECAM-1 
Short term exposure of HUVECs to high 
concentrations of glucose resulted in 
increased levels of ICAM-1, but no effect 
on PECAM-1. Longer term exposure 
resulted in ICAM-1 up-regulation but 
down-regulation of PECAM-1 from that of 
the control 
Baumgartner-Parzer et 
al 1995 
VWF Increased expression of VWF following 
incubation of BAECs with HG 
Increased expression in diabetics and 
people with impaired glucose tolerance 
Ascher et al. 2001 
 
Leurs et al. 2002 
 
(Key: CAM – cell adhesion molecule; VCAM - vascular cell adhesion molecule; HAECs - human 
arterial endothelial cells; PKC - protein kinase C; ICAM - intercellular adhesion molecule; 
HUVECs - human umbilical vein endothelial cells; HSVECs - human saphenous vein endothelial 
cells; PECAM - platelet-endothelial cell adhesion molecule) 
 
 
 
5.2.2.1. Immunocytochemistry 
Protein expression of the cell adhesion molecules was investigated using 
immunocytochemistry. Endothelial cells were cultured in 6-well plates 
containing coverslips. Treatments of the various concentrations of glucose 
and/or AGEs (as previously described) along with the relevant controls were 
administered when the cell were approximately 75-80% confluent (dependent 
on the incubation period). The cells were then incubated for either 24 or 48 
hours. Subsequently, the monolayers were fixed using 70% ethanol and 4% 
paraformaldehyde. P-Selectin, E-Selectin, αvβ3, and VWF were labelled using 
primary antibodies and then a FITC conjugated secondary antibody was added. 
The endothelial nucleus was stained using 4',6-diamidino-2-phenylindole 
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(DAPI) and then a mounting medium was also applied to prevent loss of 
fluorescence and bleaching of fluorescein isothiocyanate (FITC).  
 
Up-regulation of the cell adhesion molecules were investigated separately to 
allow for a clear representation of which ones were expressed. ADP was used 
as a positive control and untreated cells were used as a negative control. Non-
specific binding was also investigated. All experiments were done in triplicate 
and the experiments were repeated three times to check for reproducibility. 
 
The process of fixing and staining, with its many washing steps may result in 
changes to the endothelial cells. Therefore, I believed that it was important to 
compare these findings with those produced using a different method. 
Polymerase Chain Reaction (PCR) provides a way of investigating whether 
gene up-regulation occurs. It does not rely of the physical representation of the 
corresponding protein. It may, therefore, provide a way of looking for up-
regulation prior to any expression.  Also, it would allow for determining 
whether up-regulation is sustained over a period of time.  
 
 
5.2.2.2. PCR 
To determine the gene expression the cell adhesion molecules in question it 
was decided to use real time PCR. Primers were bought from a commercial 
company. For real time PCR, cultured cells (75-85% confluent T-75 flasks) 
were treated with various concentrations of glucose (5.5mM, 11mM, 22mM) 
with or without the various glycated proteins. Non-glycated proteins and 
5.5mM glucose were used for negative controls.  They were then incubated for 
either 24 or 48 hours prior to RNA extraction. 
 
Extraction was carried out using a Total RNA Isolation Reagent (TRIR), after 
trypsination of the cells. As part of this process, chloroform allows for the 
separation of the homogenate into two phases. RNA is contained in the 
aqueous phase while the DNA and proteins are in the organic phase. RNA is 
then precipitated by addition of isopropanol. The RNA was then incubated 
with RNA inhibitor and DNase prior to quantifying using a spectrophotometer. 
The absence of genomic material was then confirmed using gel 
electrophoresis. 
The RNA samples were then reverse transcribed (RT-PCR) using a 
thermocycler. Total RNA was mixed with a RT-PCR kit and then cycled as 
per the procedure to obtain cDNA. This was then amplified using the supplied 
primers and SYBR green master mix.  
 
Comparison of genetic and protein expression give an indication of the effect 
of diabetic conditions on up-regulation of these endothelial cell adhesion 
molecules. It was expected that there would be some up-regulation of these 
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cell adhesion molecules associated with diabetic-like conditions. These 
investigations, however, were designed to be done under static conditions 
unlike in vivo.  As such, I decided that a comparison between these results and 
those obtained from dynamic flow conditions would give a better 
understanding of the processes involved in humans.  
 
 
5.2.2.3. Dynamic Flow 
Various papers have suggested that up-regulation of certain endothelial cell 
adhesion molecules can be dependent on blood flow conditions. Therefore, to 
explore this, dynamic flow studies were carried out to determine whether high 
shear rate had any effect of the expression of αvβ3, P-selectin, E-selectin, and 
VWF under diabetic conditions. These findings were then compared with 
those under static conditions.  
 
The experimental conditions used for adhesion studies were utilized for these 
studies, although no platelets or leukocytes were administered. Instead, cell 
culture medium was pumped across the cells, with or without the various 
concentrations of glucose and/or AGEs (as mentioned previously). Flow 
conditions (physiologically normal [0.9 dyne/cm
2
] and high shear rate [1.5 & 3 
dyne/cm
2
]) were maintained for 24 or 48 hours prior to analysis using either 
immunocytochemistry or PCR. 
 
The findings were then directly compared with those obtained without using 
the flow chamber. I expected that there would be greater up-regulation of the 
cell adhesion molecules under high shear rates but those low shear rates would 
be comparable with static flow. Their expression is important for leukocyte 
(and platelet) adhesion but, cell adhesion molecules are not the only indicator 
of endothelial dysfunction. Indeed, the production of reactive oxygen species 
is probably one of the main culprits for endothelial damage and therefore a key 
indication of endothelial activation. 
 
 
5.2.3. ROS Production 
Reactive oxygen species (ROS) is a term used to describe a number of highly 
reactive compounds such as free radicals, oxygen radicals and peroxides (see 
Table 16). They are produced as a by-product of respiration and are used for 
vasomotor control and for cell signalling. Their concentrations can, however, be 
significantly increased as a result of environmental stress. This can result in 
endogenous antioxidants being overwhelmed by the ROS resulting in cellular 
damage. This is known as oxidative stress. 
 
Evidence suggests that hyperglycaemia increases the production of ROS 
(Inoguchi et al., 2000). Under normal physiological conditions the production of 
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superoxide anion results in hydrogen scavenging, ultimately producing water. 
Hyperglycaemia, however, results in an increased metabolism and hydrogen 
scavenging cannot keep pace.  
 
Hyperglycaemia also results in an increase in flux through the polyol pathway 
(Van den Enden et al., 1995). The polyol pathway, indirectly, produces ROS. 
ROS are normally quenched by NADH but, because of the increase in sorbitol 
production, availability of NADH for ROS quenching is diminished. 
 
Increased concentrations of peroxynitrite, superoxide anion, and nitric oxide have 
also been reported in diabetics (Schaeffer et al., 1999, Redondo et al., 2005, 
Trovati et al., 1997). Interestingly, the increase in nitric oxide does not 
correspond with other studies that report decreased nitric oxide synthase (NOS) 
production (Schaeffer et al., 1999, Queen et al., 2003, Martina et al., 1998, Rabini 
et al., 1998). The increase in nitric oxide is likely to indicate the initial phase of 
hyperglycaemia, where there is an increase in NOS and associated nitric oxide 
production. The decrease in NOS, however, is thought to be the result of 
prolonged exposure to hyperglycaemia, which is known to lead to decreased NOS 
and NO activity. 
 
In diabetics, the increase in ROS production may be exacerbated by a decrease in 
antioxidant production. The availability of vitamin C in diabetic platelets is 
significantly lower than in controls (Sarji et al., 1979). As such, oxidative stress is 
likely to occur. Therefore, I wanted to establish whether diabetic-like conditions, 
in vitro, resulted in increased ROS production. There are, however, a number of 
different types of reactive oxygen species and many techniques for investigating 
them. All of which have their advantages and disadvantages. At present, there is 
no panacea for ROS detection. As such, I decided to choose a couple of methods 
for ROS detection that suited the available equipment. Although this is not ideal, 
it would allow for an indication of whether there was an increase in general ROS 
production under these conditions.  
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Table 16: Types of Reactive Oxygen Species  
 
Name Characteristics 
Hydroxyl radical (
.
OH) Local damage; highly reactive 
Superoxide anion (O2
-
) Formed from donation of electrons from AGE 
formation 
Hydrogen peroxide (H2O2) Formed from donation of electrons from glycated 
proteins; not a free radical but readily forms 
hydroxyl radical 
Hydroperoxide (ROOH) Highly reactive 
Peroxyl radical (ROO
.
) Reacts with DNA 
Hypochlorous acid (HOCl
.
) Reacts with bio-molecules, including proteins, 
DNA, RNA, and cholesterol 
Peroxynitrite (ONOO
-
) Formed from oxidation of nitric oxide (NO + O2
-
) 
Nitric oxide (NO) NOS catalyses NO production from L-arginine. 
Involved in vasodilation 
Chlorine monoxide (Cl O
-
) Highly reactive 
Lipid radicals (i.e. LO & 
LONO) 
Formed by oxidation of unsaturated lipids 
 
(Key: AGE - advanced glycated end-product; DNA - deoxyribonucleic acid; RNA - 
ribonucleic acid; NOS – nitric oxide synthase) 
 
 
5.2.3.1. Griess Assay 
Nitric oxide is a widely distributed free radical that is synthesized from L-
arginine. It has a very small molecular weight and therefore can cross the 
endothelium and interact with the smooth muscle cells to mediate 
vasodilation. Free NO has a half-life of about 5 seconds and therefore direct 
investigations into this molecule are very difficult and not very reproducible. 
The Griess Assay, however, allows for detection of nitrite. (Nitrite is a stable 
breakdown product of NO.)  
 
Following the usual treatments to culture cells, as detailed previously, a Griess 
Assay kit was used to firstly construct a standard curve for quantitation. The 
absorption spectrum from the culture medium for each treatment was then 
compared with this standard curve to determine how much nitrite was 
produced. 
 
Controls were used to rule out background NO2- and NO3- and therefore 
restrict false positives. There are, however, some disadvantages of this 
method. The Griess reagent reaction is variable and therefore reproducibility 
can be a problem. It is also not possible, from this method, to determine how 
much of the sample's nitrate is converted to nitrite during analysis. The 
simplicity of this method and the ease of use under culture conditions, I 
believe, make this procedure preferable to other ways of detecting NO. NO, 
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however, is only one type of ROS and therefore, on its own, may not provide a 
true indication of endothelial function, especially because NO concentrations 
are dependent on NOS expression and prolonged endothelial activation can 
lead to reduced levels of NO. Therefore, it was decided that a more generic 
method for ROS analysis would also be investigated. 
 
 
5.2.3.2. Dihydrorhodamine Oxidation 
Dihydrorhodamine 123 (DHR) is readily oxidized by peroxynitrite to 
rhodamine 123, which allows for fluorescence detection. It is also oxidized 
directly or indirectly by, (and to greater or lesser extent by,) hydrogen 
peroxide, hydroxal radical, nitric oxide, superoxide anion, hyperchlorite anion, 
and peroxyl radical. As such, it allows for a general indication of ROS 
concentrations rather than quantification. 
 
Measurement of ROS concentrations was obtained by adapting a procedure 
used to investigate hydrogen peroxide levels in human coronary artery cells 
(HCECs) (Ni et al., 2004). Instead of treatments with lead and sodium acetate, 
the usual treatments with various concentrations of glucose and/or the different 
types of AGEs (and their associated controls) were administered. Detection 
was with flow cytometry (FL1 detection) following incubation of the 
endothelial cells with 2.5 µmol/L DHR for 3 hours. Statistical analysis was by 
ANOVA and the Tukey test. 
 
It has been reported that differences in experimental procedures for DHR 
analysis can result in discrepancies (van Pelt et al., 1996). This can make 
comparison with other investigations difficult. It was not seen as a barrier to 
this research because the results were to be compared with those from the 
Griess assay to give an indication rather than quantitative analysis.   
 
The expectations were that administration of both high concentrations and 
AGEs would increase ROS production. Increased ROS concentration is likely 
to result in oxidative stress, if prolonged. This has been linked with increased 
cytokine production. Therefore, the presence of these signalling compounds 
was also investigated. 
 
 
5.2.4. Cytokine Production 
Cytokines are a structurally diverse group of immunomodulating agents involved 
in autocrine and paracrine signalling. As such, they are important in the immune 
response. They are produced by many types of cells, including endothelial cells, 
but mainly leukocytes. Cytokines are divided into lymphokines, interleukins and 
chemokines. Lymphokines and interleukins have a wide range of actions and are 
mainly produced by T-Cells, but also by monocytes and endothelial cells. 
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Chemokines are a specific group of cytokines that are involved in chemotaxis, 
leukocyte activation and migration.  
 
Therefore, cytokines have a key role in inflammation and, as such, in 
atherosclerosis. Increased cytokine expression and endothelial dysfunction are 
associated with endothelial permeability, cell migration (monocytes, smooth 
muscle cells, and endothelial cells), cell proliferation and apoptosis (Dang et al. 
2005; Shigematsu et al. 1999; Stehouwer et al. 1992).  Furthermore, it is possible 
that they have their own part in endothelial activation / dysfunction.  
 
To determine whether in vitro diabetic-like conditions increase endothelial 
cytokine production, experiments were established to detect any correlating 
increases in expression of IL-6, IL-8, fractalkine, and MCP-1. This would give an 
indication of whether this environment would increase leukocyte (and platelet) 
adhesion to the endothelium. 
 
 
Table 17: Cytokines and Chemokines Synthesised by the Endothelium  
 
Type Name Reference 
Cytokines IL-6, IL-7 (Loppnow and Libby, 1989, 
Roye et al., 1998) 
CXC Chemokines IL-8, ENA-78, GRO-α, IP-10 (Claise et al., 1996, Kinoshita et 
al., 2008, Imaizumi et al., 2004, 
Murakami et al., 1995, Luster 
and Ravetch, 1987) 
CC Chemokines Eotaxin, MCP-1 (Cushing et al., 1990, Gawaz et 
al., 1998, Haubner et al., 2007, 
Piga et al., 2007, Rothenberg et 
al., 1995) 
CX3C Fractalkine (Bazan et al., 1997) 
 
(Key: IL - interleukin; ENA - epithelial-derived neutrophil attractant; GRO - growth regulated 
oncogene, IP - interferon-γ inducible protein; MCP - monocyte chemoattractant protein; RANTES 
- regulated on activation, normal T cell expressed and secreted) 
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Table 18: Cytokines and Chemokines Involved in Endothelial Dysfunction  
   
Cytokine / 
Chemokine 
Detail Reference 
IL-8 Increased production following exposure of 
HUVECs or HAECs to hyperglycaemic conditions  
Kinoshita et al. 2007 
(brief); Teramura et al. 
1997 (long term) 
MCP-1 Glucose induced MCP-1 expression and increased 
its production rate in HUVECs (T) HAECs (P) 
Haubner et al. 2007 ; Piga 
et al. 2007; Takaiski et al. 
2003 
 
(Key: TF - tissue factor; tPA - tissue plasminogen activator; PAI-1 - plasminogen activator 
inhibitor type-1; HG -  high glucose; HAECs - human arterial endothelial cells; VSMCs - vascular 
smooth muscle cells; IL - interleukin; HUVECs - human umbilical endothelial cells; MCP - 
monocyte chemotactic protein) 
 
 
5.2.4.1. ELIZA 
To determine cytokine up-regulation in diabetic-like conditions, enzyme-
linked immunosorbent assay (ELISA) was planned. ELISA is a highly 
selective technique that allows for quantification (via the use of standard 
curves) of soluble cytokines found in the culture supernatants. 
 
To avoid the need for serial dilutions to create a standard curve for 
quantification of the cytokines detected, I decided that a commercial sandwich 
cytokine ELISA kit for IL-6, IL-8, Fractalkine, and MCP-1 (monocyte 
chemotactic protein) would be used. The kit protocol would be followed to 
compare the optical density of the controls alongside of those for high glucose 
and/or AGE incubations. Statistical significance would be determined using 
AVOVA and the Tukey test. 
 
The assumption was made that the cytokines originated from the endothelial 
monolayer, because these would be the only cells present in these studies. To 
check this, it was decided that these findings would be compared with flow 
cytometry studies.  
 
 
5.2.4.2. Flow Cytometry 
Flow cytometry allowed for detection of endothelial bound cytokines. The 
endothelial cells were prepared and treated, as detailed previously. Following 
detachment by trypsin they were fixed and permeabilised using a commercial 
cell fixing solution, and then the cytokines were labelled using FITC-
conjugated antibodies. Each cytokine was analysed separately to reduce 
interference, as well as reduce cost (FITC-labelled antibodies tend to be 
cheaper than those detected by other filters) and allow for experimental 
simplicity by not needing to compensate for fluorescence spectral overlap.  
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It was expected that comparison of the density plots for IL-6, IL-8, 
Fractalkine, and MCP-1 would indicate that diabetic-like conditions increased 
cytokine production in a time dependent fashion. I did, however, expect to find 
that this was more pronounced in the ELISA studies and would be further 
exacerbated by high shear flow rates. 
 
 
5.2.4.3. Dynamic Flow 
Shear stress is known to lead to opening of the calcium-activated and 
potassium-activated channels. The resulting flux causes hyperpolarisation of 
the endothelial cells and activation of transcription factors, such as NF-kB. 
This transcription factor is known to induce cytokine and endothelial nitric 
oxide synthase (eNOS) expression. Therefore, it is likely that there is an 
associated increase in cytokine production as well as cell adhesion molecule 
up-regulation and nitric oxide production.  
 
As such, both the ELISA and flow cytometry studies were repeated under flow 
conditions, as detailed previously. For ELISA, the supernatant was collected 
over the period of the treatments to determine total concentrations. The flow 
cytometry experiments were done at specific incubation times (0, 24 and 48 
hours). This allowed for assessment of whether high shear flow rates increased 
cytokine production under diabetic-like conditions.  
 
All of these experiments would allow for a more encompassing view of how 
high glucose and AGEs affected endothelial activation and dysfunction. From 
this, it could be determined whether one of these environments, or a 
combination of the two had the greatest effect on normal endothelial function. 
This would give insight into what causes accelerated atherosclerosis in 
diabetics. Insight would also be gained, by comparison with the adhesion 
studies, into whether platelet adhesion or interaction with the endothelium is 
an initiator of lesion formation in these conditions. 
 
 
5.3.  Research to Date 
There has been a wealth of studies investigating endothelium dysfunction. It is still, 
however, not known what initiates it. Endothelial dysfunction encompasses a number 
of changes to the vessel wall, including changes in ROS production, cell adhesion 
molecule up-regulation, and vascular tone. It is therefore difficult to determine what 
the initiating factor is. All these changes impact on each other and it is likely that 
circumstances dictate the order of events. Studies that have involved investigating the 
effect of diabetic conditions on the endothelium are reviewed here. 
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5.3.1. Cell Viability and Proliferation 
One indicator of endothelial dysfunction is abnormal cell proliferation. There 
have been a number of in vitro studies that have found that  high glucose 
incubation resulted in a decreased cell count (Han et al., 2005, Ascher et al., 
2001, Lorenzi et al., 1985, Varma et al., 2005) and reduced cell proliferation 
(Curcio and Ceriello, 1992). An increase in endothelial apoptosis has also been 
reported (Sheu et al., 2005, Chai et al., 2000, Piconi et al., 2006, Quagliaro et al., 
2007, Baumgartner-Parzer et al., 1995, Tsuneki et al., 2007). It was found that by 
treating HUVECs with stable or oscillating high concentrations of glucose 
resulted in ROS mediated apoptosis (Piconi et al., 2006). This suggests that it is 
possible that hyperglycaemia, in vivo at least, may trigger endothelial apoptosis 
and therefore leukocyte and platelet adhesion.  
 
Investigations into cell viability, the proportion of living cells, are not so clear 
cut. It would appear that different types of glucose can affect viability. In one 
study, decreased HUVEC count was not associated with cell viability (the number 
of living cells was measured by excluding Trypan blue stained cells) when the 
cells were incubated with L-glucose (Varma et al., 2005). Others have reported 
that D-glucose decreased cell viability (Trypan blue staining) of human arterial 
endothelial cells (HAECs) as well as HUVECs, therefore suggesting that it is not 
cell dependent (Morishita et al., 1997, Rojas et al., 2003). With D-glucose being 
the sugar available in vivo, it is likely that these studies give a more correct 
indication of the effect of hyperglycaemia on cell growth and viability.  
 
This research suggests that in vitro induced hyperglycaemia reduces cell 
proliferation and viability, although viability is dependent on the type of sugar. A 
number of studies have investigated the effect of AGEs on cultured endothelial 
cells. A 40% reduction in cell proliferation has been reported as a consequence of 
treatments with glycated foetal serum albumin (AGE-FSA) (Ruggiero-Lopez et 
al., 1997). Treatment with glycated bovine serum albumin (AGE-BSA), however, 
resulted in an increase in cell numbers of 156%. Other studies have also reported 
increased cell proliferation following incubations with AGE-BSA (Hoffmann et 
al., 2002, Chibber et al., 1997). These studies have used relatively high 
concentrations of glycated albumin. Lower concentrations of AGE-BSA appear to 
reduce cell proliferation and increases endothelial apoptosis (Chibber et al., 1997, 
Kowluru, 2005). With concentrations of glycated proteins increasing with age and 
exposure to increased sugar concentrations, it is likely that lower concentrations 
are more representative of initial lesion formation. As such, cell repair is likely to 
be diminished. This may, however, be the result of the endothelial cells not 
initiating cell repair quickly under these conditions and that extended periods of 
exposure may result in increased proliferation. This theory was therefore explored 
with the research proposed in this thesis.  
 
It is clear that diabetic-like conditions have an effect on cell proliferation and 
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viability. However, it would appear that type and concentration of sugar and 
AGEs play a significant role in this. As such, is this also the case for expression 
of cell adhesion molecules? This is explored in the next section along with 
general research into the effect of diabetic conditions on cell adhesion molecule 
expression. 
 
Table 19: Endothelial Integrity  
 Detail Reference 
Permeability & 
migration 
HG increased cell migration 
 
Increased permeability linked with metal ions in 
PBS (used to prepare the AGEs) not the AGEs 
HG induced changes to actin-binding proteins and 
focal adhesion proteins 
Increased permeability is associated with PKC 
 
HG increased albumin permeability in non-diabetic 
rats 
(Stehouwer et al., 1997) 
(Hui et al., 2001) 
(Lee et al., 2004) 
 
(Dang et al., 2005) 
(Scalia et al., 2007) 
Cell number 
(proliferation & 
apoptosis) 
HG induces decreased HUVEC cell count  
 
 
HG induces decreased HUVEC cell count 
(probably by apoptosis and not decreased cell 
viability)  
Incubation of HAECs and VSMCs with high 
concentrations of D-glucose decreased cell 
viability, but L-Glucose and mannitol did not 
Cell proliferation is reduced following HG culture  
 
Decreased  BAECs cell count following incubation 
with HG 
HUVECs incubated with HG underwent apoptosis 
 
 
 
 
 
 
HG up-regulated COX-2 expression via NF-kB, 
this lead to HUVEC apoptosis via caspase-3 
activation. A combination of  HG, high insulin, and 
ox-LDL resulted in greater apoptosis than each one 
alone 
AGE-FSA decreased while AGE-BSA increased 
cell proliferation 
AGE-BSA increased cell proliferation 
 
Low concentrations of AGE-BSA decreased while 
high concentration increased cell proliferation 
AGE-BSA increased bovine retinal EC apoptosis 
(Han et al., 2005, 
Lorenzi et al., 1985) 
(Varma et al., 2005) 
 
 
(Morishita et al., 1997) 
 
(Curcio and Ceriello, 
1992) 
(Ascher et al., 2001) 
(Piconi et al., 2006, 
Quagliaro et al., 2007, 
Sheu et al., 2005, 
Tsuneki et al., 2007, 
Baumgartner-Parzer et 
al., 1995) 
(Chai et al., 2000) 
 
 
 
 
(Ruggiero-Lopez et al., 
1997) 
(Hoffmann et al., 2002) 
(Chibber et al., 1997) 
(Kowluru, 2005) 
77 
 
 
(Key for Table 19: HG - high glucose; HUVECs - human umbilical vein endothelial cells; PKC - 
protein kinase C; PBS - phosphate buffered saline; AGEs - advanced glycation end-products; 
HAECs - human aortic endothelial cells; VSMCs - vascular smooth muscle cells; BAECs - bovine 
aortic endothelial cells; PI - phosphatidyl inositol; LDL - low density lipoproteins); ECs – 
endothelial cells 
 
 
5.3.2. Cell Adhesion Molecule Expression 
The up-regulation of cell adhesion molecules may well be a marker of endothelial 
dysfunction (Liuba et al., 2003). It is known that activation of the endothelium 
initiates or increases the expression of numerous adhesion receptors and therefore 
it is likely to be a key determinant in endothelial dysfunction, as well as initiating 
atherosclerosis. Investigation into expression of adhesion molecules via protein 
and gene analysis, as well as immunocytochemisty and blocking antibodies, 
should indicate whether adhesion molecules for leukocytes and platelets are 
present in diabetic conditions. 
 
There is evidence to suggest that hyperglycaemia increases the expression of 
certain endothelial receptors (Table 15). It is generally recognised that the levels 
of soluble adhesion molecules should give an indication of expression and are 
known to be a good indicator of endothelial dysfunction (Serebruany and Gurbel, 
1999, Peng et al., 2005, Barbaux et al., 2001, Xie et al., 2000). Khare and 
colleagues, however, found that there was no correlation between soluble cell 
adhesion molecules and endothelial damage in patients with cardiovascular 
disease (Khare et al., 2005). This was based on 120 patients that had stabilized 
within 8-10 weeks following a myocardial infarction. Patients with diabetes and 
hypertension were ruled out. Family members without visible signs of 
cardiovascular disease as well as non-related controls were used to compare 
levels of soluble levels of cell adhesion molecules (sP-selectin, sE-selectin and 
sPECAM-1) using immunoassays. The results may well have been because there 
was a decreased clearance rate of adhesion molecules present in the plasma, 
rather than increased production.  Or they may have been related to advanced 
stages of atherosclerosis and therefore might not represent levels of soluble 
adhesion molecules in the early stages of atherosclerosis.  
 
When looking at the plasma levels of adhesion molecules and ligands it is also 
important to note that some are produced by more than one cell type, for instance 
VWF is synthesised by platelets as well as endothelial cells. With cell culture 
studies this is not a problem but is a key factor for in vivo research. When looking 
at patient studies of adhesion molecule it is also difficult to determine the 
originating cause of up-regulation. For instance, when looking at diabetics, to 
understand whether hyperglycaemia increases expression of both soluble and cell 
adhesion molecules, hypertension and hypercholesterolaemia need to be 
considered. Research has suggested that both of these risk factors for diabetes are 
linked the up-regulation of soluble adhesion molecules (Lim et al., 2004, Steiner 
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et al., 1994). 
 
Cell adhesion studies therefore allow for determining what effect hyperglycaemic 
conditions have to cell adhesion molecule expression. Research has indicated that 
vascular cell adhesion molecule-1 (VCAM-1) expression is increased following 
incubation of endothelial cell monolayers with high concentrations of glucose. 
This is thought to be a protein kinase C (PKC)-dependent mechanism because 
inhibition of PKCβ inhibited glucose induced up-regulation of VCAM-1 
(Altannavch et al., 2004, Kouroedov et al., 2004, Piga et al., 2007, Tsuneki et al., 
2007). 
 
Altannavch and colleagues not only found increased expression of VCAM-1,  
they also noted that E-selectin and ICAM-1 were also up-regulated under these 
conditions (Altannavch et al., 2004). Further investigations support the 
expression of E-selectin, suggesting that accelerated atherosclerosis in diabetes 
could be the result of E-Selectin dependent leukocyte adhesion (Haubner et al., 
2007). 
 
Other cell adhesion molecules have been found to be up-regulated under 
hyperglycaemic conditions. There was increased expression of P-selectin and von 
Willebrand factor (VWF) in endothelial cells incubated with high concentrations 
of glucose (Ascher et al., 2001, Puente Navazo et al., 2001). Raised levels of 
VWF have also been reported in diabetics with insulin intolerance (Baumgartner-
Parzer et al., 1995). This suggests that VWF could mediate platelet and leukocyte 
adhesion in diabetics. 
 
Platelet-endothelial cell adhesion molecule-1 (PECAM-1), on the other hand, 
does not appear to have a major role in adhesion to endothelial cells.  It has been 
reported that there was no change in PECAM-1 expression following short-term 
incubation with glucose, but long-term exposure resulted in down-regulation of 
this receptor (Baumgartner-Parzer et al., 1995). There does not, however, appear 
to be any other evidence to support or contradict this research. 
 
Hyperglycaemia increases VCAM-1, ICAM-1, E-Selectin, P-Selectin and VWF 
expression but possibly not PECAM-1. This would indicate that leukocyte and 
possibly platelet adhesion is likely to be increased under these conditions. 
Obviously, extended periods of hyperglycaemia is also associated with increased 
AGE concentration. Indeed, leukocyte rolling has been reported to be 
significantly increased following endothelial incubation with AGEs but reduced 
by blocking E-Selectin, ICAM-1, and VCAM-1. This would suggest that both 
high glucose and AGEs increase endothelial cell adhesion molecule expression. 
 
Rabbit studies have shown that daily intravenous injections of low concentrations 
(16mg/kg/day) of glycated rabbit serum albumin (AGE-RSA) led to increased 
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expression of VCAM-1 and ICAM-1 but not E-Selectin, following 4 months of 
treatment (Vlassara et al., 1995). This was observed at areas where lesions had 
formed. Expression, determined by monoclonal antibodies, was more pronounced 
in animals that were also fed on a cholesterol-rich diet. 
 
Cell culture studies show contradictions in the cell adhesion molecules up-
regulated, see Table 20. There are reports that both PECAM-1 and ICAM-1 have 
increased expression in some reports and not in others (Meng and Liu, 2003, 
Negrean et al., 2007, Otero et al., 2001, Schmidt et al., 1995, Sengoelge et al., 
1998, Mamputu and Renier, 2004). The difference in expression of PECAM-1 
appears to be related to the treatments. Incubations with glycated bovine serum 
albumin (AGE-BSA) had no effect, while glycated fibrinogen (AGE-Fibrinogen) 
increased both transcriptional as well as surface expression. 
 
As mentioned previously, ICAM-1 expression has been reported to be increased 
in rabbits injected with AGE-RSA (Vlassara et al., 1995). It would appear, 
however, that the concentration of glycated protein used can affect expression of 
this adhesion molecule. Incubations with AGE-BSA and AGE-Fibrinogen have 
been reported to both increase expression and have no significant effect (Schmidt 
et al., 1995, Sengoelge et al., 1998, Mamputu and Renier, 2004). The studies that 
showed increased expression used higher concentrations of AGE-BSA than the 
other. It should be noted, however, that the presence of endotoxins could have 
been involved. These studies either do not mention whether precautions were 
taken to minimize their presence or reported that small levels were present and 
therefore they may have contributed to ICAM-1 up-regulation. 
 
VCAM-1 is reported to be increased following incubations with both AGE-BSA 
and AGE-Fibrinogen. There have, however, been some discrepancies relating to 
methodologies. It has been suggested that the presence of endotoxins in the 
preparations can affect VCAM-1 up-regulation. Valencia and colleagues treated 
human microvascular endothelial cells (HMECs) with AGE-BSA for 18 hours 
(Valencia et al., 2004). (It should be noted that they found a difference in 
VCAM-1 expression based on the sugar used for BSA glycation.) Kunt and team, 
however, incubated human umbilical vein endothelial cells (HUVECs) with 1 
µM of AGE-BSA for 5 hours (Kunt et al., 1999). Therefore, the differences may 
well be as a consequence of experimental differences, possibly cell origin, 
concentration, (it was not possible to determine the molar concentration of AGE-
BSA administered in the paper of Valencia et al.,) or exposure time.  
 
Treatment with an anti-oxidant, α-lipoic acid, reduced VCAM-1 expression 
(Kunt et al., 1999). Antioxidant co-incubations were also found to decreased 
ICAM-1 expression (Mamputu and Renier, 2004). This would suggest that both 
ROS as well as cell adhesion molecules closely interact and therefore are difficult 
to investigate in isolation. Therefore, we can establish from the literature that it is 
80 
 
likely that hyperglycaemia and increased concentrations of AGEs increase the 
expression of some endothelial cell adhesion molecules. Treatments with 
antioxidants indicate that the expression of these cell adhesion molecules can be 
modulated by ROS concentrations. As such, the information available on the 
effect of diabetic-like conditions on ROS has been investigated here. 
 
Table 20: Effect of AGEs on Cell Adhesion Molecule Expression 
Model CAM Expression Reference 
Rabbit VCAM-1&ICAM-1 but not E-Selectin 
expression was increased following AGE-RSA 
injections for 4 months 
(Vlassara et al., 1995) 
HUVECs No effect on PECAM-1 expression following 
incubations with AGE-BSA 
(Meng and Liu, 2003, Otero et 
al., 2001) 
HUVECs Increased expression of VCAM-1 but not 
ICAM-1 following incubations with AGE-BSA 
(Schmidt et al., 1995) 
HUVECs Treatments with AGE-Fn & AGE-Alb. 
Increased transcription levels of E-Selectin at 
2.5 hours but not at 10 hours. No increase in 
surface expression. Increased surface expression 
of ICAM-1 & VCAM-1. Increased surface and 
transcriptional expression of PECAM-1 
(Sengoelge et al., 1998) 
HUVECs Increased VCAM-1 expression following 
treatment with endotoxin-free AGE-BSA. This 
was reduced by pre-treatment with α–lipoic acid 
(Kunt et al., 1999) 
HMECs AGE-BSA increased VCAM-1 expression 
unless it was endotoxin-free 
(Valencia et al., 2004) 
BRECs AGE-BSA (low endotoxin) treatments increased 
ICAM-1 expression. This was reduced by 
treatment with antioxidants 
(Mamputu and Renier, 2004) 
 
(Key: VCAM – vascular cell adhesion molecule; ICAM – intracellular adhesion molecule; AGE – 
advanced glycation endproduct; RSA – rabbit serum albumin; HUVECs – human umbilical 
endothelial cells; PECAM – platelet-endothelial cell adhesion molecule; BSA – bovine serum 
albumin; Fn – fibronectin; Alb – albumin; HMECs – human microvascular endothelial cells; 
BRECs – bovine retinal endothelial cells) 
 
 
5.3.3. Reactive Oxygen Species Production 
Oxidative stress has been linked with diabetes (Aydin et al., 2001, Leoncini et al., 
1997). This phenomenon occurs when the concentration of ROS outnumber those 
of antioxidants. The result can be endothelial dysfunction. This, in turn, sets off a 
series of events, including up-regulation of cell adhesion molecules (as mentioned 
previously), prostanoid production, and changes in vasomotor status. 
 
Hyperglycaemia has been linked with the production of ROS. It has been 
suggested that high glucose concentrations increase ROS production 1.5-fold 
(Graier et al., 1999). High glucose concentrations have also been shown to reduce 
antioxidant binding affinity (Ülker et al., 2004, Weidig et al., 2004, Kunisaki et 
al., 1993). As such, it would appear that there is not only an increase in ROS 
formation but that there is also a decrease in the ability to counter them. 
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There are a number of different ways of detecting ROS. All of which have their 
advantages and disadvantages. Most concentrate on specific ROS but some are 
more general. There is not, however, one method that can be used successfully to 
give the whole picture. As such, a lot of research appears to concentrate on one 
ROS. Superoxide anion levels, for instance, has been used quite substantially. 
The research indicates that this ROS is elevated following incubation of various 
endothelial cell lines with high concentrations of glucose (Cosentino et al., 1997, 
Graier et al., 1999, Tsuneki et al., 2007, Inoguchi et al., 2000).  There may, 
however, be some time-dependent factors. 
 
It has been reported that, initially, hyperglycaemia resulted in an increase in gene 
and protein expression of eNOS (Tsuneki et al., 2007, Srinivasan et al., 2004a, 
Ho et al., 1999). This resulted in an increase in production of the main 
vasodilator, nitric oxide, resulting in vasodilation and increased blood flow 
(Sobrevia et al., 1996, Kasai et al., 2001, Tesfamariam and Cohen, 1992). 
 
Long-term hyperglycaemia, on the other hand, results in a decrease in the 
concentration or reduction of the efficiency of eNOS (Cosentino et al., 1997, 
Noyman et al., 2002, Quagliaro et al., 2007, Kasai et al., 2001, Pieper et al., 1996, 
Srinivasan et al., 2004a). Therefore, although there is an increase in the 
production of eNOS, there is a decrease in nitric oxide due to the inefficiency of 
eNOS in producing nitric oxide. Decreased nitric oxide is coupled with increased 
endothelin-1 to result in vasoconstriction (Keynan et al., 2004, Park et al., 2000, 
Yamauchi et al., 1990). 
 
There may well be a cell-dependent response. It has been reported that coronary 
microvascular endothelial cells are unaffected, in relation to nitric oxide and 
eNOS (Weidig et al., 2004). The experiments were carried out using similar 
concentrations of glucose to others (22mmol/L) and incubation was for 7 days. 
All the other investigations have used endothelial cells from either arteries or 
veins and therefore this appears to account for this difference. It, however, may 
just be the result of culture conditions – for instance, passage number, 
infrequency of medium replenishment and infection. 
 
The availability of nitric oxide has an impact on vasomotor control, in that it is a 
vasodilator. Therefore, initial high glucose concentration will increase vascular 
dilation but with continued exposure vasoconstriction will occur. Added to this, 
research has demonstrated that there is impairment in the production and response 
of the endothelium to vasodilatory stimuli and an increase in the production of 
vasoconstrictors in diabetic patients, even in the absence of pathological 
complications (Title et al., 2000).  
 
Other ROS have been reported to be increased in hyperglycaemic conditions, see 
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Table 21. There is not a lot of research, but what there is suggests that both 
superoxide anion and peroxide are increased following exposure to high 
concentrations of glucose. It should be noted, however, that peroxide expression 
was only increased following 48 hours of exposure and superoxide anion was 
only reported following exposure for 5 days. 
 
ROS are also known to stimulate production of prostanoids. Prostanoids are 
prostaglandins, prostacyclins, and thromboxanes, and include the vasoconstrictor 
thromboxane A2 and the vasodilator PGI2. Hyperglycaemia induced in tissue from 
animal diabetic models was reported to exhibit increased levels of prostanoids, 
possibly as a result of synthesis of ROS (Tesfamariam et al., 1990, Tesfamariam 
and Cohen, 1992, Shirahase et al., 1987).  Blocking prostacyclin and 
thromboxane receptors was shown to induce vasodilation. Inhibition of 
prostacyclin production on its own, however, had no effect (De Vriese et al. 
1999). Other studies have also found that increased thromboxane and decreased 
prostacyclin production accounts for vasoconstriction under conditions of high 
glucose (Cosentino et al., 2003, Sobrevia et al., 1996). 
 
Therefore, hyperglycaemia appears to result in time-dependent changes to the 
expression of ROS. Nitric oxide, a potent vasodilator, is increased on initial 
exposure to high glucose concentrations but is reduced after medium to long term 
exposure. Peroxide and superoxide anion production are likely to be only 
expressed following non-intermittent exposure. Whether the presence of AGEs 
also alters ROS availability is explored. 
 
There does not, however, appear to be much published research indicating the 
effect of AGEs on endothelial ROS production, other than relating to nitric oxide. 
A decrease in both nitric oxide and eNOS has been reported following AGE 
exposure (Xu et al., 2003, Hogan et al., 1992, Rashid et al., 2004, Rojas et al., 
2000). This correlates with the effect of hyperglycaemia on nitric oxide and 
eNOS production. Interestingly, it has also been reported that nitric oxide 
decreases both AGE formation and AGE-dependent leukocyte adhesion (Asahi et 
al., 2000, Xiang et al., 2006). This would, again, link ROS with cell adhesion 
molecules and associated leukocyte adhesion. Whether or not this allowed for 
increased platelet adhesion has been addressed in this proposed research. 
 
Overall, it would appear that diabetic conditions (both hyperglycaemia and 
AGEs) increase the production of some ROS, notably peroxide and superoxide 
anion. Nitric oxide, however, is decreased upon medium to long term exposure. 
This, along with increased vasoconstrictor production, causes vasoconstriction.  
This leads to an  increase in the shear rate; rates greater than 70 dyn/cm
2
 are 
thought to cause endothelial erosion, platelet adhesion, and plaque rupture, 
however, atherosclerotic plaque fissures only develop in areas where the shear 
rate  is low (< 6 dyn/cm
2
) (Esper et al. 2006). As such, the increase in nitric oxide 
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may provide conditions more suitable for lesion formation. 
 
 
Table 21: Reactive Oxygen Species Production by Endothelial Cells under 
Diabetic Conditions 
 
Compound Detail Reference 
ROS Increased ROS concentrations following 
endothelial incubation with HG 
(Inoguchi et al., 2000, 
Tsuneki et al., 2007) 
NO Increased 
 
Trovati et al. 1997 
 
NOS Increased in HUVECs treated with HG 
 
Initial increase. Reduced levels after 24 
hours of HUVEC incubation with HG 
(Tsuneki et al., 2007) 
(Ho et al., 1999) 
NO & NOS Decreased levels of NO but increased levels 
of NOS in HAECs treated with HG 
No effect on expression of either in CMECs 
treated with HG 
Short term exposure caused an increase 
while long term reduced expression 
Decreased expression following treatment 
of HUVECs with AGEs 
(Cosentino et al., 1997) 
(Weidig et al., 2004) 
(Srinivasan et al., 2004a) 
(Xu et al., 2003, Hogan 
et al., 1992, Rashid et al., 
2004, Rojas et al., 2000) 
NO, NOS 
& SO 
Increased levels in HAECs treated with HG (Cosentino et al., 2003) 
SO Increased (Graier et al., 1999) 
H2O2 Increased expression following 48 hours of 
HUVEC incubation with HG 
(Ho et al., 1999) 
 
(Key: ROS - reactive oxygen species; HG – high glucose; HUVECs – human umbilical 
endothelial cells; NO - nitric oxide; NOS - nitric oxide synthase; HAECs – human artery 
endothelial cells; CMECs – coronary microvascular endothelial cells; AGEs – advanced glycated 
endproducts; SO - superoxide anion) 
 
 
5.3.4. Cytokine Expression 
 
ROS production can also be increased by production of cytokines (Yang et al., 
2007). It has also been reported that oxidative stress can stimulate production of 
certain cytokines, including IL-8 (Vlahopoulos et al., 1999). There has, however, 
been very little breadth to investigation into the effect of diabetic-like conditions 
on cytokine production by the endothelium.  
 
There has, however, been a reasonable amount of research looking into the effect 
of high concentrations of glucose on IL-6, IL-8 and MCP-1 expression in cultured 
endothelial cells. Increased expressions of IL-6, IL-8 and MCP-1 have been 
reported (Piconi et al., 2004, Srinivasan et al., 2003, Temaru et al., 1997, 
Kinoshita et al., 2008, Piga et al., 2007, Takaishi et al., 2003, Srinivasan et al., 
2004c, Srinivasan et al., 2004b).  It is interesting to note that in one of these 
studies it was reported that intermittent incubations of high glucose significantly 
increased IL-6 production above that of stable high glucose (Piconi et al., 2004).  
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The in vitro research correlates with increased levels of IL-6 and MCP-1 in 
diabetics (Gomez et al., 2008). There are, however, some discrepancies when 
these studies are compared endothelial cells obtained from diabetics. Haubner and 
colleagues only reported increased levels of MCP-1, not IL-6 or IL-8 in 
saphernous vein endothelial cells removed during a coronary artery bypass 
(Gomez et al., 2008, Haubner et al., 2007).  The differences are likely to be as a 
result of the diabetics having advanced vascular disease. (Those use for the in 
vivo studies had no associated complications.) 
 
Overall, however, it would appear that it is likely that hyperglycaemia, whether 
short-term, long-term, or intermittent results in increased production of cytokines 
in vitro. The increased expression of both IL-6 and IL-8 has also been linked with 
increased monocyte adhesion to the endothelium. 
 
There does not appear to be any studies that have investigated the effect of AGEs 
on cytokine production by endothelial cells. There have, however, been some that 
have looked at IL-8 and MCP-1 expression by human corneal keratocytes and 
mesangial cells (Bian et al., 1998, Yamagishi et al., 2002). These found an 
increase in production following incubation with various AGEs. It is therefore 
possible that these conditions would also induce production of these cytokines by 
endothelial cells, therefore initiating monocyte adhesion and activation. Indeed, 
the research proposed within this thesis proposed to address this gap in the 
research and allow for determining whether diabetic-like conditions induce 
changes to the endothelium that account for accelerated atherosclerosis. 
 
 
Table 22: Cytokine Production by Endothelial Cells under Diabetic Conditions 
 
Cytokine Detail Reference 
IL-6 Increased expression under 
hyperglycaemic conditions 
Increased in diabetics 
Unchanged in diabetic ECs 
(Srinivasan et al., 2004b, Piconi et al., 
2004) 
(Gomez et al., 2008) 
(Haubner et al., 2007) 
IL-8 Increased expression under 
hyperglycaemic conditions 
 
Unchanged in diabetic ECs 
(Kinoshita et al., 2008, Srinivasan et al., 
2004c, Srinivasan et al., 2003, Temaru et 
al., 1997) 
(Haubner et al., 2007) 
MCP-1 Increased expression under 
hyperglycaemic conditions 
Increased in diabetics 
 
(Piga et al., 2007, Takaishi et al., 2003) 
(Gomez et al., 2008, Haubner et al., 2007) 
 
(Key: IL – interleukin; ECs – endothelial cells; MCP – monocyte chemotactic protein) 
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5.4. What can be concluded? 
Diabetes is associated with oxidative stress, endothelial dysfunction and accelerated 
atherosclerosis. Both oxidative stress and endothelial dysfunction are closely related 
conditions, in that they are both associated with increased ROS production and cell 
adhesion molecule up-regulation. Oxidative stress occurs when ROS production 
overwhelms that of antioxidants. Endothelial dysfunction is not clearly defined, but it 
is associated with abnormal endothelial function (including activation, cell adhesion 
molecule up-regulation, ROS and cytokine production, as well as decreased cell 
viability). As such, they are possible contenders for accelerated atherosclerosis under 
diabetic conditions.  
 
Hyperglycaemia has been reported to have a wide array of effects upon the 
endothelium. It has been linked with decreased cell viability (potentially as a result of 
apoptosis), up-regulation of cell adhesion molecules, as well as increased production 
of ROS and cytokines. Up-regulation of a number of cell adhesion molecules has been 
reported, including VCAM-1, E-selectin, ICAM-1, P-selectin, and VWF. It also 
increases the production of pro-inflammatory and pro-thrombogenic cytokines, 
including IL-6, IL-8 and MCP-1.  However, it would appear that diabetic endothelium 
from patients with advanced stages of atherosclerosis only exhibit heightened levels 
of MCP-1. There did not appear to be any published research that investigated the 
effect on other endothelial cytokines, including IL-7, ENA-78, GRO-α, IP-10, 
eotaxin, and fractalkine. This appears to be strange, especially when fractalkine has 
been associated with inflammatory diseases such as atherosclerosis.  
 
AGEs have also been reported to decrease cell viability, cell adhesion molecule up-
regulation, as well as ROS production. There do, however, appear to be differences 
dependent on the type of protein glycated, the type of sugar, the preparation, and 
concentration of the glycated protein used; there is also no information on cytokine 
production.  The research that has been done generally gives similar results to those 
reported for hyperglycaemia – reduced cell viability, up-regulation of VCAM-1, 
ICAM-1, and production of IL-6, IL-8 and MCP-1. 
 
These are, therefore, likely to indicate that the endothelium behaves in an abnormal 
fashion after exposure to high concentration of glucose and AGEs. The reports would 
correlate with the endothelium being dysfunctional. There is still however, some 
aspects that have not been fully covered in the literature. Most of the research has 
been in vitro. There are a number of discrepancies in the findings. Various reasons 
can be proposed for this, including glucose preparations and the cell line, but it is 
clear that more research is needed to gain a clearer understanding of the effect of 
hyperglycaemia on the endothelium.  
 
To continue these investigations on the different aspects of endothelial dysfunction in 
diabetic-like conditions, a number of studies were proposed. They incorporated 
general experiments, such as cell viability (cell proliferation and viability studies), cell 
86 
 
adhesion molecule up-regulation, ROS production, as well as cytokine expression. 
Expansion of current studies was part of this and included analysis of a range of 
cytokines, not just IL-6, IL-8 and MCP-1, various concentrations of glucose and 
different glycated proteins. The aim was to fill in some of the gaps in the literature 
and, by doing so, provide a better understanding of whether hyperglycaemia and 
AGEs could account for accelerated lesion formation in diabetics. This research 
would also allow for a greater understanding of whether platelet adhesion/interaction 
with the endothelium could initiate atherosclerosis via endothelial dysfunction. 
 
With only in vitro experiments possible for this research, further investigations would 
be required. Although, they provide a good understanding of isolated effects, in 
humans there are many more factors involved. These cannot be covered in laboratory 
based investigations and are difficult to interpret. With new techniques becoming 
available, it would be important to build on this work to gain a clearer understanding 
of how everything pieces together. 
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6. Conclusion 
Atherosclerosis is characterized by fatty deposits, known as foam cells, within the 
vascular wall. Over time, these deposits build up to form more complex lesions that 
consist of a lipid core and a cap, which leads to partial occlusion of the blood vessel. The 
core contains lipid laden macrophages along with cellular debris, free lipids and 
cholesterol. The cap is made up of layers of smooth muscle and endothelial cell. This can 
become calcified and vasculated, making it brittle and liable to fissuring. As such, these 
more advanced lesions are often associated with causing conditions such as myocardial 
infarction, strokes and claudication. These result from fissuring of the lesion cap, 
exposure of cell adhesion molecules and cytokines that attract platelets and therefore 
thrombus formation and occlusion of the blood vessel.  
 
There are a number of human conditions associated with accelerated rates of lesion 
formation. These include diabetes, systematic lupus erythematosus and arthritis. These 
diseases all involve an immune response. There are, however, a number of 
immunological conditions that are not linked to accelerated atherosclerosis, such as 
coeliac disease and asthma. There are also some non-immunological conditions 
associated with accelerated atherosclerosis, including smoking and radiation.  
 
The processes involved in initiating atherosclerosis are not fully understood at present. 
There have been a number of hypotheses published including that of Ross and Glomerset 
who suggested that atherosclerosis may result from injury to the endothelium resulting in 
denudation. This has been built on by others including the response to injury theory that 
suggested that injury did not cause denudation but, instead, resulted in functional 
changes to the endothelial cells. Suggested changes included ROS and cytokine 
production as well as cell adhesion molecule upregulation. Recently there have been a 
number of papers that have suggested that platelets may be involved. As such, this thesis 
proposed to investigate whether increased platelet interaction with the endothelium could 
hold the key. In doing so, it aimed to gain a better understanding of the processes 
involved in both atherogenesis and endothelial dysfunction. Further research could then 
be done to target foam cell production, providing a preventative treatment strategy. This 
would reduce the suffering of many patients and also reduce the massive health care 
costs associated with treatments linked to atherosclerosis. 
 
For platelets to be involved in atherogenesis they must be some sort of interaction with 
the endothelium. It was initially thought that platelet adhesion only occurred following 
endothelial denudation, it is now clear that this is not the case. There is a wealth of 
information to suggest that platelets can adhere to the endothelium, under various 
conditions.  
 
It is now generally accepted that platelet-endothelial interactions play a key role in acute 
coronary events associated with advanced atherosclerosis, such as myocardial infarction, 
but there is some evidence to suggest that they are also involved in initiating plaque 
formation. Over the last 10 years, however, a number of papers have been published 
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suggesting that platelet adhesion may initiate lesion formation. These include studies that 
have shown that monocyte transmigration is accelerated by platelets. It has also been 
suggested that platelets are involved because monocytes do not have receptors for 
oxLDL and therefore platelets, which do, are a prerequisite for foam cell formation. 
 
The majority of research investigating lesion formation has not reported platelet 
adhesion. There are, however, some papers that have found platelets adhered prior to 
lesion formation. This has been reported in humans (15-34 year olds that had no visible 
signs of cardiovascular disease), Apo E-/- mice and rabbits. There is also a number of 
studies that have shown that there is increased lesion formation when platelet are present 
than when there are only leukocytes. It does not, however, conclusively show that 
platelets are involved in atherogenesis because it was not possible to definitively say 
what happened to these platelets. Indeed, without carrying specific studies to investigate 
this it is difficult to conclusively show cause and effect. 
 
There have been a number of studies that have investigated the cell adhesion molecules 
involved in these platelet interactions with the endothelium by using monoclonal 
antibodies. There are some discrepancies based on the type of cells and antibody used. It 
is, however, possible to conclude that endothelial and GPIb, and platelet GPIIb/IIIa, as 
well as VWF and fibrinogen are involved. The extent of inhibition created by using 
blocking studies was dependent on the type of interaction investigated, for instance, 
different adhesion molecules are involved in transient attachments and firm adhesion. 
 
Inhibition of platelet binding has also been investigated by looking at anti-platelet drugs. 
The use of anti-platelet drugs suggests that platelets may well be involved in 
atherogenesis. Administration of many of these drugs has resulted in reduced lesion 
coverage and few layers / intimal thickness. These include low levels of aspirin, S18886, 
triclopidine, clopidogrel, celecoxib, cilostazol, dipyridamole, and sulfinpyrazone. A 
cocktail of anti-platelet drugs appears to have a greater effect on reducing lesion 
formation compared to administration of only one. This would suggest that there are 
numerous ways that platelets could be involved, for instance aspirin inhibits platelet 
activation while clopidogrel, ticlopidine, cilostazol and S18886 inhibit platelet 
aggregation. Aspirin also inhibits endothelial prostacyclin synthesis and availability of 
oxLDL. As a consequence, it has been suggested that a reduction in lesion formation 
associated with treatment with aspirin may be as a result of its anti-inflammatory and 
antioxidant properties. This is potentially supported by the report of celecoxib treatment 
significantly reducing lesion formation.  
 
Conditions associated with platelet abnormalities, such as von Willebrand disease, 
Glanzmann Thrombasthenia, and Bernard-Soulier disease have been shown to develop 
atherosclerosis. Deficiencies in VWF in mice and pigs, however, suggest that adhesion 
mechanisms may be involved in lesion formation. This might be because the process of 
atherogenesis is different between species, but there are a number of other factors that 
may contribute to the differences, including differences in methodology. Humans were 
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often treated for bleeding episodes, but pigs would not be.  Patients with type 3 disease 
were given clotting factors and they were always part of a small investigation. The 
condition is rare and therefore a large cohort is not possible.  
 
Other investigations in to platelet abnormalities have given conflicting results. It is 
therefore difficult to form any clear understanding from the studies that have been done 
so far. As such, it is not possible to say that platelet adhesion occurs in the initial stages 
of atherosclerosis. There is circumstantial evidence to suggest that it does but no definite 
proof. It is likely that it does because it is known that endothelial dysfunction is involved 
in atherogenesis. The disruption to the endothelium results in upregulation of cell 
adhesion molecules and therefore leukocyte and platelet adhesion.  
 
As such, my research proposed to investigate whether platelets adhered, either directly or 
indirectly via leukocytes, to the endothelium in the early stages of atherosclerosis under 
diabetic-like conditions. Diabetic-like conditions were chosen because diabetes is 
associated with accelerated rates of lesion formation and this results in increased 
presentation of cardiovascular disease. I hoped to be able to gain a better understanding 
of the processes involved in atherogenesis. By doing so, it would allow for more targeted 
research into drugs to reduce the onset of this condition. 
 
To investigate this, in vitro studies were proposed, under both static and dynamic flow 
conditions. Endothelial cells were cultured in conditions that are associated with 
diabetes. These included hyperglycaemia and the presence of AGEs. Hyperglycaemia 
was created by incubations with high concentrations of D-glucose. The cells were treated 
with high glucose concentrations or with various types of AGEs as well. Selections of 
different purities of albumin, or haemoglobin, were glycated with D-glucose to determine 
whether the purities could have an effect on adhesion. Platelet adhesion (either isolated 
or in the presence of leukocytes) was detected by flow cytometry and 
immunocytochemistry. The results from this were to be compared alongside time-lapse 
studies to investigate the effect of dynamic flow. Cell culture studies were to be 
compared with those obtained when using diabetic vascular tissue (with no visible signs 
of atherosclerosis) to see whether the presence of other cell types could have an effect. I 
expected that there would be variations seen between these because, for lesions to 
develop, monocytes migrate through the intima. For this to occur, there are likely to be 
changes to the subendothelium as well as the endothelium.  
 
If hyperglycaemia and AGEs increase platelet adhesion it is likely that they have an 
effect on the endothelium. Indeed, diabetes has been linked with endothelial dysfunction 
and reactive oxygen species (ROS) formation. High levels of glucose has been reported 
to result in decreased cell proliferation, viability, increased apoptosis, expression of 
certain cell adhesion molecules (VCAM-1, ICAM-1, E-selectin, and P-selectin), ROS 
and cytokine expression. These do, however, appear to be dependent on the type of 
glucose (although D-glucose is the only isomer found in humans and the results for this 
90 
 
sugar are consistent) and the origin of the cells.  It would also appear that cytokine 
production is greater following intermittent exposure to hyperglycaemic conditions.  
 
Although there have been a lot of investigations looking into the effect of 
hyperglycaemia on the endothelium there have been less looking at the effect of AGEs or 
a combination of high glucose and AGEs. The studies that have been reported show lots 
of contradictions. It would appear that the effect of AGEs is dependent on a number of 
factors. It is possible that these include the origin of the cells, the type of protein 
glycated, the concentration of AGEs, and impurities or endotoxins present in the AGE 
solution. Overall, however, it is possible that AGEs decrease cell proliferation, increase 
apoptosis, leukocyte adhesion, cell adhesion molecule expression (VCAM-1, ICAM-1, 
and PECAM-1), and nitric oxide expression. There does not appear to be any research 
showing the effect of these proteins on other ROS or on cytokine production. 
 
Therefore, further to the platelet adhesion studies planned as part of this research, I also 
planned to investigate what effect diabetic-like conditions had on endothelial cells. It was 
hypothesized that hyperglycaemia and AGEs would lead to endothelial dysfunction 
(upregulation of cell adhesion molecules, cytokine production, and decreased cell 
proliferation and viability). These are likely to result in adhesion of leukocytes, and 
possibly platelets, to the endothelium, decrease lumen diameter and increase shear stress. 
This could lead to increased formation of foam cells by phagocytosis of ox-LDL and 
activate platelets, and therefore account for accelerated lesion formation seen in 
diabetics. Again, it was hoped that by gaining greater understanding of the processes 
involved it would allow for the development of drugs to reduce lesion formation and 
therefore the effects of morbidity and mortality following the manifestation of 
cardiovascular disease. 
 
To investigate this, cell proliferation, cell adhesion molecule expression, ROS production 
and cytokine production experiments were to be done under diabetic conditions. This 
was to be achieved by culturing cells with various concentrations of glucose, and / or 
different types of AGEs, for a range of time periods. Normal, medium and high 
concentrations of glucose would then be administered. AGEs were produced both using 
albumin and haemoglobin. A variety of purities of albumin were glycated to investigate 
the effect on the endothelium. Samples were taken throughout the glycation process to 
allow for determination of the amount of glycation and map this to the effect on the 
endothelium.  Cells were either cultured with medium containing high glucose or in 
combination with the various AGEs.  
 
Cell proliferation was determined using cell counts and a commercial cell viability kit. 
Protein and gene expression of cell adhesion molecules (αvβ3, P-selectin, E-selectin as 
well as VWF) were to be investigated using flow cytometry, immunocytochemisty, and 
PCR. Both in situ and dynamic flow conditions were to be studied to see whether the 
high shear rates associated with vessel bifurcation had any effect on upregulation. Nitric 
oxide levels would then be determined by Griess assay while a more general overview of 
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ROS levels would be gained by looking at dihydrorhodamine oxidation. Cytokine 
production (IL-6, IL-8, and Fractalkine) was to be determined by using commercial 
ELISA kits and flow cytometry. ELISA was chosen to investigate cytokines present in 
the supernatant and flow cytometry for bound cytokines. 
 
I hypothesized that a combination of hyperglycaemic conditions and AGEs would 
increase the levels of endothelial dysfunction. I expected to find shorter exposure to high 
levels would increase the expression of cell adhesion molecules, cytokines, and ROS 
production, while decreasing cell proliferation and viability. I thought that the greater the 
amount of glycation and the more impurities the greater the effect. 
 
Overall, my research proposed to address the following research questions in the hope to 
provide greater understanding in this field: 
 Are platelets involved in the initial stages of atherosclerosis? 
 Do platelets directly adhere to the endothelium under diabetic-like conditions? 
 Do platelets adhere to the endothelium via platelet-leukocyte complexes? 
 Do diabetic-like conditions induce endothelial dysfunction? 
 Could endothelial dysfunction in diabetics account for accelerated 
atherosclerosis? 
 
There were, however, limitations to my studies. Cultured endothelial cells, although a 
very useful tool, have their restrictions. There are variations in characteristics between 
cell lines and also between batches. Immortalised cell lines tend to be poorly 
characterised and show non-endothelial traits, such as chromosomal instability and 
different responses to stimuli. Primary cells, as in this case, differ as a result of origin 
and donors, as mentioned previously. They are also sensitive to changes in culture 
conditions, be that slight variations in media constituents or conditions, and show 
diminished function with passage number.  
 
I believe that in vitro studies can only show part of the picture. For a more encompassing 
view of the processes involved in endothelial dysfunction and atherogenesis, I think that 
it is important to look to human studies. Further investigations would therefore be 
necessary. These could include investigations similar to the PDAY trial that instead 
specifically investigate platelet adhesion at sites that have a high prevalence of lesion 
formation, adhesion at sites that have individual foam cells, and also where fatty streaks 
are developing.  
 
From looking at the research available so far, I believe that it is likely that platelets are 
involved in lesion formation under diabetic-like conditions. The presence of both high 
concentrations of glucose and AGEs, over long periods of time, activate platelets and are 
likely to cause changes to the endothelium that result in endothelial dysfunction. I think 
that my research would have found that, although these diabetic-like conditions would 
not have significantly changed cell proliferation, that there would have been an increase 
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in up-regulation of cell adhesion molecules and production of cytokines and ROS. This 
would have resulted in monocyte adhesion, especially in the presence of activated 
platelets. I do, however, think that platelets are unlikely to be the initiating factor. They 
are not a prerequisite for foam cell formation, but are likely to accelerate atherogenesis. 
While the reduction in lesion formation by targeting platelet activation and adhesion 
would not directly result in eliminating atherosclerosis, it may well allow for a 
significant reduction in lesion formation in diabetics. It will also add to the general 
understanding of the processes involved in atherosclerosis and endothelial dysfunction. It 
will also assist others in future research. 
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